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Abstract
Redirecting a patient’s T-cells against cancer shows tremendous clinical responses in certain tumor types,
but potent therapies for ovarian cancer remain limited. Here we describe the preclinical development of
three novel cancer immunotherapy platforms. We first isolated an ErbB2(369-377)-specific T-cell receptor
(TCR) from a patient who was previously vaccinated against ErbB2, a protein ubiquitously overexpressed
in ovarian cancer. We hypothesized that an ErbB2(369-377)-specific TCR can recognize endogenously
processed ErbB2 protein in human cancer. This strategy re-directed human T-cells against
ErbB2(369-377), conferring recognition of ErbB2(+) HLA-A2(+) tumor cell lines in vitro and in vivo.
Together, our results provide a potential therapeutic for adoptive immunotherapy of ErbB2-expressing
malignancies.
We next targeted B7-H4, a protein highly expressed in cancer with low expression in healthy human
tissues. We engineered T-cells with novel B7-H4-specific chimeric antigen receptors (CAR) that
recognized both human and murine B7-H4 to test the hypothesis that B7-H4 CAR T-cell therapy can be
applied safely in preclinical models. B7-H4 CAR T-cells displayed anti-tumor reactivity against B7-H4(+)
human ovarian tumor xenografts followed by delayed, lethal toxicity. Comprehensive study of murine
B7-H4 protein distribution uncovered expression in multiple tissues that correlated with widespread
histologic lesions. We concluded that long-term engraftment of B7-H4 CAR T-cells mediates lethal, offtumor toxicity that is likely due to wide expression of B7-H4 in healthy mouse organs.
While preclinical murine models of CAR T-cell therapy are widely applied, they are limited by their inability
to model the complex human tumor microenvironment and adequately predict safety and efficacy in
patients. Therefore, we established a large, outbred canine model of CAR therapy to test the hypothesis
that functional tumor-specific CAR T-cells can be generated and applied in patient dogs with spontaneous
cancer. Anti-canine CD20 (cCD20) mRNA CAR electroporated T-cells exhibited antigen-specific
recognition and lysis of cCD20(+) targets. In a first-in-canine study, autologous transfer of cCD20-Zeta
CAR T-cells was well tolerated in a dog with relapsed B cell lymphoma. However, anti-tumor activity was
transient, suggesting that product optimization is needed. Our study demonstrates feasibility for the use
of CAR therapy in companion dogs to evaluate safety and efficacy prior to application in humans.
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ABSTRACT
TREATING CANCER WITH ENGINEERED T CELL THERAPIES:
MURINE AND CANINE MODELS OF SAFETY AND EFFICACY
Jenessa B. Smith
Daniel. J. Powell Jr., PhD

Redirecting a patient’s T-cells against cancer shows tremendous clinical responses in certain
tumor types, but potent therapies for ovarian cancer remain limited. Here we describe the
preclinical development of three novel cancer immunotherapy platforms. We first isolated an
ErbB2369-377-specific T-cell receptor (TCR) from a patient who was previously vaccinated against
ErbB2, a protein ubiquitously overexpressed in ovarian cancer. We hypothesized that an
ErbB2369-377-specific TCR can recognize endogenously processed ErbB2 protein in human cancer.
This strategy re-directed human T-cells against ErbB2369-377, conferring recognition of ErbB2+
HLA-A2+ tumor cell lines in vitro and in vivo. Together, our results provide a potential
therapeutic for adoptive immunotherapy of ErbB2-expressing malignancies.

We next targeted B7-H4, a protein highly expressed in cancer with low expression in healthy
human tissues. We engineered T-cells with novel B7-H4-specific chimeric antigen receptors
(CAR) that recognized both human and murine B7-H4 to test the hypothesis that B7-H4 CAR Tcell therapy can be applied safely in preclinical models. B7-H4 CAR T-cells displayed anti-tumor
reactivity against B7-H4(+) human ovarian tumor xenografts followed by delayed, lethal toxicity.
Comprehensive study of murine B7-H4 protein distribution uncovered expression in multiple
tissues that correlated with widespread histologic lesions. We concluded that long-term
viii

engraftment of B7-H4 CAR T-cells mediates lethal, off-tumor toxicity that is likely due to wide
expression of B7-H4 in healthy mouse organs.

While preclinical murine models of CAR T-cell therapy are widely applied, they are limited by
their inability to model the complex human tumor microenvironment and adequately predict
safety and efficacy in patients. Therefore, we established a large, outbred canine model of CAR
therapy to test the hypothesis that functional tumor-specific CAR T-cells can be generated and
applied in patient dogs with spontaneous cancer. Anti-canine CD20 (cCD20) mRNA CAR
electroporated T-cells exhibited antigen-specific recognition and lysis of cCD20+ targets. In a
first-in-canine study, autologous transfer of cCD20- CAR T-cells was well tolerated in a dog
with relapsed B cell lymphoma. However, anti-tumor activity was transient, suggesting that
product optimization is needed. Our study demonstrates feasibility for the use of CAR therapy in
companion dogs to evaluate safety and efficacy prior to application in humans.
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CHAPTER 1. INTRODUCTION
Cancer
Cancer is the uncontrolled outgrowth of abnormal cells, resulting in formation of tumor cells that
can interfere with the proper functions of the body and lead to death. Although the overall cancer
death rate has declined since the early 1990s (Kohler et al., 2015), in 2016 approximately 1.7
million new cases of cancer will be diagnosed in the United States alone and over 595,000 people
will die from this disease (SEER Surveillance, 2016). Work in our studies will focus on the
development of novel therapies for ovarian cancer.

Ovarian Cancer
Ovarian cancer is the fifth most common cause of cancer-related death among women,
accounting for approximately 15,000 deaths and 22,000 new cases in 2015 in the United States
(Society, 2016a, b). Treatment involves optimal surgical resection of tumor, followed by
induction of first-line chemotherapy including platinum-based (carboplatin or cisplatin) and
taxane-based (paclitaxel or docetaxel) agents that became the standard of care in 1998. However,
less than 46% of women survive greater than five years, a rate that has not shown tremendous
improvement over the rate of 38% in the 1980s (SEER Surveillance, 2016).

Most women diagnosed with ovarian cancer are asymptomatic and diagnosed late in the cancer’s
progression. In these cases, responses to first-line treatment are generally not durable and greater
than 80% of women have recurrence of their disease. Induction of second-line chemotherapeutic
agents is generally not as effective and most women ultimately die of the disease (Nelson, 2008).
The overall 10-year survival rate is 35% (Society, 2016a, b). Therefore, further interrogation of
modalities to prevent and treat ovarian cancer is warranted.
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Anti-cancer Immunity
In 1909, Paul Ehrlich proposed that the immune system may repress the formation of tumors
(Ehrlich, 1909). 50 years later Lewis Thomas and Frank MacFarlane Burnet postulated that the
attack of the immune system against cancer cells may be led by a specific cells of the immune
system- the lymphocytes (Burnet, 1970; Thomas, 1959), coining the term cancer
immunosurveillance. However, the idea that immune cells could fight cancer lost traction when
Osias Stutman reported that athymic-nude mice, supposedly lacking all T and B cells, were not
any more susceptible to tumor outgrowth in comparison to immune competent mice (Stutman,
1974, 1979a, b). These observations stunted investigations concerning the role of the immune
system against cancer for almost 20 years.

In 2001, Shankaran et al. in the laboratory of Robert Schreiber elegantly demonstrated that
lymphocytes and IFN-γ, a potent pro-inflammatory cytokine, are essential to prevent
development of chemically induced and transplanted spontaneous epithelial tumors. Further, their
work implicated the existence of cancer immunoediting or the “Three E Hypothesis” whereby a
three phase battle exists between the immune system and cancer defined by elimination of
transformed cells by immune cells (Elimination), an equilibrium state between the two sides
where editing occurs (Equilibrium), and an escape of tumor cells resulting in tumor outgrowth
(Escape) (Shankaran et al., 2001).

The renewed excitement in the field of cancer immunosurvelliance and immunoediting since
2001 has resulted in countless studies of the impact of lymphocytes- specifically IFN-γ-secreting
CD8+ T cells- on cancer outgrowth. In ovarian cancer, patients with detectable tumor infiltrating
T cells (TIL) had a 38% 5-year overall survival rate compared to 4.5% for patients who did not
2

have detectable TIL (Zhang et al., 2003). A more recent meta-analysis reviewed 10 studies that
investigated CD3+ or CD8+ T cells in ovarian cancer, and all studies showed significantly longer
survival with intraepithelial TIL (Hwang et al., 2012).

The presence of intratumoral T cells also correlates with a favorable prognosis in several other
cancer types (Pages et al., 2010) including breast (Mahmoud et al., 2011; Marrogi et al., 1997;
Menegaz et al., 2008), lung (Al-Shibli et al., 2008; Dieu-Nosjean et al., 2008; Hiraoka et al.,
2006; Ito et al., 2005; Kawai et al., 2008), bladder (Sharma et al., 2007) colon (Funada et al.,
2003; Galon et al., 2006; Jass, 1986), prostate (Richardsen et al., 2008; Vesalainen et al., 1994),
pancreatic (Fukunaga et al., 2004; Ino et al., 2013), head and neck (Badoual et al., 2006; Reichert
et al., 2001; Shibuya et al., 2002), esophageal (Cho et al., 2003; Schumacher et al., 2001),
gallbladder (Nakakubo et al., 2003), renal cell carcinoma (Nakano et al., 2001) and melanoma
(Clark et al., 1989; Clemente et al., 1996). All together, these observations imply that therapies
could be applied that enhance or re-direct the T cell-based immune response to eliminate cancer.

T cell Response
Recognition and elimination of tumor cells requires a robust anti-tumor T cell response that
involves coordination of many aspects of tumor biology and immunology. First, a T cell needs to
recognize specific proteins expressed in tumor cells called tumor-associated antigens (TAAs). A
T cell must express a T cell receptor (TCR) capable of recognizing a small 8-11 amino acid
peptide derived from a TAA that is bound to patient’s unique major histocompatibility (MHC)
molecules and presented on the surface of tumor cells. The TAA-specific T cell must be primed
and stimulated by a professional antigen presenting cell (APC) such that the T cell receives three
signals necessary for activation: TCR engagement of the TAA-specific peptide/MHC complex
3

(signal 1), co-stimulation through CD28 ligation of secondary activation molecules such as CD80
and CD86 expressed on the APC (signal 2), and through uptake of immune-stimulatory cytokines
secreted by the APC (signal 3). After receiving all three signals, the activated TAA-specific T cell
must then traffic to the tumor site and encounter a tumor cell that has processed and presented the
specific TAA epitope on its MHC molecules. Engagement of the TAA-specific TCR with TAApeptide/MHC on the tumor can then trigger killing of the tumor cell. These processes are
summarized in Figure 1.1.

Tumor-Associated Antigens (TAAs)
Self-peptide antigens
In addition to controversy surrounding the role of immune cells in preventing or eliminating
cancer cells as discussed above, contention also existed about the existence of antigens that could
be recognized by the adaptive arm of the immune response. Studies in virology and infectious
disease established the paradigm that immune cells recognize “non-self” foreign antigens while
“self” antigens should not be recognized. Rather, high affinity self-antigen-specific TCRs should
be eliminated during clonal selection or rendered anergic via central or peripheral tolerance
(Thaxton and Li, 2014). This implies that tumors, derived from self-tissue, may only express
“self” antigens for which TAA-reactive TCR-bearing T cells may not exist.

The notion that tumors were not antigenic or immunogenic was promoted by studies in murine
models which concluded that only chemically-induced tumors, and not transplant of
spontaneously-derived tumor cells, induced an immune response (Hewitt et al., 1976). However,
later studies demonstrated that self-peptide antigens could be recognized by T cells once selftolerance was broken and/or the tumor micro-environment was modified to favor inflammation
(Boon et al., 1994).
4

Neo-epitopes and Mutational Heterogeneity
In addition to self-peptide TAAs, tumors can also express mutated non-self-proteins termed “neoantigens,” which may facilitate immune recognition by high avidity T cells.

Recent work

indicates that certain tumor types accrue a far greater number of somatic mutations than other
cancers, with melanoma demonstrating an approximate 10 fold increase in somatic mutation
frequency per megabases of DNA versus ovarian cancer (Lawrence et al., 2013) and other
cancers of epithelial origin (Vogelstein et al., 2013). Use of a new tandem minigene approach has
successfully identified non-synonymous neo-antigens that are recognized ex vivo by autologous
tumor infiltrating lymphocytes (TIL) in patients with melanoma (Kalaora et al., 2016; Lu et al.,
2014) and gastrointestinal cancers (Tran et al., 2015; Tran et al., 2014)- two cancers that have
higher mutational loads in comparison to ovarian cancer. However, analyses performed by Brad
Nelson’s group revealed that T cell responses against neo-epitopes in ovarian cancer are rare
(1/79 mutations recognized), transient, and, fail to prevent disease progression (Wick et al.,
2014). Therefore, heterogeneity in mutational load should be taken in to consideration in order to
implement successful immune modulatory therapies in specific types of cancer.

Tumor Microenvironment (TME)
Beyond the existence of TAAs, others obstacles can impede the induction of a productive
immune response. The tumor itself can “hide” from tumor reactive T cells by down regulating
MHC molecules (Bubenik, 2003) and components of antigen processing machinery required to
display peptide on MHC molecules (Han et al., 2008; Smith et al., 2014a). Additionally, tumors
in solid and semi-solid cancers exist in a tumor microenvironment (TME) composed of cancer
cells and non-tumor cells, including cells of the stromal, endothelial, and immune compartment.
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Cancer cells often co-opt the normal cells to aid in formation of the malignancy, creating a protumor, immune suppressive milieu in the TME.
Tumor-associated macrophages
One of the most highly studied immune components in the TME are tumor-associated
macrophages (TAMs). Although oversimplified and highly plastic, TAMs are classified in to two
states based on their pro or anti-tumor effects in the TME (Mills et al., 2000). M1 TAMs are
considered to have anti-tumor properties, while M2 macrophages are considered to be
dysfunctional, pro-tumor macrophages that promote tumor growth, metastasis, angiogenesis, and
immune evasion (Martinez and Gordon, 2014). The differentiation into the M1/M2 axis is
dependent on the cytokine milieu that polarizes the macrophages. Due to the immune suppressive
nature of the TME, M2-polarized macrophages are more heavily recruited by chemokines and
cytokines such as (CCL2, MCSF, IL4, IL10, and TGFβ) (Mantovani et al., 2002). Notably, in
ovarian cancer, an increased number of TAMs correlated with a worse overall prognosis (Zhang
et al., 2012).

Immune Checkpoint Proteins
Additionally, tumor and non-tumor cells in the TME can express negative immune modulatory
proteins that can dampen an anti-tumor immune response. Two of the most widely studied and
therapeutically targeted negative immune molecules are PD-L1 (B7-H1) and PD-L2 (B7-H2).
Identified as members of the B7 family in 1999 and 2001 (Driessens et al., 2009), these molecules
are expressed on the surface of tumor cells and TAMs and can engage with PD-1 expressed on
activated T cells, sending an inhibitory signal through the T cell that lessens its ability to function.
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CTLA-4 is another negative checkpoint protein that is up-regulated and expressed on the surface
of T cells post activation. CTLA-4 competes with the immune stimulatory protein CD28 on
activated T cells for ligation with their ligands B7-1 (CD80) and B7-2 (CD86), which are
expressed on professional APCs (Krummel and Allison, 1996). Inhibition through CTLA-4 is
believed to primarily occur during priming of the immune response in secondary lymphoid
organs, instead of at the site of the tumor in the TME (Chambers et al., 1996; Greenwald et al.,
2005; Okazaki and Honjo, 2006). Finally, many other inhibitory receptors/pathway exist that
could be targeted with therapies. Together, immune checkpoints such as PD-L1, PD-L2, CTLA-4,
and others may need to be overcome when designing immune-based therapies for cancer.

Immunotherapy
Cytokines
Cytokines are a class of small molecules that bind cell surface receptors resulting in downstream
cell signaling events that can create either a pro or anti-inflammatory immune environment.
Administration of pro-inflammatory cytokines was one of the first methods utilized to tip the
balance in favor of the immune response. Administration of Interleukin-2 (IL-2) therapy for the
treatment of metastatic melanoma and renal cell carcinoma (RCC) was the first cytokine therapy
approved by the United State Food and Drug Administration (FDA) in 1992 based on induction
of durable complete responses (CRs) or partial responses (PRs) in patients with metastatic RCC
(Fyfe et al., 1995).

Interferon-α (IFN-α) therapy has been applied in RCC and was approved by the FDA for use in
certain hematologic malignancies (Mocellin et al., 2010) and in high risk melanoma in 1996
(Kirkwood et al., 1996). Administration of Interferon-γ (IFN-γ) and Interleukin-12 (IL-12) have
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also been tested in the clinic, but results have been underwhelming (Gleave et al., 1998; Gollob et
al., 2000). Combination therapies utilizing cytokines and other treatments are still under
investigation (clinicaltrial.gov NCT02014636), however, toxicities induced by high dose,
systemic injection of cytokines has greatly limited application of these approaches (Kirkwood et
al., 2002; Schwartzentruber, 2001). The significant toxicities paired with objective response rates
lower than 15% following high dose IL-2 treatment (Fisher et al., 2000) point to a need for
development and use of more specific therapies that could facilitate a productive anti-tumor
immune response against cancer.

Immuno-modulatory Antibodies: Breaking the Brakes
One of the best therapeutic methods to efficiently disrupt the functionality of cell surface proteins
in the tumor microenvironment is the use of monoclonal antibodies (mAbs), a strategy that has
shown promise targeting negative immune modulators such as PD-L1, PD-1, and CTLA-4. Other
negative checkpoint molecules have not yet been targeted clinically with any treatment modality,
including monoclonal antibody treatment.

The CTLA-4 antibody ipilimumab (Yervoy) was FDA approved for melanoma in 2011, and is
currently being investigated as a single therapy in recurrent platinum sensitive ovarian cancer
patients in a Phase II trial (clinicaltrials.gov). Hodi et al. 2008 treated 9 stage IV ovarian cancer
patients with ipilimumab with antitumor effects, including one patient with a durable regression
with dramatic decline in CA-125 with regression of hepatic metastasis (Hodi et al., 2008). Three
other patients achieved stable disease for several months.

Blocking the PD-1 pathway with an anti-PD-1 antibody resulted in objective responses in 20-25%
patients with non-small-cell lung cancer, melanoma, and renal-cell cancer (Topalian et al., 2012).
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Since higher PD-L1 expression is associated with poorer prognosis in patients with ovarian
cancer (Hamanishi et al., 2007), this pathway was thought to be a good target for ovarian cancer,
yet a subsequent Phase I trial in 2012 by Brahmer et al. demonstrated responses in only 1/17
patients with ovarian cancer and these samples were not evaluated for expression of PD-L1
(Brahmer et al., 2012). Still, synergistic targeting of multiple negative immune-modulatory
pathways may be necessary to fight disease. Additionally, augmenting the immune response
requires the presence of TAA-specific T cells that can be potentiated. We can build upon the
limitations of monoclonal antibody therapy by applying modalities that can effectively induce an
anti-cancer T cell response such as cancer vaccines and T cell therapies.

Cancer Vaccines
Cancer vaccines attempt to generate anti-tumor immunity through injection of TAAs. TAAs can
be injected themselves as protein or DNA, however, clinical efficacy using short peptides has
been limited (Rosenberg et al., 2005). Alternatively, TAA can be loaded as tumor lysate, DNA, or
RNA onto professional antigen presenting cells (APCs) and re-injected into a patient (Melero et
al., 2014). APCs, such as dendritic cells (DCs), are used as immunogenic vehicles that can
present the TAAs to CD8+ or CD4+ T cells via MHCI or MHCII, respectively. DCs can also
provide co-stimulation through ligation of secondary activation signals, such as CD80 and CD86,
and through tertiary activation signals such as secretion of immune-stimulatory cytokines.
In 2010 the FDA approved the first therapeutic tumor vaccine, Provenge (sipuleucel-T), for
prostate cancer. The vaccine is cellular based, consisting of autologous transfer of a patient’s own
DCs that were previously activated and antigen-loaded ex vivo. Phase 3 studies demonstrated a
4.5 month increase in median survival (Anassi and Ndefo, 2011). Other cancer vaccines have not
yet been FDA approved, however, exploration is ongoing. In ovarian cancer, a peptide vaccine
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against the cancer testis antigen NY-ESO consistently generated an immune response in all 28
patients tested (Sabbatini et al., 2012).
ErbB2369-377 E75 peptide
Other vaccination strategies have targeted ErbB2 (HER2/neu), a protein that is highly
overexpressed in several cancer types including ovarian and breast cancer and significantly
correlates with reduced overall survival (Lanitis et al., 2012a; Pils et al., 2007). The most widely
studied ErbB2 epitope, called the E75 peptide, spans the amino acids 369-377 of ErbB2 protein.
Reports utilizing E75 peptide vaccination have demonstrated an induction in E75 peptide-specific
T cell-mediated immunity in 4/8 patients (Murray et al., 2002) and 2/4 patients, however, the
response was short-lived (Knutson et al., 2002). Additionally, a study utilizing an ErbB2 E75 DC
vaccination protocol detected peptide-specific CTL in 5/10 patients (Brossart et al., 2000). In
2007 Czerniecki et al. sought to improve earlier findings by creating a novel DC-based
immunization approach utilizing several CD8+ and CD4+ ErbB2 epitopes, including the E75
peptide. This cocktail of peptides was used previously with adjuvant, resulting in a reduction in
ErbB2 expression in 7/11 patients, with 5/7 patients showing decreases in residual disease
following autologous transfer (Czerniecki et al., 2007).

Although efficacious in certain patients, current therapeutic vaccination-based strategies benefit
only a minority of patients (Ophir et al., 2016). Still, these studies provide evidence for the ability
to break self-tolerance and generate T cell responses against non-mutated, self-antigens.
Additionally, the vaccine field is seeing successes in combinatorial therapies that use vaccines
with cytokines and checkpoint blockade (Morse and Lyerly, 2015), however, we can also directly
treat patients with T cells to increase the chances of generating an effective anti-tumor immune
response.
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Tumor Infiltrating Lymphocyte (TIL) Therapy
The therapies discussed so far have relied upon activation of TAA-specific T cells in vivo in a
cancer patient. Instead, TIL therapy involves the activation and expansion of potentially tumor
reactive T cells ex vivo in a non-immunosuppressive environment with high levels of stimulation.
TIL can further be selected for anti-tumor reactivity or re-infused as bulk TIL back into the
patient, completing the cycle of autologous cell transfer (ACT) (Figure 1.2).

The Rosenberg group at the National Cancer Institute (NCI) has pioneered this approach for the
treatment of patients with melanoma. Since the group reported this work in 1998 (Rosenberg et
al., 1988), greater than 200 metastatic melanoma patients have been treated with TIL in
conjunction with IL-2 therapy and various lymphodepleting regimes. Objective response rates
range from 50 to 75%, with 19/93 (20%) patients achieving complete tumor regression beyond
three years post treatment (Rosenberg et al., 1988; Rosenberg et al., 2011). Notably, these results
drew attention to the factors that correlated with objective responses including persistence of the
infused cells and the added benefits of non-myeloablative, lymphodepleting conditioning
(Gattinoni et al., 2005; Klebanoff et al., 2005; Robbins et al., 2004; Rosenberg et al., 2011).

In ovarian cancer, TIL therapy in combination with cisplastin-containing chemotherapy induced a
complete clinical response in 4/7 patients that lasted greater than 15 months (Aoki et al., 1991).
A follow-up study showed an increase in overall survival in 13 patients that had received TIL
with chemotherapy, however, only patients with no evidence of disease (NED) following
chemotherapy were enrolled on the study (Fujita et al., 1995). Currently, a clinical trial to treat
metastatic ovarian cancer patients with TIL is actively recruiting patients (clinicaltrial.gov
NCT02482090).
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Although TIL therapy is under investigation in other types of cancer, melanoma is still the most
highly studied cancer type for TIL therapy. As discussed previously, melanoma has the highest
mutational load (Lawrence et al., 2013), a high frequency of tumor-infiltrating T cells (Erdag et
al., 2012), and an increased number of neo-epitopes (Kalaora et al., 2016; Lu et al., 2014; Tran et
al., 2015; Tran et al., 2014; Wick et al., 2014) in comparison to other tumor types. Taken
together, these observations imply that melanoma may be a highly immunogenic tumor that is an
outlier amongst the spectrum of other tumor types. Therefore, exploration of platforms that can
re-direct the specificity of potent T cells through genetic modification that do not rely on the
existence of TAA-specific cells may induce more robust anti-tumor effects in a wider array of
cancer types.

Genetic modification of T cells: A Rationale for Development of Novel
Targeted Immune Therapies

T cell Receptor (TCR) therapy
The antigen specificity of T cells isolated from patients can be re-directed permanently or
transiently through the introduction of exogenous genes (Figure 1.3). TCR gene transfer has been
developed over the last decade as a reliable method to generate large numbers of T cells of a
given antigen specificity for adoptive cellular therapy of viral infectious diseases, virus-associated
malignancies, and cancer (Engels and Uckert, 2007). In 2006, Morgan et al. reported the first
clinical application of TCR adoptive cell transfer for patients with melanoma. Their approach
utilized retroviral vectors to introduce the alpha and beta chain of an exogenous TCR (DMF4)
specific for MART-1 antigen and provided evidence that the treatment was safe (Morgan et al.,
2006). In 2009, a follow-up study utilizing a MART-1-specific TCR (DMF5) with increased
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functional avidity showed enhanced objective responses and durability. However, patients also
had damage of normal melanocytes in the skin, eye, and ear that was likely due to expression of
MART-1 antigen in normal melanocytes (Johnson et al., 2009).

TCR gene therapy also been used to target the cancer-testis antigen NY-ESO. This approach was
applied clinically in 2011, demonstrating objective clinical responses in 4/6 synovial cell sarcoma
patients and 5/11 melanoma patients (Robbins et al., 2011). Additionally, the treatment was
shown to be safe and long-term follow-up indicated that 50-60% of melanomas and synovial cell
sarcoma patients had objective clinical responses (Robbins et al., 2015). More recently, treatment
of myeloma patients with an affinity-enhanced version of the NY-ESO TCR demonstrated
clinical responses in 16/20 patients (Rapoport et al., 2015), further establishing promise for this
platform in non-melanoma tumor types.

In ovarian cancer, MART-1 antigen expression has not been reported and NY-ESO is only
expressed in approximately 40% of patient tumors (Odunsi et al., 2003), greatly limiting the use
of an NY-ESO TCR therapy for the vast number of patients. As an alternative approach, several
groups have attempted to establish a TCR therapy against the ErbB2369-377 E75 peptide- a TAA of
great interest as described in the Cancer Vaccines section. As summarized above, the E75 peptide
was identified as an immune-dominant epitope recognized by ovarian tumor-specific cytotoxic T
cells (CTL) (Fisk et al., 1995) and has been widely and safely used in vaccination studies
(Mittendorf et al., 2008). However, durable anti-tumor efficacy of reported vaccination strategies
remain elusive (Brossart et al., 2000; Czerniecki et al., 2007; Disis et al., 2002; Knutson et al.,
2002; Murray et al., 2002) and long-term follow-up studies describing anti-tumor efficacy in
large patient cohorts have not been reported.
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The clinical trial reported by Czerniecki et al.at the University of Pennsylvania utilized an
innovative DC strategy described in Figure 1.4. The therapeutic strategy utilized IFN-γ and
lipopolysaccharide (LPS) to activate the ErbB2 peptide-pulsed DC, creating high IL-12-secreting
DC prior to administration to the patient (Czerniecki et al., 2007; Koski et al., 2012). The ErbB2
DC vaccine contained several MHC class I and class II ErbB2 peptides, including the E75
peptide. Notably, 11/13 HLA-A2+ patients mounted a CTL response that specifically produced
IFN-γ cells against E75-peptide pulsed DCs and tumor cells expressing endogenous levels of
HLA-A2 and ErbB2 protein. This direct recognition of tumor is of great value since earlier
studies reported that CTL generated by direct immunization with the E75 peptide were unable to
recognize tumor cells (Zaks and Rosenberg, 1998), calling in to question the endogenous
processing and presentation of the E75 peptide (Henle et al., 2013).

Therefore, due to the ubiquitous expression of ErbB2 protein in ovarian cancer (Lanitis et al.,
2012a) and the availability of CD8(+) T cells from a DC-ErbB2 E75 vaccine-primed patient that
recognized a HLA-A2(+) ErbB2(+) breast cancer cell line ex vivo, we sought to accomplish the
goal below:

Aim 1. Isolate a novel human ErbB2-specific TCR that could confer potent anti-tumor effector
functions in genetically engineered primary cytotoxic lymphocytes as a novel TCR immune
therapy for ErbB2+ cancers. This aim will test the hypothesis that an ErbB2369-377-specific TCR
can recognize endogenously processed ErbB2 protein in human cancer.

Chimeric Antigen Receptor (CAR) therapy
Continued efforts by our work and others continue pushing forward promising TCR gene therapy
platforms toward the clinic. One of the greatest advantages of TCR therapy is the ability to
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recognize TAA-derived peptides from both intracellular and extracellular proteins, encompassing
the full repertoire of available TAA. Greater than 80 on-going clinical trials are assessing the
safety and efficacy of TCR gene therapy (clinicaltrials.gov) as of March 2016.

However, several drawbacks exist in redirecting the specificity of a T cell utilizing an exogenous
TCR. First, TCRs are restricted by MHC, many to the HLA-A2 locus that is expressed by
approximately 50% of the population (Ellis et al., 2000) , thereby excluding the remaining 50% of
patients. Second, activation through the TCR requires the presence of cellular machinery proteins
termed the antigen processing machinery (APM) that are involved in the processing of proteins
into small peptides that are presented on MHC molecules. Tumor cells often lose components of
the APM through genetic or protein changes and down-regulate MHC expression resulting in
evasion of recognition by TCR(+) T cells (Leone et al., 2013).

In 1989 Zelig Eshher described a strategy to overcome the limitations of TCR gene therapy by
combining the antibody-like recognition of B cells with the TCR activation signals from a T cell
(Gross et al., 1989) (Figure 1.5). These molecules, known first as T-bodies and then chimeric
antigen receptors (CARs), are composed of a single chain variable fragment (scFv) that binds
molecules on the surface of the target cell joined to the intracellular signaling domains of a T cell.
The first generation of CAR T cells utilized a CD3ζ intracellular domain (ICD), providing “signal
one” for T cell activation through ligation of surface antigen. However, later iterations of secondgeneration CAR T cells utilized various T cell signaling domains in series with antigen
recognition to provide co-stimulation. The most widely studied platforms have used CD28 ICD,
providing “signal two” for optimal T cell effector function or 4-1BB (CD137) ICD, a member of
the tumor necrosis factor receptor (TNFR) family recognized to confer persistence and survival
properties to T cells. Both CD28 (Finney et al., 2004; Friedmann-Morvinski et al., 2005; Maher et
15

al., 2002) and 4-1BB (Carpenito et al., 2009; Imai et al., 2004; Milone et al., 2009) CAR T cell
platforms have demonstrated improved in vitro and in vivo anti-tumor efficacy and persistence in
comparison to first generation CAR T cells in the studies.

Since 2011, the clinic success of CAR T cell therapy against B cell malignancies has been
tremendous. Many institutions have reported success utilizing a CAR against the B cell leukemia
antigen CD19 including the University of Pennsylvania, National Cancer Institute (NCI), Baylor
College of Medicine, City of Hope, MD Anderson Cancer Center, Fred Hutchinson Cancer
Center, and Memorial Sloan Kettering Cancer Center (Batlevi et al., 2016). Current CRs in the
University of Pennsylvania trials in adults and children with acute lymphoblastic leukemia (ALL)
and heavily pretreated chronic lymphocytic leukemia (CLL) have reached 90% and 57%,
respectively (Maude et al., 2014; Porter et al., 2015).

CAR therapy in Solid Tumors
The success of CAR T cell therapy in solid tumors is under active investigation. Currently, there
are ongoing CAR T cell clinical trials targeting epidermal growth factor receptor variant III
(EGFRvIII) in glioblastoma, mucin-1 (MUC1) in hepatocellular carcinoma, non-small cell lung
cancer (NSCLC), pancreatic carcinoma, triple-negative breast cancer (TNBC), brain gliomas,
colorectal cancer, and the disialoganglioside GD2 antigen in gastric cancer, sarcoma, melanoma,
osteosarcoma, and neuroblastoma (clinicaltrials.gov). One of the most promising completed
studies to date reported CR in 8/11 high-risk neuroblastoma patients with active disease, with
persistence of anti-GD2 CAR T cells correlating with improved clinical outcome (Louis et al.,
2011) .
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Targeting solid epithelial tumors, such as ovarian cancer, has not yet been as successful as
targeting hematological cancers. One of the first CAR studies in ovarian cancer utilized T cells
targeting folate receptor- alpha (FRα) (Miotti et al., 1987; Parker et al., 2000) a glycosylphosphatidyl inositol-linked (GPI-linked) membrane protein involved in folic acid uptake that is
overexpressed in >90% of ovarian cancer (Toffoli et al., 1997). Unfortunately, the T cells did not
persist in circulation and no reduction in tumor burden was observed (Kershaw et al., 2006),
likely due to use of a first generation CAR T cell platform. A revised Phase I study utilizing a
different anti-FRα scFv and a 4-1BB 2nd generation CAR characterized by our group (Song et al.,
2011) will investigate the safety and efficacy of FRα CAR therapy in ovarian cancer (Kandalaft et
al., 2012). Additional clinical studies are investigating CAR T cell therapy targeting mesothelin
(Carpenito et al., 2009), a GPI-linked membrane glycoprotein overexpressed on the surface of
22-100% of ovarian cancers (Hassan and Ho, 2008).

Although therapies against promising clinical targets are under active investigation, the barriers to
a productive endogenous immune response against cancer discussed above in the T cell Response
section can also hinder the anti-tumor efficacy of CAR T cell therapies. Difficulties exist in
targeting TAA that are expressed on tumor cells without concomitant expression on normal vital
tissues. Additionally, heterogeneity of TAA expression in tumor cells may allow for escape of
TAA(-) tumor cells, suggesting that multifaceted and combinatorial therapies may be necessary to
eliminate the last cancer cell. Lastly, if CAR T cells can traffic and penetrate the tumor they must
then be functional in the immune suppressive TME, evading ligation of negative immune
modulatory proteins that can dampen an anti-tumor immune response.
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B7-H4: A Target for Cancer Therapy?
B7-H4 was identified in 2003 as a negative checkpoint molecule in the B7 family. B7-H4 is less
characterized than its fellow B7 family members and shares only 25% amino acid homology with
PD-L1 and PD-L2 (Hansen et al., 2009). As depicted in Figure 1.6, B7-H4 protein is found on
tumor cells (Choi et al., 2003; Salceda et al., 2005; Tringler et al., 2006) and on TAMs (Dangaj et
al., 2013a; Kryczek et al., 2006b), suggesting that modalities targeting this protein would have a
two-pronged effect in the TME. B7-H4 protein has demonstrated immune inhibitory effects on
activated murine and human T cells in vitro (Prasad et al., 2003; Sica et al., 2003; Zang et al.,
2003) and in preclinical models of autoimmunity (Azuma et al., 2009; Lee et al., 2012; Wei et al.,
2011), infection (Hofmeyer et al., 2012; Suh et al., 2006; Zhu et al., 2009), and cancer (Abadi et
al., 2005; Leung and Suh, 2013). Additionally, tumor cells expressing B7-H4 demonstrate
augmented tumor cell proliferation (Cheng et al., 2009; Zhang et al., 2013), superior antiapoptotic ability (Salceda et al., 2005), and increased tumor growth even in the absence of a
competent immune system (Cheng et al., 2009; Salceda et al., 2005; Zhang et al., 2013).

Limitations of Previous B7-H4 Therapies
As we reviewed previously (Smith et al., 2014b), many potential methods could be utilized to
target B7-H4 in the TME (Figure 1.7). Some of these approaches are under investigation in
preclinical animal models, but have not yet been applied in clinical trials. These modalities
include short interfering RNA (siRNA)(Kryczek et al., 2006b), tumor vaccines (Mu et al., 2014),
blocking antibodies (Chen et al., 2012; Prasad et al., 2003; Sica et al., 2003), and antibody
drug conjugates (ADC) (Leong et al., 2015). Preclinical assessment of an ADC developed by
Genentech demonstrated durable tumor regression against human B7-H4(+) cell lines and patient
xenografts in nude or severe combined immunodeficient (SCID) mice, possibly due to antibody18

dependent cellular cytotoxicity (ADCC), antibody-dependent phagocytosis (ADP), and
complement mechanisms. Notably, the study did not report any evidence of toxicity in targeting
B7-H4 in preclinical models. Although not yet reported, immunotoxin or bi-specific therapy
could also be tested for anti-tumor efficacy.

Notably, in vivo analysis of the ability of an anti-B7-H4 B7-H4/B7-H4R blocking mAb to reduce
human tumor burden in a xenograft model has not been reported. A review by He et al. 2011
highlighted the fact that efficient neutralizing antibodies specific for human B7-H4 are not yet
widely available. To this end, Dangaj et al. identified and characterized several, novel anti-B7-H4
recombinant single chain variable fragments (scFv) isolated from a yeast display library. These
anti-B7-H4 scFvs specifically rescued T-cell function from B7-H4-mediated T-cell inhibition, as
demonstrated by increased IFN-γ secretion, up-regulation of CD69 expression, and augmented Tcell proliferation in response to anti-CD3 stimulation and inhibition through recombinant, human
B7-H4 protein (Dangaj et al., 2013a). The group also reported delayed human ovarian cancer
tumor growth with intraperitoneal injections of the anti-B7-H4 scFv in humanized NSG mice.

Rationale for B7-H4 CAR T cell Therapy
Although promising, moving forward with clinical trials utilizing scFv alone as systemic therapy
may be difficult due to problems with tumor penetration, rapid renal clearance, and lack of
effector functions. However, scFvs are versatile and can be utilized to generate a CAR. Since B7H4 plays a role in immune evasion and tumorigenesis, eliminating B7-H4 in the TME utilizing
CAR therapy could positively affect the host immune response and negatively affect tumor cell
survival simultaneously (Figure 1.8).
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An important consideration for therapeutic intervention of CAR therapy is the distribution of
antigen in normal tissue. The protein expression of B7-H4 was reported to be absent in normal
tissue from 2003-2011 (Smith et al., 2014b). However, a 2015 study reported widespread
expression in ductal epithelium of several normal human tissues (Leong et al., 2015). Reports
describing B7-H4 protein expression in normal murine tissues are limited (Hofmeyer et al., 2012;
Lee et al., 2012; Wei et al., 2011), warranting further examination.
Due to high levels of B7-H4 expression in tumor and possible limited expression in normal tissue,
we sought to accomplish the goal of Aim 2 below:

Aim 2: Develop novel B7-H4-specific CAR T-cell platforms that cross-react with both human
and murine B7-H4 in order to test the hypothesis that B7-H4 CAR T cell therapy can be
applied safely in xenograft tumor models.

Safety of engineered T cell Therapy
Toxicity in Human Clinical Studies
Severe adverse events including deaths of treated patients with TCR and CAR therapy have
occurred in clinical studies. A high affinity TCR therapy targeting the assumed cancer testis
antigen melanoma associated antigen A3 (MAGE-A3) resulted in neurologic toxicity and death
due to cross reactivity of the TCR with endogenously expressed MAGE-A family members in the
brain (Morgan et al., 2013). A concurrent study utilizing a different MAGE-A3 TCR resulted in
death following heart damage due to TCR recognition of peptide derived from titin, an unrelated
protein expressed in striated muscle (Linette et al., 2013).
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Additionally, on-target off-tumor effects can also result in toxicity. A high affinity CAR against
ErbB2 resulted in death of a patient, presumably due to expression of low levels of normal ErbB2
protein expressed in the pulmonary epithelium (Morgan et al., 2010). Toxicities utilizing TCR
platforms have been reported in clinical studies targeting MART-1 and gp100 melanoma antigens
that are also expressed in normal melanocytes in the skin, ear, and eye (Johnson et al., 2009) and
in targeting an carcinoembryonic antigen (CEA) colorectal cancer antigen that is also expressed
in differentiated epithelial cells in the GI and colon (Lamers et al., 2013; Parkhurst et al., 2011).
Lastly, patients treated with CD19 CAR therapy (Maude et al., 2014) have experienced severe
cytokine release syndrome (CRS), a release of high levels of pro-inflammatory cytokines which
correlates with patient disease burden. All CRS cases have been manageable with clinical
intervention.

Limitations of Xenograft Murine Models: Development of a Large, Outbred Model
Preclinical safety studies of T cell therapies for human cancers are typically performed in
xenograft immune deficient NOD/SCID/IL2-γnull (NSG) mouse models. These studies aim to
assess the anti-tumor efficacy of transferred human T cell treatments against human tumors prior
to translation in the clinic. In Aim 2 of our study we sought to interrogate the feasibility of safe
application of B7-H4 CAR therapy in an NSG xenograft model by devising a strategy that
targeted both human and murine B7-H4 protein. However, the specificity of most T cell therapies
is not cross reactive with the murine homolog of the TAA. Therefore, we cannot accurately
predict the safety profile of therapy directed at the antigen of interest. This is exemplified by the
studies discussed above where observed toxicities or deaths were not predicted by preclinical
murine xenograft models.
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Further, xenograft NSG models do not recapitulate many of the genetic and environmental factors
that occur in humans and in human malignancy. First, NSG mice are an inbred population that is
genetically identical. Second, mice are housed in sterile-germ free facilities that do not represent
the environmental risk factors in human disease such as diet, smoke inhalation, and lack of
exercise. Lastly, human tumors transplanted into mice may not recapitulate the complex tumor
microenvironment observed in human cancer. Therefore, we sought to accomplish the goal of
Aim 3 below:

Aim 3: Develop the methodology for treatment of companion dogs with spontaneous cancer in
order to test the hypothesis that functional tumor-specific CAR T-cells can be generated and
applied in patient dogs with spontaneous cancer to establish a large animal model for
immune therapy.
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Tables and Figures

Figure 1.1

Figure 1.1. Activation of tumor associated antigen (TAA)-specific cytotoxic T lymphocytes
(CTL). CD8+ cytotoxic T lymphocytes (CTL) provide surveillance of infected or abnormal cells. T cells
are able to “see” through expression of a T cell Receptor (TCR) comprised of an alpha (α) and beta (β)
chain in complex with CD3. TCR αβ chains interact with other cells by engaging with small 8-11 amino
acid peptides that are displayed on Major Histocompatibility Complex (MHC) molecules expressed on the
surface of the target cell. Here, a tumor cell has presented a tumor peptide derived from a native tumorassociated protein that was processed by the cell’s antigen processing machinery (APM). T cells will
recognize a target cell and become activated if a T cell’s TCR αβ chains are specific for a particular tumor
peptide/MHC complex on target cells. Activation of the T cells results in destruction of the target cell
through various mechanisms, including release of granzyme/perforin, IFN-γ, and other immune
inflammatory cytokines. Modified schematic from Kershaw et al. 2013.
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Figure 1.2

Figure 1.2.Adoptive T cell Therapy with Tumor infiltrating lymphocyte (TIL). Adoptive cell
therapy (ACT) involves manipulating a person’s T cells ex vivo outside of the human body and
reintroducing those T cells in to a patient. TIL therapy is a form of ACT that isolates T cells from the tumor
of the patient. Step 1: Tumor is resected. Step 2: The tumor mass is cut in to small samples that are grown
separately. Step 3: Tumor samples are grown in cell culture conditions optimized to preferentially activate
and expand human T cells. Following activation, T cells with anti-tumor reactivity are selected. Step 4:
Anti-tumor reactive T cells are expanded to high numbers ex vivo. Step 5: The patient is infused with high
numbers of anti-tumor reactive T cells following a lymphodepletion preconditioning regime. IL-2,
interleukin-2. Modified schematic from Rosenberg et al. 2008.
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Figure 1.3

Figure 1.3. Genetic modification of any T cell with TCR Therapy. We can re-direct the
specificity of any T cell toward a tumor associated antigen (TAA) through introduction of an exogenous
anti-TAA specific TCR. Most engineering approaches utilize retroviral vectors that enter a primary human
T cell and insert the DNA for the exogenous TCR αβ chains permanently into the T cell’s genome.
Following transduction with the retroviral vector, the T cell will express the anti-TAA TCR and can engage
and lyse cancer cells displaying that TAA peptide/MHC on the cell surface. Endogenous TCR, the natural
TCR αβ chains.

25

Figure 1.4

Figure 1.4. Schematic representation of the ErbB2 dendritic cell (DC) vaccine trial
performed by Dr. Brian Czerniecki. Peripheral blood mononuclear cells (PBMCs) were isolated from
patients with ductal carcinoma in situ (DCIS) using apheresis under monocyte enrichment settings.
Following elutriation, monocytes were cultured overnight with granulocyte macrophage colony-stimulating
factor (GM-CSF) followed by addition of one of six ErbB2 MHC class II binding peptides, three
extracellular domain peptides, and three intracellular domain peptides. If the patient was HLA-A2+,
additional MHC class I peptides were added, including the ErbB2 369-377 (E75) peptide. After additional
8-12 hours of incubation, IFN-γ was added for overnight culture. Prior to harvest, LPS was added and
peptide-pulsed DC vaccines were stored for administration. Image modified from uphs.upenn.edu.
Methodology reported by Cznerniecki et al. 2007 and Koski et al. 2012.
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Figure 1.5

Figure 1.5. Adoptive Cell Transfer of Genetically modified T cells: TCR versus CAR
Therapy. T cells can be re-directed with chimeric antigen receptors (CARs) that can overcome many of
the limitations of TCR-based therapy. CAR proteins are composed of a single chain variable fragment
(scFv) that binds tumor antigen expressed on the surface of the target cell, allowing the T cell to engage
with the tumor cell with antibody-like recognition. The scFv is combined with T cell signaling domains that
activate the T cell following scFv engagement with target antigen. The CD3ζ intracellular domain (ICD) is
used to provide signal 1 for T cell activation. The 2 nd signal is afforded by incorporation of the ICD for
various co-stimulation molecules such as CD28, 4-1BB, CD27, ICOS, and others. The scFv is joined to the
T cell signaling domains through a hinge and transmembrane domain.
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Figure 1.6

Figure 1.6. B7-H4 attenuates optimal T-cell function and augments tumor cell growth. B7H4 protein expressed on either the cancer cell or tumor-associated macrophages (TAMs) binds the putative
B7-H4 Receptor on Tumor-associated antigen (TAA)-specific T-cells. Subsequent inhibitory signaling in
the TAA-specific T-cells cause cell cycle arrest, decreased proliferation, and reduced IL-2 production. This
leads to sub-optimal cytotoxic effector functions of CD8+ TAA-specific T-cells including reduced
secretion of cytokines (IFN-γ, IL-2, and TNF) and perforin/granzyme compared to non-inhibited T-cells.
TCR, T cell receptor. Modified schematic from Smith et al. 2014 Gynecologic Oncology.
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Figure 1.7

Figure 1.7. Rescue of T-cell function by anti-B7-H4 treatment modalities. Although not yet
tested in clinical or pre-clinical models, several therapies targeting B7-H4 could have important antiinhibitory effects in the tumor microenvironment. Anti-B7-H4 oligonucleotides could destroy B7-H4
mRNA and potentially eliminate B7-H4 protein from the surface of tumor or tumor-associated
macrophages (TAMs). Anti-B7-H4 blocking antibodies could prevent B7-H4 ligation with the putative B7H4 Receptor on T cells, thereby hindering B7-H4 inhibitory signals in the TAA-specific T cells. Anti-B7H4 Immunotoxins composed of an anti-B7-H4 blocking antibody could impede B7-H4 signaling and
deliver an immunotoxin to B7-H4+ target cells. Finally, an anti-B7-H4/anti-CD3 bi-specific antibody could
also dampen B7-H4 inhibitory signaling and direct T cells to tumor cells/TAMs. All these modalities would
“rescue” Tumor-associated antigen (TAA)-specific T-cell function from B7-H4-mediated functional
inhibition. Schematic from Smith et al. 2014 Gynecologic Oncology.
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Figure 1.8

Figure 1.8. Direct Killing of B7-H4(+) Targets by Anti-B7-H4 CARs. Genetic engineering of
primary CD8+ T-cells to express anti-B7-H4 chimeric antigen receptors (CARs) that could directly kill
both B7-H4+ tumor cells and tumor-associated macrophages (TAMs), resulting in destruction of both
tumor and key components of the negative immune-modulatory tumor microenvironment. This opens the
door for further destruction of non-B7-H4-expressing tumor cells by host immune cells that may have been
previously inhibited by B7-H4. Schematic from Smith et al. 2014 Gynecologic Oncology.
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The data in the following chapter are published in Human Gene Therapy 2014 Aug;25(8):730-9.
doi: 10.1089/hum.2014.006. Data are used with permission from the publisher, Mary Ann
Liebert.
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CHAPTER 2. A novel human ErbB2-specific T cell receptor confers
potent antitumor effector functions in genetically engineered
primary cytotoxic lymphocytes

Summary
ErbB2 protein is a member of the tyrosine kinase family of growth factor receptors that is
overexpressed in cancers of the breast, ovary, stomach, kidney, colon and lung, and therefore
represents an attractive candidate antigen for targeted cancer immunotherapy. Cytotoxic Tlymphocytes (CTLs) specific for various immunogenic ErbB2 peptides have been described, but
they often exhibit both poor functional avidity and tumor reactivity. In order to generate potent
CD8+ T cells with specificity for the ErbB2369-377 peptide, we performed one round of in vitro
peptide stimulation of CD8+ T cells isolated from an HLA-A2+ patient who was previously
vaccinated with autologous dendritic cells pulsed with MHC class I ErbB2 peptides. Using this
approach, we enriched highly avid ErbB2-reactive T cells with strong ErbB2-specific, anti-tumor
effector functions. We then stimulated these ErbB2-reactive T cells with ErbB2+ HLA-A2+ tumor
cells in vitro and sorted tumor-activated ErbB2369-377 peptide T cells, which allowed for the
isolation of a novel T cell receptor (TCR) with ErbB2369-377 peptide specificity. Primary human
CD8+ T cells genetically modified to express this ErbB2-specific TCR specifically bound
ErbB2369-377 peptide containing HLA-A2 tetramers, and efficiently recognized target cells pulsed
with low nM concentrations of ErbB2369-377 peptide as well as non-pulsed ErbB2+ HLA-A2+
tumor cell lines in vitro. In a novel xenograft model, ErbB2-redirected T cells also significantly
delayed progression of ErbB2+ HLA-A2+ human tumor in vivo. Together, these results support
the notion that redirection of normal T cell specificity by TCR gene transfer can have potential
applications in the adoptive immunotherapy of ErbB2-expressing malignancies.
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Introduction
The ERBB2 (Her-2/neu) proto-oncogene encodes a member of a group of epithelial tyrosine
kinase receptors involved in the initiation and progression of diverse malignancies including
breast, ovarian, and gastric cancers (Engel and Kaklamani, 2007; Wong et al., 1995). ErbB2 gene
amplification and overexpression leads to uncontrolled cell growth and survival, increased colony
formation, (Bartsch et al., 2007) and impaired DNA repair (Pietras et al., 1994). Several different
immunotherapeutic approaches directed against ErbB2-expressing breast and ovarian tumors
have been developed to date. Anti-ErbB2 antibody based immunotherapies, such as the
monoclonal antibody trastuzumab, can treat breast cancer patients with ErbB2 overexpression,
but this approach has not been as efficacious in ovarian cancer patients (Bookman et al., 2003).
Additionally, cancer vaccines have been utilized to induce specific anti-tumor immunity, but
produced only weak T cell responses and did not induce objective tumor regression (Disis et al.,
2004; Knutson et al., 2002; Peoples et al., 2005).

T cell receptor (TCR) gene transfer has been developed over the last decade as a reliable method
to generate large numbers of T cells of a given antigen specificity for adoptive cellular therapy of
viral infectious diseases, virus-associated malignancies, and cancer (Engels and Uckert, 2007).
The clinical feasibility of TCR gene therapy was first demonstrated in melanoma using a TCR
specific for MART1, a commonly expressed melanoma antigen (Morgan et al., 2006). Adoptive
transfer of MART1 TCR-transduced CD8+ T cells in 15 patients resulted in durable engraftment
of the transferred population and significant tumor regression in two patients (Morgan et al.,
2006). We later identified a higher affinity MART-1-specific TCR that conferred improved
functional avidity and clinical efficacy in melanoma, albeit with greater incidence of vitiligo,
uveitis and hearing loss resulting from collateral destruction of normal melanocytes (Johnson et
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al., 2006; Johnson et al., 2009). Development of TCR therapy targeting MART1 demonstrates a
proof of concept of adoptive T cell transfer. However, MART1 antigen expression is restricted to
melanoma. ErbB2-directed TCR gene therapy would appear to hold significant promise for
patients with common epithelial cancers, such as ovarian and breast cancer. However, isolation of
highly avid ErbB2-specific TCRs directly from cancer patients has been challenging and not
clinically tested.

One promising strategy to generate ErbB2-specific T cells relies on vaccination of patients
bearing ErbB2+ tumors with powerful immune regimens that can overcome immunological
ErbB2 self-tolerance and prime preexisting T cell immunity. We previously demonstrated that
administration of an autologous, matured dendritic cell (DC) vaccine pulsed with ErbB2-derived
MHC class I and II peptides to HLA-A2+ patients with ErbB2+ breast tumors efficiently primed
ErbB2-specific T cells, increased their frequency, and resulted in measurable tumor regression in
some patients in an ErbB2/DC vaccine study (Czerniecki et al., 2007). In this report, we
characterize a novel ErbB2-specific TCR that was isolated from ErbB2369-377-specific CD8+ T
cells expanded from an HLA-A2 patient that was previously vaccinated on the ErbB2/DC study.
The isolated TCR conferred transduced CD8+ T cells with high specificity and avidity for the
HLA-A2 restricted ErbB2369-377 epitope, demonstrating reactivity against peptide-loaded targets
and tumor cells expressing endogenous antigen.
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Methods and materials
Cells. Retroviral packaging was performed in immortalized normal fetal renal 293GP cells kindly
provided by Dr. Paul Robbins (Center of Cancer Research, National Cancer Institute, Bethesda,
MD). Human cell lines: ovarian cancer cell lines SKOV3, OVCAR3, OVCAR-2, and OV55-2,
the human breast cancer cell lines MDA231, the human melanoma cell lines 624 and 938
(Marincola et al., 1994; Rivoltini et al., 1995), the human T cell lymphoblastic lymphoma cell
line SupT1, and the T2 lymphoblastoid cell line. Cell lines were maintained in RPMI-1640
(Invitrogen) supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum (FBS),
2mmol/l L-glutamine, 100μg/ml penicillin, and 100U/ml streptomycin. All cell lines were
routinely tested for mycoplasma contamination.

Preparation of ErbB2 peptide-loaded monocyte-derived dendritic cells. Patient MD10 treated
on Brian Czerniecki’s autologous ErbB2 peptide-pulsed DC vaccine study underwent
pretreatment leukapheresis on a Baxter CS3000 using monocyte enrichment setting in the
Apheresis Unit at the Hospital of the University of Pennsylvania under an IRB approved protocol
(Czerniecki et al., 2007). This patient’s post vaccination T cells showed evidence of a strong,
vaccine-induced anti-HER2 response against ErbB2 E75 peptide-pulsed DC cells and HLAA2(+) ErbB2(+) breast cancer cell lines ex vivo . Patient MD10’s peripheral blood monocytes
were enriched from the leukapheresis product by elutriation. Monocytes were washed, counted,
and cultured at 3x106/ml in sterile 24-well plates in RPMI medium supplemented with 10% Fetal
Bovine Serum (FBS), 500 IU/ml of recombinant research grade human granulocyte-macrophage
colony stimulating factor (GM-CSF) and 250IU/ml of interleukin-4 (IL-4) for four days. On day
5, 1,000 units/ml of IFN-γ was added in the culture followed by overnight incubation at 37°C. On
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day 6, LPS was added at 10ng/ml for 6 hours to complete maturation of the dendritic cells. The
dendritic cells’ DC1 phenotype was analyzed by flow cytometry using monoclonal antibodies
against CD80, CD86, CD83 and CD40. The DC1 were subsequently pulsed with MHC class I
binding ErbB2369-377-specific peptide at 10ug/ml, for 2 hours as described previously (Czerniecki
et al., 2007). The cells were harvested 2 hours later, washed, counted and assessed for viability
prior to co-culture with CD8+ T cells. Evripidis Lanitis completed this worked.

In vitro CD8+ T cell priming with ErbB2 peptide-pulsed dendritic cells (DC1). For collection
of vaccine primed T cells, patients underwent post-treatment leukapheresis on a Baxter CS3000
under an IRB approved protocol for human subjects research two weeks after last vaccine dose
(Czerniecki et al., 2007). Autologous ErbB2 E75 peptide-loaded dendritic cells were co-cultured
with column-purified post-vaccination CD8+ T cells at a ratio of 10:1 in 48-well plates. IL-2
(50IU/ml) was added to the cultures on day 2. After 10 days of sensitization, the CD8 + T cells
were harvested and restimulated with T2 cells pulsed with either relevant or irrelevant peptides or
tumor cell lines. Supernatants were harvested after 24 hours and analyzed by ELISA. Evripidis
Lanitis completed this worked.

Cytokine release assays. Cytokine release assays were carried out by co-culture of 1x105 T cells
with 1x105 tumor cells or peptide-loaded T2 cells per well in triplicate in 96-well round-bottom
plates in 200ul complete media. For the preparation of peptide-loaded T2 APCs, the latter were
resuspended at 1x107/ml and loaded with ErbB2 or MART1 peptides at various peptide
concentrations (1ng/ml-10ug/ml) at 37oC for 2 hours. T2 cells were then washed twice with PBS
and resuspended at 1x106/ml with RPMI-1640 supplemented with 10% heat-inactivated FBS.
After 20-24 hours, cell-free supernatants were assayed for presence of IFN-γ using the BioLegend
ELISA MAX™ Deluxe kit.
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Construction of retroviral vectors. To identify the sequences of the TCR genes, a 5’-RACEPCR (Kit) amplifying the variable regions of the TCRα and TCRβ-chains including CDR3 was
performed with RNA isolated from the T cell clones. RACE-PCR products were sequenced.
TCRα and TCRβ-chains were linked by 2A peptide linker (TCRb-P2A-TCRa) and the complete
constructs were cloned into the retroviral vector plasmid pMSGV1 vector backbone, a derivative
of the vector pMSGV [murine stem cell virus (MSCV)-based splice-gag vector] that utilizes a
MSCV long terminal repeat (LTR) (Cohen et al., 2005). 5’-RACE was completed by Paul
Robbins and Yong Li at the NCI. Evripidis Lanitis and Seleeke Flingai in our laboratory
performed molecular cloning in to the MSGV1 backbones.

Recombinant retrovirus production. Replication-defective retroviral vectors were produced as
previously described (Wargo et al., 2009). Briefly 1x106 of 293-GP cells (transient viral producer
cells) in a 6-well plate were co-transfected with 1.5μg of retroviral vector DNA from each of the
constructs and 0.5μg of envelope DNA (RD114) using the Lipofectamine 2000 reagent
(Invitrogen) and Optimem medium (BD Biosciences). Media was changed to DMEM with 10%
FBS after 18 hours and viral supernatants were harvested at the 48-hour time point.

Human T cell transduction. Primary human CD8+ T cells were purchased from the Human
Immunology Core at University of Pennsylvania and were isolated from healthy volunteer donors
following leukapheresis by negative selection. All specimens were collected under a University
Institutional Review Board-approved protocol, and written informed consent was obtained from
each donor. T cells were plated at 1x106/ml in 24-well plates (Costar) in complete media (RPMI
1640 supplemented with 10% heat-inactivated FBS, 100U/ml penicillin, 100μg/ml streptomycin
sulfate, 10mM HEPES), and stimulated with anti-CD3 and anti-CD28-mAbs coated beads as
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described by manufacturer (Invitrogen) (Levine et al., 1997) for 18-24h prior to transduction. For
retroviral transduction, non-tissue culture-treated 12-well plates (Becton Dickinson Labware,
Franklin Lakes, NJ) were treated with 25μg/ml of recombinant retronectin at 4°C as directed by
the manufacturer (RetroNectin, Takara, Otsu, Japan). After an overnight incubation, the
retronectin was removed and wells were blocked with 2% BSA in PBS at room temperature for
30 minutes. The retroviral vector supernatant (2-3ml) was then applied by centrifugation (2000x g
for 2 hours) and removed by aspiration. 5x105 of stimulated T cells were added to each well in a
final volume of 1ml RMPI growth medium. Plates were centrifuged for 10min at 1000x g and
incubated overnight. The transduction process was repeated the following day. After transduction,
the cells were grown in RPMI with 10% FBS and human recombinant interleukin-2 (IL-2)
(Novartis) was added every other day to 100IU/ml final concentration. Cell density of 0.5-1x106
cells/ml was maintained.

Flow cytometry. To determine T cell antigen specificity, CD8+ T cells were stained with antiCD8-FITC and allophycocyanin (APC)-labeled ErbB2369-377 or MART127-35 tetramer (Becton
Dickinson, San Jose, CA). To assess T cell activation phenotype, T cells were stained with the
above reagents plus a PerCPCy5.5-labeled anti-human CD69 mAb. Dendritic cell phenotype was
assessed using CD14-PerCPCy5.5, CD11c-APC, HLA-DR-PE, CD80-FITC, CD86-FITC, CD83FITC, and CD40-FITC. All antibodies were purchased from BD Biosciences.

Real Time PCR. RT-PCR was used to analyze the expression of human TAP1, TAP2, tapasin,
LMP2 (APM components) in tumor cell lines. RNA was firstly isolated from tumor cells using
the RNA easy kit (Qiagen). cDNA was then generated from 1ug of RNA using First Strand
Ready-To-Go beads (GE Healthcare). Real-time PCR was then performed in triplicates using
Applied Biosystem’s taqman primers specific for TAP1, TAP2, tapasin, LMP2 and β-actin.
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mRNA levels were normalized to β-actin and compared to mRNA levels of APM-deficient T2
cells. Data are presented as fold mRNA level. Evripidis Lanitis completed this worked.

Xenograft model of breast cancer.

All animals were obtained from the Stem Cell and

Xenograft Core of the Abramson Cancer Center, University of Pennsylvania. Mice were bred,
treated, and maintained under pathogen-free conditions in-house under University of
Pennsylvania IACUC approved protocols. For in vivo T cell functional assessment, 6-12-weekold female NSG mice were subcutaneously injected on the flank with 1x106 MDA231 cells
previously mixed with 1x106 ErbB2-specific T cells in 0.2 ml PBS. Control mice were injected
with MDA231 tumor cells mixed with 1x106 MART1-specific T cells. Each group consisted of 5
mice. Tumor growth was determined by caliper measurement over time and tumor volumes
calculated using the formula V = 1/2(length × width2), where length is the greatest longitudinal
diameter and width is the greatest transverse diameter. Mice were terminated after 40 days or
earlier if they became distressed and moribund. Following termination, tumors were resected,
photographed, and weighted.

Statistical analysis. GraphPad Prism 4.0 (GraphPad Software) was used for the statistical
analysis.
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Results
Induction of ErbB2-specific CD8+ T cells with ErbB2 peptide-loaded dendritic cells
Peripheral blood monocytes and peripheral blood T cells were obtained from an HLA-A2+ patient
(M10) that had previously been vaccinated with autologous dendritic cells (DCs) pulsed with a
cocktail of MHC class I and class II peptides, including the MHC Class I-restricted ErbB2369-377
peptide (Czerniecki et al., 2007). This patient’s post-vaccination CD8+ T cells demonstrated a
robust IFN-γ response (>350ng/mL) against autologous DCs pulsed with ErbB2369-377 peptide
following one round of in vitro stimulation and demonstrated a 73-fold increase in IFN- γ
secretion against the HLA-A2+/ErbB2+ breast cancer cell line MDA231 in comparison to IFN- γ
secretion against control cell lines (Czerniecki et al., 2007) (Koski et al., 2012). Of note, the
patient’s pre-vaccination CD8+ T cells showed low levels of IFN-γ against either target,
establishing evidence of a strong, vaccine-induced anti-ErbB2 response.

The patient’s peripheral blood monocytes were matured into DCs utilizing an in vitro protocol
and showed relatively high expression levels of CD80, CD86, CD83 and CD40 (Figure 2.1). The
matured DCs were then pulsed with ErbB2369-377 peptide and used for the in vitro stimulation of
CD8+ T cells purified from the patient’s post vaccination peripheral blood. Following 7 days of in
vitro stimulation, nearly 3% of the viable CD8+ T cell population recognized the stimulating
ErbB2369-377 peptide as assessed by binding of an HLA-A2/ErbB2369-377 tetramer (Figure 2.2).
This represented a 17-fold increase over 1 week, relative to the starting percentage of ErbB2specific T cells observed in the blood of the post-vaccinated patient. ErbB2-specific T cells did
not bind to MART-126-35 tetramer complexes, demonstrating their specificity for ErbB2369-377
peptide. In contrast, MART-1 TCR transduced T cells did not bind to ErbB2369-377 tetramer
complex, but exhibited strong binding to MART-126-35 tetramer complexes (Figure 2).
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Collectively, ErbB2 peptide-loaded DCs were capable of boosting the frequency of ErbB2369-377
peptide-specific T cells.

ErbB2-specific CD8+ T cells exert potent effector functions against ErbB2 peptide-loaded
targets and ErbB2-expressing cancer cells
To evaluate their effector functions, ErbB2-specific T cells were initially exposed to HLA-A2+
T2 cells pre-loaded with ErbB2369-377 peptide. ErbB2-specific T cells displayed high peptidespecific IFN-γ production upon co-culture with antigen presenting cells (T2 cells) loaded with
relevant ErbB2 peptide. As expected, no IFN-γ was produced upon exposure to T2 cells pulsed
with irrelevant MART-126-35 peptide. As a positive control for functionality, MART-1 specific T
cells recognized and reacted against MART-126-35 peptide-loaded T2 cells (Figure 2.3a).

We further evaluated the functional avidity of these T cells by analyzing the production of IFN-γ
in response to incubation with T2 target cells pulsed with titered amounts of ErbB2369-377 peptide.
ErbB2369-377-specific T cells exerted high functional avidity, as they were capable of secreting
high amounts of IFN-γ even at low concentrations (1nM) of specific peptide (Figure 2.3b). We
therefore investigated if the ErbB2-specific T cells were able to recognize endogenously
processed ErbB2369-377 peptide. Co-culture assays were performed utilizing ErbB2-specific T cells
with HLA-A2 matched or mismatched ovarian, breast, and melanoma cancer cells that express
different levels of ErbB2 protein (Lanitis et al., 2012a). ErbB2369-377-specific CD8+ T cells
specifically recognized and secreted IFN-γ upon interaction with ErbB2+ HLA-A2+ ovarian or
breast cancer cells, while no recognition of HLA-A2- or ErbB2- tumors was observed (Figure
2.3c) There was no correlation between the intensity of ErbB2 surface expression by tumor cell
lines and the IFN-γ secretion by T cells (data not shown).
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To this end, we investigated the expression of various components of antigen processing
machinery (APM) by tumor cells, including TAP1, TAP2, tapasin and LMP2 via real time PCR
(RT-PCR) to determine if deficiencies existed in the peptide-processing pathway of these tumor
cells. ErbB2+ tumor cell lines that were recognized to a lesser extent by the ErbB2369-377-specific
T cells (SKOV-3 and OVCAR-3) (Figure 2.3c) displayed a reduced mRNA expression of tested
APM molecules (Figure 2.3d). Tumor cell lines that were well recognized by the ErbB2369-377specific T cells (OVCAR-2, OV55-2 and MDA231) (Figure .3c) displayed a higher level of
expression in most of the APM molecules investigated (Figure 2.3d). Therefore, lack of
recognition of some ovarian tumors by ErbB2369-377-specific T cells may be attributed, in part, to a
lack of necessary APM components in the tumor cells, as observed elsewhere (Han et al., 2008).
This observation highlights that both ErbB2 and HLA-A2 molecules are required, but not
sufficient, for optimal immune recognition. Together, we conclude that vaccine-primed ErbB2369377-specific

T cells exert potent effector functions against peptide-loaded targets and HLA-A2

matched ErbB2-expressing tumor cells.

Identification and isolation of ErbB2-specific TCR α/β genes
Tumor recognition by T cells is often accompanied with specific up-regulation of T cell
activation surface antigens such as the early activation marker, CD69. In order to capture
ErbB2369-377-specific T cells with high avidity for tumor-presented ErbB2369-377 peptide, we cocultured the ErbB2-specific T cells with HLA-A2+ ErbB2+ MDA231 cells for 24 hours. ErbB2specific T cells that up-regulated CD69 (Figure 2.4) and bound HLA-A2/ ErbB2369-377 tetramer
were then isolated via fluorescence-activated flow sorting (FACS). In order to determine the TCR
variable (TCRV) α-chain and TCRVβ-chain repertoire of the captured ErbB2-specific T cells,
total RNA was isolated from the sorted cells and subjected to 5′ RACE. Twenty-three individual
α-chain cDNA clones and fourteen individual β-chain cDNA clones were fully sequenced from
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two independent PCR reactions. Sequence data demonstrated two relatively dominant sequences
in the TCRVβ repertoire that belonged to the BV3-1(9S1) family of β-chains. More heterogeneity
was observed in the TCRVα repertoire, with two repeats each for the AV3 and the AV12-1 αchains (Table 2.1).

TCR α and β chains were subcloned into the MSGV-1 retroviral backbone. Combinations were
combined empirically, beginning with the α and β chains that appeared more than once in the
sequencing results (Table 2.1, left). We began testing by constructing eight retroviral vectors
harboring the α- and β-chain cDNAs (Table 2.1, right). Retroviruses encoding the eight different
TCR α/β combinations were produced and utilized for the transduction of SupT1 cells.
Subsequently, the genetically-modified SupT1 cells were stained with HLA-A2/ ErbB2369-377
tetramer and assessed via flow cytometry to identify TCRs with specificity for the ErbB2369-377
peptide. One out of eight (1/8) TCR combinations exhibited specific and strong binding to the
HLA-A2/ ErbB2369-377 tetramer (Figure 2.5a). Hence, this paired TCR harboring the AV3 α-chain
and the BV3-1 β-chain was chosen for further characterization (herein referred to as HLAA2/ErbB2 TCR7).

Retroviral transfer of ErbB2369-377-specific TCR7 into CD8+ T cells confers antigen
specificity
We next investigated the functional properties that TCR7 confers upon expression in primary
human T cells. Retroviral TCR gene transfer into CD8+ T cells resulted in specific HLA-A2/
ErbB2369-377 tetramer binding (Figure 2.5b). However, the percentage of tetramer+ cells was low
(~10%) when compared to SupT1 cells, suggesting that transduced TCRs may not be well enough
assembled to be detected or that mispairing with endogenous α-chains may occur. Importantly,
however, even at low tetramer binding frequencies the ErbB2 TCR7 transduced T cells
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demonstrated specific, robust reactivity against peptide-pulsed APC targets (Figure 2.6a). ErbB2
TCR T cells demonstrated high peptide avidity, as they secreted high IFN-γ levels at peptide
concentrations as low as 1ng/ml (Figure 2.6c). Upon analyzing the tumor reactivity of the ErbB2
TCR CD8+ T cells, we observed IFN-γ secretion in response to HLA-A2+ ErbB2+ OVCAR-2 and
MDA231 tumor cells at levels similar to that produced by the initial ErbB2 polyclonal T cell
population (Figures 2.3c and 2.6b). No reactivity was observed against tumors lacking HLA-A2
or ErbB2 expression or HLA-A2+ 624 melanoma cells expressing very low levels of ErbB2
(Figure 2.6b). Additionally, recent work has demonstrated that ErbB2369-377-specific T cells cross
react with overlapping MHC Class I-restricted ErbB2373-382 peptide (Henle et al., 2013). We tested
the reactivity against ErbB2

373-382

peptide-pulsed APC targets and were unable to detect IFN-γ

production by ErbB2369-377 TCR7-transduced T cells, suggesting that our TCR does not cross react
with the ErbB2373-382 peptide (Figure 2.7).

Lastly, we tested the hypothesis that ErbB2 and HLA-A2 protein expression is necessary for the
specific recognition of MDA231 by ErbB2369-377-specific T cells. This work was reported in Datta
et al. 2015 and performed by members of Dr. Brian Czerniecki’s laboratory at the University of
Pennsylvania. Knocking down ErbB2 and HLA-A2 revealed that specific recognition of
MDA231 by HER2369-377-specific T cells is abrogated by reduction of either ErbB2 or HLA-A2
protein expression (Figure 2.8). These data provide additional evidence to support our finding
that ErbB2369-377 TCR7-transduced T cells recognize endogenously processed and presented
ErbB2 protein in a HLA-dependent manner (Datta et al., 2015).

T cells expressing ErbB2369-377-specific TCR7 delay tumor growth in vivo
To determine the anti-tumor efficacy of T cells expressing ErbB2369-377-specific TCR7 in vivo, we
subcutaneously co-injected equal numbers of TCR7- or control MART-126-35 TCR-transduced
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CD8+ T cells and MDA231 tumor cells into NOD/SCID/IL2-gcnull (NSG) mice and monitored
tumor outgrowth. MDA231 tumors grew aggressively with palpable tumors evident 14 days after
injection. Compared to MART-1 TCR-specific T cells, ErbB2 TCR7-transduced T cells were
capable of significantly delaying tumor burden over time (Figure 2.9a). At the termination of the
study, mice were euthanized and tumors were excised. Consistent with measured tumor volume
(Figure 2.8a), resected tumors from the ErbB2 TCR7 group were visibly smaller (Figure 2.9b)
and weighed significantly less compared to those in mice treated with the MART-1 TCR (Figure
2.9c).
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Discussion
Introduction of tumor-specific TCR genes has been proposed as a method to produce de novo
antitumor lymphocytes for cancer immunotherapy without the need to isolate tumor-reactive T
cells (Cordaro et al., 2002; Sadelain et al., 2003; Schumacher, 2002; Willemsen et al., 2003).
This proposition requires the existence of tumor antigens common to divergent human cancers
and the isolation of a tumor-reactive TCR from the appropriate T cell population that recognizes
these natural tumor antigens.

Since its discovery, the synthetic ErbB2369-377 peptide has been widely investigated for the ex vivo
and in vivo generation of ErbB2-specific CTLs following stimulation in vitro (Anderson et al.,
2000; Brossart et al., 1998; Keogh et al., 2001; Liu et al., 2004; Rongcun et al., 1999; Seliger et
al., 2000; zum Buschenfelde et al., 2002) or vaccination (Brossart et al., 2000; Knutson et al.,
2002; Murray et al., 2002; Peoples et al., 2005; Zaks and Rosenberg, 1998).

Although some

ErbB2-specific T cells exert high reactivity against ErbB2-peptide, many fail to recognize
endogenously processed peptide presented by ErbB2+ tumors (Conrad et al., 2008; Zaks and
Rosenberg, 1998).

Recent work has demonstrated that ErbB2369-377-specific T cells cross react with overlapping
MHC Class I-restricted ErbB2373-382 peptide (Henle et al., 2013). ErbB2373-382 has been shown to
be naturally processed and ErbB2373-382-specific T cells demonstrated cross reactivity with
ErbB2369-377 peptide (Henle et al., 2013). Therefore, we determined if our ErbB2369-377 TCR7 cross
reacted with ErbB2373-382 peptide. ErbB2369-377 TCR7-transduced CD8+ T cells were co-cultured
with 1ug/mL of ErbB2369-377, ErbB2373-382, or control peptides for 24 hours. Analysis of IFN-γ by
ELISA revealed recognition of ErbB2369-377, but not ErbB2373-382,-peptide pulsed T2 cells. These
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data demonstrate that activity of the ErbB2369-377 TCR7(+) T cells is not due to recognition of the
overlapping ErbB2373-382 peptide.

We sought to isolate and test ErbB2-reactive T cells from HLA-A2+ patients with ErbB2+ breast
tumors that had been vaccinated with autologous preconditioned dendritic cells (DC1) pulsed
with ErbB2 MHC class I and II peptides (Czerniecki et al., 2007). Dendritic cells polarized
toward the DC1 phenotype produce cytokines and chemokines critical for maximizing antitumor
immunity (Xu et al., 2003) and therefore may enhance the efficacy of antitumor vaccines and
offer a strong approach to induce and expand tumor-reactive T cells in vivo and ex vivo. After one
round of ex vivo stimulation with DC1 cells loaded with ErbB2369-377 peptide, the frequency of
ErbB2369-377 peptide-specific T cells increased to a level (~3.4%) sufficient for robust downstream
functional analysis. Of note, these T cells we capable of recognizing peptide loaded onto T2 cells
at nM levels, but also HLA-A2+ ErbB2-expressing tumors. Fluorescence-activated cell sorting
allowed us to maximize the purity of ErbB2-specific T cells (~95%), and molecular analysis of
the TCR repertoire and subsequent testing of various TCR α and β combinations led us to identify
and isolate a novel ErbB2369-377-specific TCR (TCR7 AV3/BV3-1).

Retroviral particles encoding the ErbB2 TCR were propagated and utilized for the genetic
engineering of primary T cells. We routinely observed nearly a10% TCR expression efficiency by
transduced T cells, as measured by binding to ErbB2369-377 multimers. Although the percentage of
multimer+ cells was low in primary human T cells, we observed high expression of ErbB2 TCR in
SupT1 cells (~80%) that lack endogenous TCR α and β chains. Additionally, transduction of
primary human T cells with a HER TCR7 third-generation lentiviral vector that included a green
fluorescent protein (GFP) reporter demonstrated a similar frequency of tetramer(+) cells (~10%),
despite a high frequency (>50-90%) of GFP(+) T cells (data not shown). These data suggest that
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mispairing with endogenous TCR α/b-chains may impair proper assembly of the exogenous TCR
chains on the surface of the transduced T cells. Nevertheless transduced T cells demonstrated
HLA-A2-restricted, ErbB2-specific effector T cells functions, as measured by cytokine release
against peptide-pulsed targets and HLA-A2+ ErbB2+ ovarian and breast cancer tumor cells lines.
Similar to the starting ErbB2-specific T cell population, high functional avidity of the ErbB2369-377
TCR transduced T cells was demonstrated by their ability to recognize T2 cells pulsed with very
low amounts of the cognate peptide (1ng/ml) and their ability to significantly delay tumor
outgrowth in a human breast cancer xenograft model.

Further preclinical refinement of this TCR gene approach is warranted in order to lessen chimeric
dimer formation and increase the expression of the exogenous TCR on the T cell surface. This
can be achieved by replacing the constant region of the human TCR chains by their murine
counterparts (Cohen et al., 2006), the introduction of additional cysteine residues within the
constant region of the TCR α and β chains (Cohen et al., 2007; Voss et al., 2008), the provision
of exogenous CD3 molecules (Ahmadi et al., 2011), and/or the inclusion of zinc finger nuclease
(Provasi et al., 2012), CRISPR technology or small interfering RNA (siRNA) to specifically
down-regulate the endogenous TCR (Okamoto et al., 2009). We expect that methods to increase
the frequency of ErbB2369-377 TCR transduced T cells will lead to enhanced anti-tumor efficacy in
vivo. Loss of ErbB2369-377 antigen/MHC-I expression may, in part, also explain tumor outgrowth
seen in the xenograft model system. Alternatively, the reactivity of ErbB2 TCR T cells can be
potentiated by immune checkpoint blockade via the co-administration of recombinant human
antibodies specific for negative immunoregulatory molecules, such as B7-H4, which is often
expressed by tumor cells (Dangaj et al., 2013a).
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In summary, the ErbB2369-377-specific TCR described here represents an “off-the-shelf” reagent
that can be utilized to generate autologous tumor antigen-specific T cells without the need to
identify antitumor T cells unique for each patient. This approach can yield sufficient numbers of
T cells with high avidity and specificity for the ErbB2369-377 peptide for the treatment of a variety
of common epithelial malignancies.
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Tables and figures

Table 2.1
Table 2.1: TCR α and β DNA constructs
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Figure 2.1

Figure 2.1. Polarized DC1 cells exhibit characteristics of mature dendritic cells. Peripheral
blood monocytes were differentiated to immature dendritic cells (iDCs) upon culture in complete medium
in the presence of GM-CSF and IL-4 for four days. Mature dendritic cells (mDCs) were obtained upon
stimulation of iDCs with IFN-γ and LPS. mDCs were harvested and assayed for their expression of CD80,
CD86, CD83 and CD40 via flow cytometry analysis using specific antibodies. mDCs demonstrated high
levels of expression of CD80, CD83, CD86 and CD40.
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Figure 2.2

Figure 2.2. ErbB2–pulsed DC1 increase the frequency of ErbB2-directed T cells. CD8+ T cells
were purified from a patient with ductal carcinoma in situ (DCIS) post administration of the ErbB2-pulsedDC1 vaccine and co-cultured for 7 days with ErbB2369-377 peptide-pulsed autologous dendritic cells. After 1
week, CD8+ T cells were harvested and analyzed via flow cytometry with labeled tetramer bound to
ErbB2369-377 or MART126-35. MART1 T cells served as negative control effector cells. The percentage of
positive cells for CD8 and ErbB2 are indicated on the dot plot.
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Figure 2.3

Figure 2.3. ErbB2369-377-specific T cells strongly recognize peptide-pulsed T2 cells and
differentially recognize HLA-A2-restricted ErbB2-expressing tumor cells. (a)IFN-γ production
of ErbB2369-377-specific T cells in response to peptide-pulsed targets. ErbB2 or MART1–specific T cells
were co-cultured with T2 cells loaded with HLA-A2-restricted ErbB2369-377 or MART126-35 peptide for
18hours. (b) ErbB2369-377-specific T cells exhibit high avidity against the relevant peptide. ErbB2369-377specific T cells were incubated for 18hours with T2 cells pulsed with a range of titrated concentrations of
ErbB2369-377 peptide. MART1 T cells served as negative control effector T cells and T2 pulsed with the
MART126-35 served as negative control target T cells. (c) ErbB2 or MART1-specific T cells were cultured
alone (none) or stimulated overnight with human HLA-A2-restricted ErbB2+ established cancer cell lines.
SKOV-3 (HLA-A2- ErbB2+) and CEM (HLA-A2- ErbB2–) served as negative control tumor targets. (d)
Antigen processing machinery (APM) expression of HLA-A2-restricted ErbB2-expressing tumor cell lines.
The mRNA levels of human TAP1, TAP2, TAPASIN and TAP2 were quantified by real time PCR. mRNA
levels are expressed as fold increase over the APM-negative T2 cell line. β-actin was used as an
endogenous gene control. Results depict the mean ± SD of triplicate wells. For all assays, IFN-γ was
quantified from cell-free supernatants by ELISA and is reported as the mean concentration (pg/ml) ± SEM
of duplicate wells.
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Figure 2.4

Figure 2.4. ErbB2-expressing cancer cells stimulate an activated phenotype of ErbB2specific T cells. ErbB2-specific T cells express the CD69 early activation antigen in response to ErbB2specific stimulation. ErbB2-specific T cells were cultured without target cells (none) or with the indicated
ErbB2-negative or -positive established tumor cell targets for 24 hours. After the incubation period, the T
cells were stained for CD8, ErbB2 tetramer and CD69 and analyzed by flow cytometry. CD8+
ErbB2
tetramer+ CD69+ T cells were then sorted using FACS.
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Figure 2.5

Figure 2.5. Expression of the ErbB2 TCR on retrovirally transduced SupT1 cells and CD8+
T cells. (a)Screening of TCR α/β pairs by retroviral transduction of SupT1 cells. Retroviruses encoding
eight different TCR combinations were screened for ErbB2 369-377 specificity by transduction of SupT1 cells.
HLA-A2/ErbB2369-377 tetramer staining of the genetically modified SupT1 cells was performed five days
after transduction and analyzed by flow cytometry. Two representative SupT1 populations are shown, each
bearing different TCRs whose alpha and beta chains were isolated from the ErbB2-specific polyclonal
CD8+ T cells. Untransduced (NV) and MART1 SupT1 cells served as negative controls for HLAA2/ErbB2369-377 tetramer binding. (b) HLA-A2/ErbB2369-377 tetramer staining of primary TCR-transduced
CD8+ T cells. CD8+ T cells transduced with either the ErbB2 TCR7 or the MART1 TCR and untransduced
CD8+ T cells (NV) were stained with the indicated HLA-A2/peptide tetramers. Numbers represent the
percentage of tetramer+ cells.
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Figure 2.6

Figure 2.6. IFN-γ production in response to ErbB2-peptide loaded targets and ErbB2expressing cancer cell lines in vitro. (a). ErbB2 or MART1 TCR transduced T cells were co-cultured
with T2 cells loaded with HLA-A2-restricted ErbB2369-377 or with MART126-35 for 18 hours. (c). ErbB2 or
MART1 TCR transduced T cells were cultured alone (none) or stimulated overnight with human HLA-A2restricted ErbB2+ established cancer cell lines. SKOV-3(HLA-A2- ErbB2+) and CEM (HLA-A2- ErbB2–)
served as negative control tumor targets.(c)CD8 + T cells transduced with the ErbB2369-377-specific TCR as
well as the control MART1 TCR were incubated 11 days after transduction for 18 hours with T2 cells
pulsed with a range of titrated concentrations of ErbB2 369-377 peptide. T2 pulsed with MART126-35 peptide
served as negative control target T cells. (d). ErbB2 or MART1 TCR transduced T cells were co-cultured
with T2 cells loaded with 1ug/mL of ErbB2 369-377 or MART126-35 for 24 hours. For all assays, IFN-γ was
quantified from cell-free supernatants by ELISA and is reported as the mean concentration (pg/ml) ± SEM
of duplicate wells.
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Figure 2.7
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Figure 2.7. ErbB2369-377 TCR7-transduced T cells do not cross react with ErbB2373-382
peptide. Primary human T cells transduced to express ErbB 369-377 TCR7 were co-cultured with
T2 antigen presenting cells (APCs) pulsed with the with the indicated peptide. All conditions
utilized 1ug/mL peptide. IFN-γ was assessed in 24-hour supernatant by ELISA. Error bars
represent mean +/- SD.
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Figure 2.8

Figure 2.8. ErbB2369-377 TCR7-transduced T cells recognize endogenously processed and
presented ErbB2 protein in a HLA-dependent manner. (a) surface ErbB2 and HLA-A2
expression in MDA231 cells following treatment with non-targeting (NT) or ErbB2 siRNA evaluated by
flow cytometry (PE anti-HER2:x-axis vs. FITC anti–HLA-A2:y-axis) and Western blot analysis (vinculin
as loading control). Representative images are shown. ErbB2 369–377-sensitized (left) and ErbB2369–377-TCR–
transduced (right) CD8 T cell recognition of MDA231 cells was abrogated by ErbB2 silencing. (b) HLAA2 silencing with HLA-A2, but not NT, siRNA confirmed by flow cytometry. In representative panels,
filled traces represent isotype-matched control staining, and open traces represent FITC anti–HLA-A2
staining. Erbb2369–377-sensitized CD8 T-cell recognition of MDA231 was abrogated by silencing HLA-A2.
All results are representative of three experiments and are expressed as mean SEM. ** p < 0.01; , ***p <
0.001.
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Figure 2.9

Figure 2.9: T cells expressing ErbB2369-377-specific TCR7 delay tumor growth in vivo. T cells
expressing ErbB2369-377-specific TCR7 delay tumor growth in vivo. Retrovirally transduced ErbB2 TCR7
CD8+ T cells and the breast cancer cell line MDA231 were co-injected subcutaneously into the flank of
NSG mice on Day 0. MART1-specific F5 TCR-transduced T cells co-injected with MDA231 were used as
controls. (a) Tumor growth was determined by caliper measurement over time. Results are expressed as
mean tumor volume (mm3 ± SEM) with n= 5 for all groups. Statistical significance of p<0.05 is reported as
*p=0.0495, **p=0.0075, ***p= 0.0029. After 35 days tumors were resected, photographed (b), and
measured for tumor weight (c). TCR, T cell Receptor; NSG,NOD/SCID/γ-chain
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CHAPTER 3. Targeting of B7-H4 with CAR T cells results in tumor
response and off-tumor toxicity in a preclinical model

Summary
B7-H4 is a protein in the B7 family that is frequently overexpressed in cancer. Here, we tested
the hypothesis that targeting of ovarian tumor cells expressing endogenous B7-H4 can be
achieved using B7-H4 chimeric antigen receptor (CAR) T cells. We generated four, independent
anti-B7-H4 CAR lentiviral vectors that were efficiently expressed in primary human T cells. Each
CAR was capable of binding human and murine recombinant B7-H4 protein with distinct binding
patterns, establishing cross reactivity of the therapy. High binding B7-H4 CAR T cells
specifically secreted IFN-γ and lysed B7-H4(+) targets. In vivo, transferred B7-H4 CAR T cells
exerted anti-tumor activity against B7-H4(+) ovarian tumor xenografts. Unexpectedly, B7-H4
CAR T cell-treated mice reproducibly showed delayed, lethal toxicity 6-8 weeks after therapy.
We therefore comprehensively determined murine B7-H4 protein distribution via IHC,
uncovering expression in ductal and mucosal epithelial cells in several tissues including the lung,
liver, and pancreas. Postmortem analysis revealed the presence of widespread histologic lesions
that correlated with B7-H4(+) tissues, and were inconsistent with graft versus host disease
(GVHD). Lastly, expression patterns of B7-H4 protein in normal human tissue were comparable
to distribution in mice, advancing our understanding of B7-H4. We conclude that CAR T cellbased targeting of B7-H4 mediates control of B7-H4(+) cancer outgrowth in vivo. However,
long-term engraftment of B7-H4 CAR T cells mediates lethal, off-tumor toxicity that is likely due
to wide expression of B7-H4 in healthy mouse organs. This model system provides a unique
opportunity for preclinical evaluation of safety approaches that limit CAR-mediated toxicity after
tumor destruction in vivo.
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Introduction
Ovarian cancer (OC) is the fifth most common cause of cancer-related deaths among women in
the United States. In 2015, approximately 21,000 women will receive a new diagnosis and 14,180
women will die of OC (Society, 2015). Primary treatments include cytoreductive surgery and
chemotherapy, however, many women relapse and ultimately die of their disease (Coleman et al.,
2013).

Engineering T-cells with chimeric antigen receptors (CARs) is a pioneering therapy afforded by
expression of a synthetic receptor that engages potent T-cell signaling domains through MHCindependent, B cell receptor-like recognition (Gross et al., 1989). CAR therapy has successfully
targeted hematological malignancies (Grupp et al., 2013; Maude et al., 2014; Porter et al., 2011).
However, antigen-specific T-cell therapies targeting solid, epithelial tumors have not been
efficacious to date. Many factors contribute to the lack of success including heterogeneity of
tumor-associated antigens, inefficient trafficking and penetration of solid tumor masses, and
expression of the target antigen in vital healthy tissues (Kakarla and Gottschalk, 2014).

B7-H4 was identified in 2003 and is less characterized than its fellow B7 family members PD-L1
and PD-L2, which only share 25% amino acid homology with B7-H4 (Hansen et al., 2009).
Notably, the murine B7-H4 homolog shares 87% amino acid homology with human B7-H4
(Prasad et al., 2003; Sica et al., 2003; Zang et al., 2003). B7-H4 messenger RNA (mRNA) and
protein are highly overexpressed in various types of human malignancies, including ovarian
cancer (Choi et al., 2003; Dangaj et al., 2013b; Salceda et al., 2005; Tringler et al., 2006). In
normal murine and human tissue, B7-H4 mRNA is widely expressed in non-lymphoid tissues
(Choi et al., 2003; Rahbar et al., 2015; Sica et al., 2003; Wei et al., 2011; Zang et al., 2003), but
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evaluation of protein expression has been inconsistent across publications (Smith et al., 2014b).
In 2015, Leong et al. reported positive B7-H4 staining in the ductal epithelium of several normal
tissues including the breast, pancreas, and kidney (Leong et al., 2015), notably distinct from the
primarily lymphoid distribution of PD-L1 and PD-L2 under non-inflammatory conditions
(Ritprajak and Azuma, 2015). Additionally, use of an anti-B7-H4 antibody-drug conjugate did
not result in toxicity in preclinical models, suggesting that B7-H4-targeted therapy could be
applied safely. Reports describing B7-H4 protein expression in normal murine tissues are limited
(Hofmeyer et al., 2012; Lee et al., 2012; Wei et al., 2011), warranting further examination.

Surface B7-H4 protein binds a currently unknown receptor(s) on activated T-cells that results in
inhibition of T-cell effector function via cell cycle arrest (Sica et al., 2003), decreased
proliferation (Prasad et al., 2003; Sica et al., 2003; Zang et al., 2003), and reduced

IL-2

production (Prasad et al., 2003; Sica et al., 2003; Zang et al., 2003) in vitro. In addition to B7H4’s extrinsic effects on the immune system, tumor cells expressing B7-H4 demonstrate
augmented tumor cell proliferation (Cheng et al., 2009; Zhang et al., 2013), superior antiapoptotic ability (Salceda et al., 2005), and increased tumor growth even in the absence of a
competent immune system (Cheng et al., 2009; Salceda et al., 2005; Zhang et al., 2013).
Preclinical models of autoimmunity (Azuma et al., 2009; Lee et al., 2012; Wei et al., 2011),
infection (Hofmeyer et al., 2012; Suh et al., 2006; Zhu et al., 2009), and cancer (Abadi et al.,
2005; Leung and Suh, 2013) further implicate B7-H4 as a negative immune regulator of T-cells,
neutrophils, and myeloid-derived suppressor cells. Although more recent studies suggest a
positive or bystander role for B7-H4 in spontaneous tumor development (Kreymborg et al., 2015;
Rahbar et al., 2015), its continued expression by cancer cells makes B7-H4 an attractive target for
therapy if treatment is shown to be safe in preclinical models.
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We hypothesized that B7-H4-directed CAR T-cell therapy could be a promising new therapeutic
option in OC. However, concerns about expression in normal tissue may result in toxicity post
treatment. Therefore, we comprehensively assessed expression of B7-H4 protein in murine tissue
and developed a novel B7-H4-specific CAR T-cell platforms that cross-react with both human
and murine B7-H4, allowing us to test both anti-tumor efficacy and safety of B7-H4 CAR T-cells
using in vivo xenograft tumor models.
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Methods and materials
Construction of the B7-H4 CAR vectors: Fully human anti-B7-H4 scFv sequences (Dangaj et
al., 2013b; Dangaj and Scholler, 2015) were amplified via polymerase chain reaction (PCR) from
plasmids containing each soluble scFv sequence using the following primers:
26-Sense 5’-ACGCAGATCTGATATTGTGATGACTCAGACTCCAGC-3’ (BglII), Anti-sense
5’-ACGCGCTAGCTTGTTCGGATCCCTCGAATGAAGAG-3’
ACGCAGATCTCAGCCTGTGCTGACTCAGTCCCACT-3’
GCTAGCTTGTTCGGATCCCTCGAATGAAGAG-3’

(NheI);

(BglII),

Anti-sense

(NheI);

ACGCTGATCACAGCCTGGGCTGACTCAGCCACCCT

(BclI),

ACGCGCTAGCTTGTTCGGATCCCTCGAATGAAGAGACG-3’
ACGCAGATCTCGGCCCGTGCTGACTCAGCCACCCT-3’
ACGCGCTAGCTTGTTCGGATCCCTCGAATGAGGAGA-3’

56-Sense

(NheI).

5’-ACGC

3#68-Sense

5’-

Anti-sense

5’-

(NheI);

(BglII);

5’-

54-Sense
Anti-sense
Amplified

5’5’scFv

sequences were digested with the underlined restriction enzymes and ligated into BamHI/NheI
digested backbone of a third generation, self-inactivating pELNS lentiviral vector containing GFP
(Lanitis et al., 2012b).

Control 3#68 B7-H4 CAR constructs: The 3#68-CD28 chimera (which contains the full CD28
endodomain) and the 3#68-null (which contains the first five amino acids of the CD28 domain)
were created by amplifying the CD28 intracellular domain via polymerase chain reaction (PCR)
from the parental pELNS GFP 2A 3#68-CD28Z CAR construct described in the materials and
methods. We used the following primers: 3#68 B7-H4 chimera- CD28F- Sense 5’ACGCGCTAGCACCACGACGCCAGCGC-3’ (NheI is underlined) and CD28R- Antisense 5’ACGCGTCGACTTAGGAGCGATAGGCTGCGAAGTCGC (SalI is underlined, stop codon is
bold face); 3#68 B7-H4 null- CD28F- Sense 5’-ACGCGCTAGCACCACGACGCCAGCGC-3’
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(NheI is underlined) and Antisense 5’- ACGCGTCGACTTAGCTCCTCTTACTCCT-3’ (SalI is
underlined, stop codon is bold face). The amplified CD28 domain and the short CD28 sequence
were digested with NheI and SalI restriction enzymes and ligated into the parental pELNS 3#68CD28Z CAR plasmid that was previously digested with NheI and SalI, to create the 3#68-CD28
chimera and the 3#68-null, respectively.

Recombinant lentiviral vector production: Replication-defective lentiviral vectors
produced as

were

previously described (Lanitis et al., 2012b). Briefly, HEK293T cells were

transfected with pELNS transfer plasmid and lentiviral packaging plasmids pVSV (VSV
glycoprotein expression plasmid), pRSV.REV (Rev expression plasmid), and pMDLg/p.RRE
(Gag/Pol expression plasmid). 24 and 48-hour supernatants were collected and concentrated by
ultracentrifugation (Beckman Coulter) at 26,000 rpm for 2 hours. Concentrated virus was stored
at -80oC until use. Titer was determined by GFP reporter or idiotype expression 2-3 days post
transduction in HEK293T cells.

Human T cell transduction: Primary human T cells were purchased from the University of
Pennsylvania Human Immunology Core. Specimens were obtained from healthy donors with
written consent under an approved University Institutional Review Board protocol. Human
CD4(+) and CD8(+) T cells were stimulated with anti-CD3/CD28 beads (Invitrogen) at a 3:1
ratio. Lentiviral vectors (MOI 5-10) were added 24 hours post activation. T cell cultures were
maintained in complete media (CM) composed of RPMI 1640-Glutamax, 10% heat-inactivated
fetal bovine serum (Sigma), 100IU/mL penicillin (Gibco), and 100IU/mL streptomycin (Gibco).
50-100IU/mL recombinant, human IL-2 (Peprotech) was added to CM until two days before
functional assays.
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Cell lines: Established human cell lines OVCAR3, OVCAR5, SKBR3, MDA231 (HTB-26),
MDA468 (HTB-132), and HEK293T were purchased from American Type Culture Collection
(ATCC). The human ovarian cancer cell line C30 was provided by George Coukos (Ludwig
Institute for Cancer Research). Human melanoma cell line 624 was provided by S.A. Rosenberg
(National Cancer Institute /National Institute of Health). The EBV-transformed B cell line, EBVB, was provided by Raj Somasundaram (Wistar Institute). All cell lines were cultured in CM at
37oC. B7-H4 expression was tested when cells were confluent. 624, MDA231, OVCAR3 were
transduced with lentiviral GFP.2A.firefly luciferase to generate lines for cytotoxicity and
xenograft experiments. All cells lines were routinely tested for mycoplasma contamination.

Flow Cytometry: Mouse anti-human B7-H4 (AMP6H3) and the humanized version (AMP841)
were kindly provided by Amplimmune. AMP6H3/AMP841 cross react with mouse B7-H4.
Mouse anti-human B7-H4 (MIH43)-PE was purchased from AbD Serotec. The cell viability
solutions 7AAD (BD Biosciences) or fixable viability dye eFluor506 (eBioscience) were used to
remove dead cells from analysis. Recombinant human FRα (R&D Systems), human B7-H4
(Dangaj et al., 2013b), and mouse B7-H4 (R&D Systems) proteins were biotinylated as per the
manufacturer’s instructions (EZ-Link Sulfo-NHS-LC-Biotin, Thermo). Streptavidin APC
(eBioscience) was utilized as a secondary reagent. Data was acquired on a BD FACS Canto II
with Diva Software and analyzed using Flojo 7.6.5.

Cytokine release/Cytotoxicity: Functional assays were set up once T cells were rested (size
<300-350fL, Multisizer Coulter Counter, Beckman Coulter). Viability and number of cells was
enumerated using a hemacytometer. T cell populations were normalized by addition of
untransduced T cells to achieve the same frequency of CAR(+) cells in each population.
Transduction efficiency was generally between 50-70%. Cytokine release: 1e6 T cells were co66

cultured with 1e6 tumor cell targets in 200uL CM in triplicate wells. After 72 hours, IFN-γ
production in cell-free supernatants was assessed via enzyme-linked immunosorbent assay
(ELISA)(BioLegend). Cytotoxicity: 0.2e6 luciferase(+) targets were plated in triplicate in 96-well
plates. T cells were added at the indicated E:T ratios. Co-cultures were incubated for 24hr at 37oC
in phenol-free CM. Residual luciferase activity was measured using the extended glow
bioluminescent reporter gene assay (Applied Biosystems). Percent lysis = 100–[(average signal
from indicated CAR-treated wells)/(average signal from control CAR-treated wells)] x 100.

Xenograft model (Early Treatment Model): NOD-scid IL2Rγnull (NSG) mice were obtained
from the University of Pennsylvania Stem Cell and Xenograft Core. 6-12 week old mice were
maintained under pathogen-free conditions under protocols approved by the University of
Pennsylvania Institutional Animal Care and Use Committee. 3e6 OVCAR3 tumor cells were
subcutaneously injected into the flank of NSG mice. 4e6 CAR-bearing T cells per mouse were
injected in the intraperitoneal cavity 16-22 days post tumor inoculation. Tumor growth was
assessed via bioluminescence imaging. Each cohort of mice was treated with the same number of
CAR(+) T cells as determined by flow cytometric staining of T cell populations on Day 14 with a
species-specific biotinylatyed anti-heavy chain light chain (HC/LC) IgG antibody. CD19 and
MOV19 CAR T cells were stained with rabbit anti-murine HC/LC IgG (Jackson
ImmunoResearch). 3#68 B7-H4 CAR T cells were stained with rabbit anti-human HC/LC IgG
(Jackson ImmunoResearch).

Xenograft model (Late Treatment Model): NOD-scid IL2Rγnull (NSG) mice were obtained
from the University of Pennsylvania Stem Cell and Xenograft Core. 6-12 week old mice were
maintained under pathogen-free conditions under protocols approved by the University of
Pennsylvania Institutional Animal Care and Use Committee. 4e6 OVCAR3 tumor cells were
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subcutaneously injected into the flank of NSG mice. After tumors were palpable (>200mm2; ~50
days), mice were treated with 4e6 CAR-bearing T cells. Tumor growth was assessed via
bioluminescence imaging and caliper measurement. Tumor volume = [length x (width)2]/2, where
length is the greatest longitudinal diameter and width is the greatest transverse diameter.

Bioluminescence imaging: Bioluminescence imaging of luciferase(+) tumor cells was performed
as previously described (Lanitis et al., 2012b). Living Image Software (Xenogen) was used to
quantify luciferase(+) tumor cells per animal and render a pseudocolor image representing light
intensity (scale 1e6-1e8).

TruCount: T cells in the peripheral blood were enumerated using TruCount assay as per the
manufacturer’s instructions (BD Biosciences). T cell subsets were gated using the following
antibodies for flow cytometry: mouse anti-human CD8a-APC (BioLegend), mouse anti-human
CD3-PerCpCy5.5 (eBioscience), and mouse anti-human CD45-PE (BioLegend).

T cell phenotyping: Control and experimental CARs were stimulated and transduced with
lentiviral constructs as described in the materials and methods. T cell populations were
maintained in R10 media with recombinant, human IL-2 (rhIL-2) throughout the study. The
following monoclonal antibodies were used for flow cytometric analyses: mouse anti-human CD4
PerCP-Cy5.5 (BD Biosciences), mouse anti-human CD8 APC-Cy7 (BD Biosciences), biotinconjugated rabbit anti-human IgG (Jackson ImmunoResearch), biotin-conjugated goat anti-mouse
IgG (Jackson ImmunoResearch). Mouse anti-human B7-H4 (AMP6H3) and the humanized
version (AMP841) were kindly provided by Amplimmune. AMP6H3/AMP841 cross react with
mouse B7-H4. The cell viability solutions 7AAD (BD Biosciences) or fixable viability dye eFluor
506 (eBioscience) were used to remove dead cells from analysis in all experiments.
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Compensation was performed with OneComp eBeads (eBioscience). Recombinant human FRα
(R&D Systems) protein was biotinylated as per the manufacturer’s instructions (EZ-Link SulfoNHS-LC-Biotin, Thermo). Streptavidin APC (eBioscience) was utilized as a secondary reagent in
all biotinylation steps. Data was acquired on a BD FACS Canto II with Diva Software and
analyzed using Flojo 7.6.5.

Comprehensive Autopsy Study: OVCAR3 tumor-bearing NSG mice were treated with one dose
of 4e6 CAR(+) cells. Both B7-H4 and control CAR treated cohorts were sacrificed at 37 days and
55 days post CAR T cell injection. No clinical signs were observed in both the B7-H4 CAR
treated mice at 37 days, however, nonspecific clinical signs of weight loss and ruffled fur were
observed at day 55. No clinical signs were observed in the control CAR treated mice at 37 or 55
days. One GFP control mouse was sacrificed at day 55. A complete autopsy, including gross
examination and whole body tissue collection, was performed. All tissues were fixed with 10%
neutral-buffered formalin, processed, and evaluated histologically on hematoxylin and eosin
(H&E)-stained slides. Slides were analyzed for pathology in a blinded fashion by a boardcertified anatomic veterinary pathologist.

Validation of anti-B7-H4 antibodies: Mouse malignant mesothelioma cell line AE17 was
lentivirally-transduced with either human or murine B7-H4 complementary DNA (cDNA)
sequences (Origene, RC210360 (human) and MR203847 (mouse) to generate AE17.hB7-H4 and
AE17.mB7-H4, respectively. Both lentiviral vectors also contained the reporter green
fluorescence protein (GFP) separated by a viral P2A ribosomal skipping site. AE17.hB7-H4 and
AE17-mB7-H4 were not sorted to obtain homogenous populations. Flow cytometry was
performed to validate species-specific B7-H4 protein expression using the following antibodies:
rat anti-mouse B7-H4-PE IgG1(Clone 9, eBioscience), rat IgG1-PE (eBioscience), biotinylated
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mouse anti-human B7-H4 IgG1 (MIH43,AbD Serotec), biotinylated mouse IgG1 (AbD Serotec),
biotinylated mouse anti-human/mouse B7-H4 IgG1 (AMP6H3, Amplimmune), biotinylated
human anti-human/mouse B7-H4 IgG (AMP841, Amplimmune). AMP841 is a humanized
version of AMP6H3. Cell pellets for IHC were creating by centrifuging (1200 rpm, 5 minutes) 10
million AE17, AE17.mB7-H4, and AE17.hB7-H4 cells and resuspending cells in 10% nonbuffered formalin. After overnight fixation, pellets were embedded in paraffin, sectioned, and
stained for B7-H4 with AMP6H3 at the Human Anatomic Pathology Core at the University of
Pennsylvania. Validation methodology: First, we validated the specificity of the AMP6H3
antibody by flow cytometry against the B7-H4- mouse mesothelioma cell line AE17 lentivirally
transduced to stably express either murine (AE17.mB7-H4) or human (AE17h.B7-H4) B7-H4
protein. We confirmed the species-specific B7-H4 surface expression with various commercially
available anti-B7-H4 antibodies. The anti-mouse B7-H4 Clone 9 antibody specifically bound
AE17.mB7-H4 and did not bind parental AE17 or AE17.hB7-H4 (Figure 3.7a, first column).
Likewise, the anti-human B7-H4 specific antibody MIH43 only bound AE17.hB7-H4 and did not
bind parental AE17 or AE17.mB7-H4 (Figure 3.7a, second column).

The novel AMP6H3 antibody specifically bound both AE17.mB7-H4 and AE17.hB7-H4 and did
not bind parental AE17 (Figure 3.7a, third column). The humanized version of the AMP6H3
antibody, AMP841, also specifically bound only AE17.mB7-H4 and AE17.hB7-H4 (Figure 3.7a,
fourth column). These results are consistent with previous assays performed by the manufacturer
(Amplimmune, unpublished results). These data confirmed that AMP6H3/AMP841 specifically
binds B7-H4 protein and cross react with both human and murine B7-H4. Further, we developed
an IHC protocol utilizing AMP6H3 and confirmed specific binding in formalin-fixed, paraffinembedded cell lines. Similar to our flow cytometric analyses, AMP6H3 specifically recognized
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AE17.mB7-H4, AE17h.B7-H4, and OVCAR3, and did not bind the B7-H4- parental AE17 cell
line (Figure 3.7b).

B7-H4 Immunohistochemistry: Staining was performed on FFPE tissue from the
comprehensive autopsy experiments described above. A normal human tissue microarray
previously created from tissues obtained in a de-identified manner from the surgical pathology
archives at the University of Pennsylvania (Michael Feldman) under IRB approval was obtained.
B7-H4 staining was performed with mouse anti-human/mouse AMP6H3 using the Bond Polymer
Refine Detection System (Leica Microsystems AR9800) on a Leica Bond-IIITM instrument at the
Human Anatomic Pathology Core at the University of Pennsylvania. Slides were dewaxed for 30
minutes at 72oC, and then subjected to heat-induced antigen retrieval for 20 minutes at 99oC with
ER1 solution (Leica Microsystems AR9640). AMP6H3 primary antibody (1:1500) was added for
15 minutes at room temperature followed by use of the bond polymer refine detection kit (Leica)
as per the manufacturer’s instructions. Slides were counterstained with hematoxylin (Leica). All
slides were washed three times between each step with bond wash buffer or water. Slides were
imaged using CellSens software (Olympus) on an Olympus BX53 microscope with an Olympus
DP25 camera. Images were assembled in ImageScope version 12.1.0.5029 (Aperio) or
PowerPoint (Microsoft). All B7-H4 staining evaluations were performed by a board-certified
anatomic veterinary pathologist in the Comparative Pathology Core at the University of
Pennsylvania School Of Veterinary Medicine. Three mice were evaluated per group.

Human CD3 Immunohistochemistry: Staining was performed on FFPE tissues from the
comprehensive autopsy study as described in the materials and methods. Tissue was sectioned by
the Cancer Histology Core at the University of Pennsylvania. Human CD3 was detected using the
DAKO Envision detection system. Slides were baked at 57oC for four hours before dewaxing in
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100% xylene (Sigma) followed rehydration in ethanol. Antigen retrieval was performed in citrate
buffer, pH 6 (Thermo) for two hours in a 2100 Antigen-Retriever (Aptum Biologics). Peroxidase
block (Dako), Avidin/Biotin block (Vector Labs), and Protein block (Dako) were all used as per
the manufacturer’s instructions. Human CD3 antibody (abcam ab828) (1:50) was added and
incubated for two hours at room temperature. Anti-rabbit, biotinylated secondary antibody
(1:1500)(Vector Laboratories) was added for 30 minutes are room temperature followed by the
avidin-biotin complex (ABC) method (Vectastain ABC kit, Vector Laboratories) as per the
manufacturer’s instructions. Slides were then developed using DAB chromogen (Vector Labs),
counterstained with hematoxylin (Leica), dehydrated in ethanol, and cleared in xylene (Sigma).
Cover slips were added using cytoseal-60 (Thermo Scientific). All microscopy was performed on
a Nikon Eclipse 50i microscope with Nikon NIS elements version 4.0 imaging software. Images
were assembled in PowerPoint (Microsoft).

Statistical analysis: Data are reported as mean +/- standard error of the mean (SEM) unless
otherwise noted. Unpaired, two-tailed Student t tests and Kaplain-Meier estimates using the logrank (Mantel-Cox) test were performed using GraphPad Prism 6 (GraphPad software). P-values
less than 0.05 were considered statistically significant.
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Results
Generation of B7-H4 CARs
Dangaj et al. isolated and characterized four, novel anti-B7-H4 single chain variable fragments
(scFvs) from a yeast display library (26, 56, 3#68, 3#54), two of which (3#68 and 3#54 scFvs)
were able to rescue functional inhibition of HER-2 TCR-engineered T cells (Dangaj et al.,
2013b). We utilized these four scFv sequences to generate B7-H4-specific CAR constructs. The
four anti-B7-H4 scFv sequences were cloned into previously validated lentiviral vectors
containing a human CD8α leader, CD8α hinge, a CD28 transmembrane domain, and CD28 and
CD3ζ intracellular signaling domains (Lanitis et al., 2012b). The B7-H4 constructs also contained
a green fluorescence protein (GFP) reporter separated by a viral P2A ribosomal skipping site to
assess transgene efficiency after transduction. CARs are referred to as 26, 56, 3#68, and 3#54CD28Z (Figure 3.1a, top). A CAR specific for human CD19 (Milone et al., 2009) was used as a
specificity control for antigen-independent activity in all experiments (Figure 3.1a, bottom). The
MOV19 CAR, specific for human FRα (Miotti et al., 1987), was utilized as a positive control for
tumor-specific reactivity (Figure 3.1a, bottom).

B7-H4 CARs are expressed in primary human T cells
We first confirmed expression of the various B7-H4 CARs in primary human T cells. Lentiviral
B7-H4 or control CAR constructs showed high transduction efficiency in both CD8+ and CD4+ T
cells from primary human donors, as assessed by GFP expression six days post transduction
(Figure 3.2a-b). Additionally, CAR expression on the surface of T cells was tested using
idiotype-specific antibodies for CARs composed of either human (Figure 3.2b) or murine scFvs
(Figure 3.2c). 3#68 B7-H4, 3#54 B7-H4, and control CARs CD19 and MOV19 were highly
expressed on the surface of T cells. The 26 and 56 B7-H4 CARs demonstrated lower surface
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CAR expression, despite similar GFP reporter expression (Figures 3.2b). All B7-H4 and control
CAR-transduced T cell populations maintained high levels of GFP reporter expression after
fourteen days of expansion (data not shown).

B7-H4 CAR T cells composed of different scFvs have distinct antigen-binding patterns
Next, we evaluated the capacity of the B7-H4 CAR-bearing T cells to bind B7-H4 by flow
cytometry. The four B7-H4 CARs had a differential ability to bind recombinant, human B7H4
protein (rhB7-H4). This was indicated by unique shifts in median fluorescence intensity (MFI)
(Figure 3.1b). None of the B7-H4 CARs bound the control FRα protein (Figure 3.1c, left), while
the FRα-specific, MOV19 CAR only bound its cognate antigen (Figure 3.2f, left panel).
Interestingly, the B7-H4 CARs also bound recombinant, murine B7H4 protein (rmB7-H4) with a
similar pattern seen with rhB7-H4 (Figure 3.1c, right).

B7-H4 CAR-bearing T cells specifically exhibit effector function against B7-H4(+) tumor
cell lines in vitro
We evaluated endogenous B7-H4 protein in different cancer cell lines utilizing two different antiB7-H4 antibodies. We found low to moderate surface B7-H4 expression on the human breast
cancer cell line SKBR3, the human ovarian cancer cell line OVCAR3, and the human Epstein Bar
Virus (EBV)-immortalized B cell line EBV-B, which is consistent with previous reports (Dangaj
et al., 2013b; Quandt et al., 2011)(Figure 3.3a). Interestingly, we observed differences in the
ability to detect surface B7-H4 protein between the two anti-human B7-H4 antibodies we tested.
Despite similar binding trends, the AMP841 clone detected a higher frequency and intensity shift
of surface B7-H4 in comparison to the commercially available MIH43 clone (Figure 3.3a).
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We next interrogated the effector capabilities of the different B7-H4 CARs in vitro by coculturing the CAR-bearing T cells with tumor cell lines expressing various levels of endogenous
B7-H4. As expected, the control CD19 CAR secreted interferon-γ (IFN-γ) against the CD19(+)
EBV-B cell line, but not the CD19(-) cell lines C30 and OVCAR3 (Figure 3.3b). While all four
B7-H4 CARs secreted IFN-γ in response to the highest B7-H4-expressing cell line, EBV-B, the
3#68 and 3#54 B7-H4 CAR T cells maintained high reactivity against moderate B7-H4
expression in OVCAR3 and did not recognize B7-H4(-) C30 (Figure 3.3b).

These data rationalized further preclinical assessment with the 3#68 and 3#54 B7-H4 CARs
against a wider panel of tumor cell lines. Both B7-H4 CARs demonstrated dose-dependent IFN-γ
secretion in response to B7-H4(+) cell lines, secreting more IFN-γ in response to cell lines with
higher B7-H4 surface protein (Figure 3.3c). Additionally, we observed a similar trend in
secretion of IL-2, TNF-α, and MIP1α as evidenced by cytokine bead array profiling (data not
shown).

Finally, we set up a luciferase-based killing assay to assess the in vitro cytolytic function of B7H4 CAR T cells. Positive control MOV19 CAR T cells specifically lysed human FRα(+) cells
lines MDA231 and OVCAR3, but not the FRα(-) cell line 624 (Song et al., 2012)(Figure 3.3d,
left). Both 3#68 and 3#54 B7-H4 CAR T cells specifically killed B7-H4(+) OVCAR3 without
reactivity against B7-H4(-) cell lines 624 and MDA231 (Figure 3.3d, middle and right panels).
We did not observe evidence of non-specific targeting of B7-H4(-) tumor cells such as cross
reactivity to PD-L1 as evidenced by lack of IFN-γ secretion in response to B7-H4(-)PD-L1(+)
ovarian tumor cells SKOV3 and A1847 (data not shown) or killing of the B7-H4(-)PD-L1(+)
breast cancer cell line MDA231 (Figure 3.3d). Together, these data establish the feasibility of
targeting B7-H4 with CAR T cells in vitro. We chose to continue preclinical investigation of the
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3#68 B7-H4 CAR (thereafter referred to as B7-H4 CAR) because of its enhanced killing at the
lower effector to target ratios.

B7-H4-28Z CAR T cells exhibit potent anti-tumor efficacy in vivo
Next, we investigated the anti-tumor capability of B7-H4 CAR therapy in vivo in an established
tumor model. We treated mice bearing established subcutaneous OVCAR3 tumors with CD19
negative-control, MOV19 positive-control or B7-H4 CAR T cells. B7-H4 CAR T cell-treated
mice exhibited significantly reduced tumor growth compared to CD19 control CAR-treated
animals, as measured by bioluminescence imaging (Figures 3.4a-b) and caliper measurement of
tumor volume (Figure 3.4c). We also confirmed the anti-tumor activity of B7-H4 CAR T cells in
an additional model, treating mice with therapy earlier in tumor development (Figure 3.5a). In
conclusion, B7-H4 CAR T cells significantly limited tumor growth in two in vivo treatment
models. Together, these results establish the potential efficacy of B7-H4 CAR T cell therapy in
ovarian cancer.

B7-H4 CAR T cell-treated mice show signs of toxicity after anti-tumor effects
Surprisingly, B7-H4 CAR-treated mice showed overt signs of toxicity at a late time point
following T cell treatment. They were lethargic, hunched, dehydrated, and had ruffled fur, while
control CAR-treated mice did not show evident signs of distress. B7-H4 CAR-treated cohorts in
the established tumor model presented with signs of overt toxicity 45-48 days post T cell
treatment (Figure 3.4d). Toxicity was not attributed to the anti-tumor response since MOV19
CAR therapy completely eliminated OVCAR3 tumors (Figures 3.4a-c) without evident toxicity
(Figure 3.4d).
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We also assessed CAR T cell mediated toxicity in non-tumor bearing mice. Again, we observed
apparent signs of toxicity in B7-H4 CAR-treated mice without distress in control CAR T cell
treated mice (Figure 3.4e). This occurred at a similar kinetic as in the B7-H4 CAR-treated tumorbearing mice (Figure 3.4d), suggesting that recognition of human B7-H4 in the context of tumor
xenografts was not necessary for the development of toxicity mediated by the B7-H4 CAR.

To evaluate if in vivo T cell expansion correlated with the development of toxicity, we analyzed
peripheral blood human T cells over the course of therapy. Analysis revealed an increased
presence of CD8+ and CD4+ T cells in both the MOV19 and B7-H4 CAR-treated groups at 28
days post T cell treatment in comparison to the CD19 CAR cohort, consistent with in vivo
activation and proliferation of T cells (Figure 3.4f). However, B7-H4 CAR-treated animals
showed a contraction of T cells 43 days post treatment (Figure 3.4g), possibly due an increased
in the tissue instead of the peripheral blood compartment. B7-H4 CAR-treated mice in the early
treatment model also showed signs of toxicity and died post T cell treatment (Figure 3.5b).
Peripheral T cell counts also followed a similar trend as in the established tumor model (Figure
3.5c-d). Finally, the number of T cells in the peripheral blood of B7-H4 or MOV19 CAR-treated
non-tumor-bearing mice was not statistically different 28 or 42 days post T cell injection (data not
shown). These data suggested that a high peripheral T cell count is not necessary for the observed
toxicity.

B7-H4 CAR T cells do not demonstrate an auto-active phenotype or express B7-H4
Certain CAR structures result in antigen-independent, constitutive T cell-proliferation, even in the
absence of exogenous cytokine during culture and selective outgrowth of CAR-bearing T cells
(Frigault et al., 2015). After observing the death of mice in our model system, we examined T cell
growth kinetics. Unlike the “continuous CARs” (Frigault et al., 2015), all control and 3#68 B777

H4 CAR T cell populations proliferated similarly and decreased in mean size over time post T
cell stimulation, even in the presence of recombinant human IL-2 (Figure 3.6a-b). T cell
populations maintained in the absence of rhIL-2 did not survive (data not shown). Additionally,
CAR T cell populations maintained a similar frequency of untransduced cells over time (Figure
3.6c), further suggesting that B7-H4 CARs do not have an auto-active phenotype. Lastly, we were
unable to detect surface B7-H4 antigen on control or B7-H4 CAR T cell populations (Figure
3.6d).

B7-H4 protein is expressed in numerous murine tissues
Since our B7-H4 CAR did not demonstrate an auto-active phenotype and the scFv cross reacts
with murine B7-H4 protein, we hypothesized that the toxicity after B7-H4 CAR administration
was due to recognition of B7-H4 protein expressed in normal murine tissue. Available data has
been inconsistent regarding the expression of B7-H4 on human and murine tissue (Smith et al.,
2014b). Previous studies were unable to detect B7-H4 protein in tissues including the pancreas
(Chen et al., 2014; Choi et al., 2003; Sica et al., 2003), lung (Choi et al., 2003; Sica et al., 2003),
kidney (Chen et al., 2006; Krambeck et al., 2006; Xu et al., 2014), breast (Tringler et al., 2005),
and liver (Chen et al., 2011c; Guo et al., 2012). However, more recently, B7-H4 expression was
detected in normal human endometrium (Miyatake et al., 2007) and pancreas (Cheung et al.,
2014), and cell membrane expression was reported on ductal epithelia of the breast, pancreas,
kidney, bile duct, and the trachea/lung (Leong et al., 2015). In mice, several groups were unable
to detect B7-H4 protein in immune cells in vitro (Hofmeyer et al., 2012; Lee et al., 2012; Wei et
al., 2011), despite early studies that reported expression (Prasad et al., 2003; Zang et al., 2003).
Murine B7-H4 protein is detectable in pancreatic islet cells (Hofmeyer et al., 2012; Lee et al.,
2012; Wei et al., 2011) and in epithelial cells lining the lung (Hofmeyer et al., 2012), however,
expression in other organs has not been reported.
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Therefore, we sought to develop an immunohistochemistry (IHC) protocol for both human and
murine B7-H4 utilizing a novel B7-H4 antibody (AMP6H3). We validated the antigen-specific
and species-specific reactivity of the antibody by flow cytometry and IHC as described in the
supplemental materials and methods and show that AMP6H3 cross reacts with human or murine
B7-H4(+) cell lines (Figure 3.7).

We tested numerous different murine tissues to comprehensively determine the bio-distribution of
B7-H4 protein. Murine B7-H4 was not detected in the bone marrow, spleen, heart, skeletal
muscle, tongue, thyroid, mesentery, or urinary bladder (Figure 3.8). Some, rare B7-H4(+) cells
were found in tissues of the gastrointestinal tract including the small intestine, colon, cecum
(Figure 3.8), adrenal gland, and stomach (Figure 3.9). Additionally, neurons in the spinal cord
and brain expressed B7-H4 in the cytoplasm (Figures 3.8 and 3.9).

Similar to previous reports, murine B7-H4 was detected in the islet cells of the pancreas
(Hofmeyer et al., 2012; Lee et al., 2012; Wei et al., 2011) and the epithelial lining of the lung
(Hofmeyer et al., 2012). Additionally, we found B7-H4 protein in the esophagus, trachea, salivary
gland, mammary, gallbladder, liver, kidney, uterus, and haired skin (Figure 3.9). Generally, B7H4(+) staining was restricted to ductal and mucosal epithelial cells in each tissue, such as the bile
duct in the liver, the biliary epithelium in the gallbladder, bronchiolar and tracheal mucosal
epithelium in the lung, and the transitional epithelium in the kidneys. Notably, we detected B7H4 expression in the ductal epithelium of the pancreas in addition to the previously reported
staining in islet cells (Wei et al., 2011). The endometrial glands/epithelium and the myometrium
in the uterus and oviduct also stained strongly for B7-H4. IHC staining utilizing an isotype
control did not show staining of any tissues analyzed (Figure 3.8; data not shown). Lastly, as
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expected, human B7-H4 was strongly expressed in engrafted OVCAR3 tumor xenografts (Figure
3.9). Results are summarized in Table 3.1.

B7-H4 CAR-treatment results in multiorgan lymphocyte infiltration
After determining widespread expression of murine B7-H4 in our animal model, we evaluated
tissues from B7-H4 CAR treated mice. Comprehensive autopsy and pathology analyses were
performed on hematoxylin and eosin (H&E)-stained slides from tissues of OVCAR3-tumor
bearing mice that were treated with B7-H4 CAR or control CAR T cells. One cohort of mice was
sacrificed prior to showing signs of overt toxicity (37 days) and a second cohort was sacrificed
once they showed signs of evident toxicity (55 days). The histologic lesions within all cohorts are
summarized in the Table 3.2.

We did not observe tissue damage or the presence of lymphocytes in many B7-H4(-) tissues, such
as skeletal muscle, bone, heart, tongue, adrenal gland, or thyroid gland of B7-H4 CAR or control
CAR-treated mice 37 days (Figure 3.10a) or 55 days (Figure 3.10b) post T cell administration
(Table 3.2). Notably, tissues displaying membranous B7-H4(+) staining (Figures 3.9 and Table
3.2) exhibited similar histologic lesions at 37 and 53 days post B7-H4 CAR therapy. Lesions
consisted of lymphocytic infiltration in the salivary gland, female reproductive tract, lung, liver
(portal region), and pancreas (Table 3.2). At day 37, B7-H4 CAR-treated mice exhibited
lymphocytic infiltration of the pulmonary interstitium, portal area of the liver, salivary gland,
vaginal/cervical submucosa, and periductally within the pancreas as compared to control CAR
mice, which had no significant lesions (Figure 3.10a). B7-H4 CAR T cell-treated mice sacrificed
55 days post treatment showed similar, but more severe, histologic lesions and exhibited more
extensive tissue destruction (Table 3.2 and Figure 3.10b).
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We did note histologic lesions in tissues that stained B7-H4(-), including the urinary bladder,
cecum, mesentery, peripheral nerves, and haired skin in 1/3 mice at both time points post B7-H4
CAR treatment (Table 3.2). Additionally, several tissues examined from mice sacrificed at day
55 contained lesions that were not observed within the early time point (37 days). These included
lymphocyte exocytosis along with basal cell necrosis in the squamous portion of stomach (B7H4(-)), lymphocytic infiltration and exocytosis in the oral cavity (B7-H4(-)), and interstitial
lymphocytic infiltrates within the kidney (B7-H4(+)).
Additionally, we detected human CD3(+) cells via IHC in the tumor of B7-H4 CAR T celltreated mice but not CD19 CAR T cell-treated animals (Figure 3.11a). We also observed
hCD3(+) cells surrounding B7-H4(+) areas in the pancreas (Figure 3.11b) and liver (Figure
3.11c) of B7-H4 CAR-treated animals but not CD19 CAR-treated mice (Figure 3.11d-e). These
data further support the hypothesis that B7-H4 CAR T cells mediated pathology through
recognition of murine B7-H4(+) in healthy tissues in treated mice.

B7-H4 protein is expressed in normal human tissues
To assess if our new findings of widespread murine B7-H4 expression were also true in human
tissues, we utilized our established anti-B7-H4 antibody (AMP6H3) and staining protocol to
conduct immunohistochemistry on a microarray of human tissues containing 20 tissues and an
ovarian carcinoma. Paralleling murine B7-H4 expression, human B7-H4 protein was not
expressed in heart, muscle, cerebellum (head), spinal cord, thyroid gland, lymph node, and
spleen. Additionally, human B7-H4 protein was undetectable in thymus, adipose, parathyroid
gland, and placenta. Rare cells in the adrenal gland and in colonic crypts were B7-H4(+), similar
to murine expression.
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We detected B7-H4 protein in the mammary gland, kidney, and in pancreatic islet cells,
consistent with published reports (Cheung et al., 2014; Leong et al., 2015). We also detected B7H4 expression in the esophagus, salivary gland, and liver. Positive staining was generally found
in glandular epithelial cells of the salivary and breast, ductal epithelium of the liver, and in the
tubular epithelium of the kidney. Although previously not described, ductal epithelial cells of the
pancreas also stained B7-H4 positive. Notably, the ovarian cancer sample strongly expressed B7H4. Our results are summarized in Table 3.3 and Figure 3.12.
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Discussion
Here, we establish the first report of CAR T cell therapy targeting B7-H4. We created four
different, fully human B7-H4 CAR lentiviral constructs that showed cross reactivity with murine
B7-H4 and had a differential ability to recognize B7-H4(+) targets in vitro, as assessed by IFN-γ
secretion and lysis ability after coculture. We pursued preclinical development of the 3#68 B7-H4
CAR (herein referred to as B7-H4 CAR) and saw reduction of ovarian tumor burden in a
xenograft model, demonstrating anti-tumor efficacy of this therapy in vivo. Unexpectedly, tumor
and non-tumor bearing 3#68 B7-H4 CAR T cell-treated mice reproducibly showed symptoms of
lethal toxicity emerging 6-8 weeks after therapy.

To rule out non-specific effects for B7-H4 CAR T cell toxicity, we first confirmed lack of a
“continuous” CAR phenotype (Frigault et al., 2015) though longitudinal study of T cell growth
kinetics and CAR expression. We also reproduced the results in non-tumor bearing mice treated
with B7-H4 CAR T cells, showing that effects were independent of activation in the presence of
human B7-H4(+) tumor. Additionally, toxicity was not solely attributed to the anti-tumor effect,
since MOV19 CAR T cells efficiently eliminated the tumor but treated animals did not suffer
from toxicity. Finally, we were unable to detect B7-H4 expression on CAR(+) T cells, ruling out
autoactivation due to antigen expression on the T cell surface.

Due to toxicity in our model and the inconsistent literature reports of B7-H4 expression (Smith et
al., 2014b), we found it necessary to develop new more robust assays for comprehensive B7-H4
expression analysis. Examination of murine and human tissue revealed widespread expression of
B7-H4 protein. Our results were consistent with reported murine B7-H4 expression in the
epithelial lining of the lung (Hofmeyer et al., 2012) and islet of Langerhans’s cells in the pancreas
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(Cheung et al., 2014; Lee et al., 2012; Wei et al., 2011). Additionally, we uncovered previously
unrecognized cytoplasmic and surface expression in the epithelial lining of mucosal and ductal
cells in many tissues including the trachea, mammary gland, bile duct, kidney, and pancreas,
significantly advancing our understanding of murine B7-H4 expression. We also detected B7-H4
expression

In humans, our results were consistent with reported B7-H4 expression in the ductal epithelia of
mammary gland and tubular epithelium of kidney (Leong et al., 2015), and in islet cells of the
pancreas (Cheung et al., 2014; Leong et al., 2015). We also detected previously undescribed
expression of B7-H4 in the glandular and ductal epithelial cells in the esophagus, salivary gland,
liver, and pancreas, all which are consistent with our observations in mice. Together our study
reveals the bio-distribution of B7-H4 protein. Notably, human B7-H4 expression patterns and
location is largely similar to murine B7-H4 protein expression, suggesting that preclinical studies
targeting the B7-H4 homolog in mice may be a relevant model to interrogate questions addressing
B7-H4’s function and targetability in vivo.

In our study, postmortem analysis of B7-H4 CAR T cell-treated mice revealed multiorgan
lymphocytic infiltrate observed within both time points that primarily correlated with positive
membranous B7-H4 tissue expression determined via immunohistochemistry, suggesting an ontarget effect of B7-H4 CAR therapy. However, lesions were also evident in tissues that were B7H4(-). Perivascular and perineural lymphocytic infiltrates seen within multiple soft tissues such as
mesentery, broad ligament, and other adipose tissue may be a nonspecific reaction to an
inflammatory state. Additionally, lesions in the squamous portion of the stomach and oral mucosa
only occur at the later time point, possibly due to chronic, systemic activation of B7-H4 CAR by
murine antigen causing graft-versus-host-disease (GVHD)-like pathology. Induction of
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xenogeneic GVHD phenotypes can be highly variable across cohorts of mice, but commonly
effect skin (Beilhack et al., 2005; Nervi et al., 2007; van Rijn et al., 2003), liver (Beilhack et al.,
2005; King et al., 2009; Nervi et al., 2007; Panoskaltsis-Mortari et al., 2004; van Rijn et al.,
2003), gastrointestinal tract (Beilhack et al., 2005; van Rijn et al., 2003), and the lung (King et al.,
2009; Nervi et al., 2007; Panoskaltsis-Mortari et al., 2004; van Rijn et al., 2003). We observed
only mild skin lesions in 1/3 mice at each time point and importantly, control mice did not show
evidence of widespread GVHD at concomitant time points. Although similarities in target organs
between GVHD and B7-H4 CAR treatment exist, we also observed unique lesions in B7-H4(+)
tissues that are unaffected by GVHD-like pathology, highly suggesting a contribution of on-target
CAR T cell recognition.

In our current model we determined the presence of pathologic lesions in mice at late time points
post T-cell transfer to gain insight into the observed death following B7-H4 CAR therapy.
However, this does not rule out initiation of lesions at earlier time points. Previous studies that
observed toxicity in murine models of CAR therapy targeting fibroblast activating protein
(FAP)(Tran et al., 2013) and NKG2D ligands (VanSeggelen et al., 2015) report treatmentmediated pathology within days post T cell transfer. The differences in kinetics seen in our study
may have occurred for several reasons including differences in CAR T cell dose, pre-conditioning
regimes, distribution of target antigen in normal tissue, and murine strain variability (Lynn and
Powell, 2015). Additionally, several groups have observed safe therapeutic targeting of FAP in
murine models (Spear et al., 2013; Wang et al., 2014), suggesting that differences in the therapy
could allow for safe targeting by CAR T cells.

Lastly, we did not observe clearance of the OVCAR3 tumor in our NSG xenograft experiments
following one dose of B7-H4 CAR treatment. However, use of combinatorial therapies may be
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necessary to eliminate the last cancer cell in solid tumors (Kakarla and Gottschalk, 2014). If
applied safely, the B7-H4 CAR therapy could be utilized in combination with other targeted
treatment modalities, such the anti-FRα CAR (MOV19), in order to improve upon the anti-tumor
efficacy we observed in the B7-H4 CAR cohorts.

Here, we report the first use of a B7-H4-specific CAR T cell therapy and our results indicate that
B7-H4(+) cancer outgrowth can be controlled in vivo. Long-term persistence of 3#68 B7-H4
CAR T cells, however, mediates lethal on-target, off-tumor toxicity that is likely due to wide
expression of B7-H4 in healthy mouse organs. Other models of CAR-mediated toxicity in mice
tend to cause acute toxicity (Tran et al., 2013; VanSeggelen et al., 2015). Our B7-H4 CAR model
of toxicity could provide a unique preclinical model to evaluate safety approaches designed to
limit long-term CAR-mediated toxicity following potent anti-tumor activity in vivo. Additionally,
these studies reveal the endogenous expression pattern of B7-H4, advancing our understanding of
the molecule and fostering intelligent design of novel B7-H4-specific therapeutics for the clinic.
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Tables and Figures

Table 3.1

Table 3.1. Summary of B7-H4 expression in murine tissue.
Summation of murine B7-H4 expression based on the immunohistochemical staining of tissues from
OVCAR3luc-bearing, control GFP+ T-cell-treated mice from the full autopsy study. Mice were sacrificed
77 days post tumor injection and different tissues were formalin-fixed, paraffin-embedded, sectioned, and
stained with the anti-B7-H4 antibody 6H3, which recognizes both human and murine B7-H4 protein. A
detailed examination of positive and negative staining was performed by a board-certified, anatomical
veterinary pathologist. Red blood cells in most organs are also positive, however it is likely background
and not significant. Data represents three mice per tissue.
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Table 3.2

NSL (3/3)

GFP

Not examined

NSL (1/1)

Mild-severe enlarged and reactive (3/3)

Increased myeloid to erythroid ratio (3/3)

53 days post T cell treatment

NSL (2/2)

Mild-moderate extramedullary hematopoesis (3/3)

37 days post T cell treatment
3#68-CD28Z

NSL (2/2)

3#68-CD28Z

Increased myeloid to erythroid ratio (3/3)

NSL (1/1)

NSL (3/3)

CD19-CD28Z

Mild-severly enlarged and reactive (3/3)

NSL (1/1)

CD19-CD28Z
NSL (3/3)

NSL (3/3)

NSL (1/1)

no
NSL (1/1)
NSL (3/3)

NSL (3/3)

Expect lesions?
no
NSL (3/3)
NSL (3/3)

0
0
no
NSL (3/3)

Location of B7-H4
expression

Negative
0
no

Negative

Negative
0

Mouse B7-H4
expression (IHC)
Cervical lymph node
Negative

Bone marrow

Spleen
Skeletal muscle
NSL (3/3)

NSL (1/1)

no

NSL (3/3)

0

NSL (3/3)
Negative

NSL (1/1)

Long bone (femur)

NSL (3/3)

NSL (3/3)

NSL (3/3)

no

NSL (1/1)

0

NSL (3/3)

Negative

NSL (1/1)

Heart
NSL (3/3)

NSL (2/3); Adipose tissue: Mild lymphocytpic perivasculitis and
cellulitis (1/3)
Oral mucosa: Moderate lymphohistiocytic and neutrophilic
stomatitis with lymphocytic exocytosis (2/2)
Mild-moderate lymphocytic arteritis and perineuritis with perineural
fibrosis (3/3); Severe coalescing proliferative and necrotizing
vasculitis (2/3)
NSL (3/3)

NSL (3/3)

Not examined

no

NSL (1/1)

0

Not examined

Negative

NSL (1/1)

Tongue

Mild-severe lymphocytic arteritis and perineuritis with
perineural fibrosis (3/3)

NSL (2/2)

Not examined

NSL (1/1)

no

NSL (3/3)

0
NSL (2/2)

NSL (1/1)

NSL (1/2); Moderate-coalescing lymphocytic arteritis (2/3)

NSL (3/3)

NSL (3/3)

Not examined

NSL (3/3)

NSL (2/2)

NSL (3/3)

NSL (3/3)

NSL (3/3)

NSL (3/3)

no

NSL (2/2)

NSL (3/3)

NSL (1/1)

NSL (1/1)

NSL (1/1)

NSL (3/3)

NSL (3/3)

Moderate perivascular and Severe to coalescing lymphohistiocytic interstital pneumonia (3/3).
bronchiolar lymphocytic
Moderate-severe perivascular and bronchiolar lymphocytic
infiltrate (1/1)
infiltrate (3/3)

NSL (2/3); Moderate lymphocytic and neutrophilic typhlitis
with occasional crypt loss, regeneration, and lymphocyte
exocytosis (1/3)
NSL (1/2); Moderate coalescing proliferative and
lymphocytic cystitis and exocytosis, moderate lymphocytic
infiltrate (1/2)
NSL (3/3)

no

no
NSL (3/3)

NSL (3/3)

NSL (1/1)

NSL (3/3)

NSL (3/3)

NSL (1/1)

NSL (1/1)

NSL (3/3)

NSL (3/3)

WNL (3/3)

NSL (1/1)

NSL (3/3)

NSL (3/3)

Minimal lymphocytic
interstital infiltrate (1/1)
NSL (1/1)

NSL (3/3)

NSL (3/3)

Peripheral nerves: Mild-moderate lymphocytic perianglioneurtis
with perineural fibrosis (3/3); Adipose tissue: Mild-severe
lymphocytic artertitis and cellulitis (3/3)
Mild-severe lymphocytic sialioadenitis with ductal necrosis (1/3),
gland loss and necrosis (3/3); Adipose tissue: Moderate
lymphocytic vasculitis, perivasculitis, cellulitis (2/2)

Broad ligament: Mild-moderate multifocal lymphocytic
arteritis (3/3)

NSL (3/3)

NSL (3/3)

NSL (3/3)

no
NSL (3/3)

yes

NSL (3/3)

Paneth cells and few enterocytes
Negative *rare positive
(cytoplasm)
Negative *rare positive Few colonocytes (cytoplasm)

Ductal epithelium (cytoplasm and
apical membrane)

yes

NSL (3/3)

NSL (1/1)

Peripheral nerves: Mild-moderate lymphocytic
perianglioneurtis with perineural fibrosis (3/3); Adipose tissue:
Mild-moderate lymphocytic artertitis and cellulitis
Mild-severe lymphocytic sialoadenitis, cellulitis, arteritis, and
neuritis/perineuritis with gland loss and fibrosis (3/3);
Mammary gland: Lymphocyte infiltration of ductal epithelium
(3/3)
Moderate-severe lymphocytic, histiocytic, and neutrophilic
interstital pneumonia with type II pneumoncytes (3/3);
Moderate perivascular and bronchiolar lymphocytic infiltrate
(3/3)
Mild portal lymphocytic infitrate and exocytosis of bile ducts
(2/3)
Moderate multifocal to coalescing lymphocytic
vaginitis/cervicitis with spongiosis and lymphocyte exocytosis
(3/3)

NSL (2/3); Mild-moderate lymphocytic periductal infiltrate
(1/3)

NSL (3/3)

NSL (1/3); Perivascular and intersitital lymphocytic proliferation
with tubular loss and degeneration (2/3)
Mild lymphocytic periductal and perivascular infiltrate with few
necrotic ductal epithelial cells (1/3); Severe lymphocytic arteritis
and perineuritis with perineural fibrosis (1/3); Moderate
perivascular and interstital lymphocytic infiltrates (1/3)
NSL (2/3); Mild perivascular lymphocytic dermal infiltrate (1/3)

Portal lymphocytic infiltrate (3/3) with periportal hepatocyte loss
(2/3); Lymphocytic exocytosis of bile ducts (1/3)
Moderate to severe multifocal to coalescing lymphocytic and
neutrophilic vaginitis with mucosal necrosis/apoptosis, satellitosis
and intraepithelial pustules, spongiosis, and lymphocyte exocytosis
(3/3)
Mild multifocal to coalescing lymphocytic arteritis (3/3); Broad
ligament: Moderate-severe lymphocytic arteritis and cellulitis (3/3)

NSL (2/3); Mild lymphocytic folliculitis with loss of sebaceous
gland (1/3)

NSL (3/3)

no

no

NSL (3/3)

no

Negative

Chief cells and mucus cells of the
glandular stomach (cytoplasm)

0

Negative *rare positive Medullary cells (cytoplasm)
Negative
Negative *rare positive

no

NSL (3/3)

Negative *rare positive Few colonocytes (cytoplasm)

no

0

Neuronal cell bodies and molecular
layer of cerebellum (cytoplasm)

Negative

Positive
Neuronal cell bodies (cytoplasm)

Positive

Positive

NSL (3/3)

NSL (3/3)

Positive

Squamous portion: Severe lymphocytic and neutrophilic gastritis
and perivasculitis with lymphocytic exocytosis and basal cell
necrosis/apoptosis and degeneration (3/3)
NSL (1/3); Mild-moderate lymphocytic and neutrophilic typhilitis
with occassional cypt loss and lymphocytic exocytosis (2/3)

Mesentery

Stomach

Adrenal glands
Thyroid glands

Cecum
Urinary bladder
Small intestines
Large intestines
Brain
Spinal cord

Salivary gland

Lung

Bronchiolar and tracheal mucosal
epithelium (cytoplasm and apical
membrane)

yes

NSL (3/3)

Positive

NSL (3/3)

yes

NSL (3/3)

Liver

yes

Positive

yes

NSL (3/3)

Positive

Uterus/oviduct
Positive

yes

Vagina/Cervix

Kidneys
Positive

Duct epithelium (cytoplasm and apical
memrbane); islet cells (cytoplasm)

no

Bile duct epithelium (cytoplasm and
apical membrane)
Submucosal smooth muscle
(cytoplasmic and membranous) and
superfical mucosal cells (cytoplasmic
and apical)
Endometrial epithelium and
myometrium (cytoplasm and apical
membrane)
Transitional epithelium (cytoplasm and
apical membrane)

Pancreas

The epidermis
(occasionally)(cytoplasm) and hair
follical epithelium (inner zone of outer
root sheath)(cytoplasm)

NSL (3/3)

Positive

Haired skin
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Table 3.2. Summarization of histopathologic findings along with B7-H4 expression in
B7-H4 CAR or control CAR-treated NSG mice from 37 and 53 days post treatment.
OVCAR3-tumor bearing mice were treated in the intraperitoneal cavity with one dose of 4e6 CAR+ T
cells. CD19-CD28Z CAR and GFP+ T cells (no CAR) were utilized as negative controls. Mice were
sacrificed before the 3#68 CAR-treated animals showed signs of overt toxicity (37 days post T cell
treatment) or when showing evident signs of toxicity (55 days post T cell treatment). After termination,
hematoxylin and eosin (H&E)-stained slides were reviewed by a board-certified, anatomical veterinary
pathologist. Generally, similar histologic lesions are observed in mice 37 and 53 days post B7-H4 CAR T
cell treatment, consisting primarily of lymphocytic infiltration of various tissues, however, the lesions seem
to be more severe in the later time point. Frequently the histologic lesions in B7-H4 CAR T cell treated
mice from both time points coincide with positive immunohistochemical (IHC) tissue expression. The
control GFP treated mice did not exhibit significant lesions. The number of mice per cohort that exhibited
each lesion is indicated in parentheses. NSL, no significant lesions.

Table 3.3

Table 3.3. Summary of B7-H4 expression in normal human tissue. Summation of
immunohistochemical analysis using the anti-B7-H4 antibody 6H3 in a microarray of
normal human tissues.
A detailed examination of positive and negative staining was performed by a board-certified,
anatomical veterinary pathologist. Data represents three samples per tissue. Comparison to
murine B7-H4 is shown on the right side of the table. See Table 1 for murine B7-H4 expression
details.
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Figure 3.1

Figure 3.1. CAR T-cells bearing different anti-B7-H4 scFv bind recombinant B7-H4 with
varying relative ability. (a) Schematic of lentiviral B7-H4 chimeric antigen receptor (CAR) constructs.
All constructs are second generation CARs that utilize the CD28 and CD3ζ intracellular domains. B7-H4
CARs contain a GFP reporter linked to the CAR transgene by a viral P2A ribosomal skipping peptide.
CD19-CD28Z and MOV19-CD28Z do not contain the GFP reporter. (b) GFP reporter (y-axis) expression
versus binding of biotinylated, recombinant human B7-H4 protein (rhB7-H4) (x-axis) six days after
transduction of human T-cells with the indicated CARs. Frequency and median fluorescent intensity (MFI)
of binding to rhB7-H4 is shown in the upper right quadrant. Cells are gated by size and viability (7AAD-)
(c) Binding of the indicated CAR T-cell populations to recombinant proteins human FRα (left), human B7H4 (middle), and mouse B7-H4 (right) six days post transduction. Cells are gated on size, viability (7AAD), and CAR transgene(+) (GFP+) populations. (b-c) Incubation with biotinylated protein was followed with
streptavidin-APC secondary reagent. UNT, untransduced; GFP, green fluorescent protein transduced (no
CAR). Representative donor shown. VH, variable heavy; L, linker; VL, variable light; CD28, CD28
intracellular domain; CD3ζ, CD3ζ intracellular domain.
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Figure 3.2

Figure 3.2. B7-H4 CAR expression in primary human T-cells. (a) Expression of CAR transgene
(GFP reporter) in primary human T-cells six days post transduction with the indicated CAR lentiviral
vectors. The y-axis shows CD8 staining. (b) T-cell populations stained with biotinylated anti-human heavy
chain, light chain IgG antibody (x-axis). CAR transgene expression (GFP reporter) is shown on the y-axis.
(c) CAR T-cells populations stained with biotinylated anti-mouse heavy chain, light chain IgG antibody.
(d) Indicated CAR-bearing T-cells were incubated with biotinylated, recombinant proteins FRα six days
post transduction. (a-d) Live, lymphocyte populations are shown. Incubation with biotinylated antibody or
protein was followed with the secondary reagent streptavidin-APC. UNT, untransduced; GFP, green
fluorescent protein transduced (no CAR). CD19-CD28Z and MOV19-CD28Z constructs are GFP-.
Representative donors shown.
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Figure 3.3

Figure 3.3. B7-H4 CAR T cell specifically secrete IFN-γ and lyse tumor cell lines expressing
endogenous B7-H4 protein. (a) Expression of B7-H4 on the surface of human tumor cell lines in vitro.
Anti-B7-H4 mAb staining (open histograms) overlaid with isotype control (gray, filled histograms) as
assessed by flow cytometry using two different anti-human B7-H4 antibodies. Staining of MIH43-PE (top)
and biotinylated AMP841 (bottom) are shown. (b-c) B7-H4 CAR T-cells specifically recognize B7-H4(+)
tumors. CAR T-cells were co-cultured with B7-H4(+) cell lines SKBR3, OVCAR3, and EBV-B or B7-H4cell lines C30 and OVCAR5 at a 1:1 effector to target (E:T) ratio. IFN-γ in 72 hour supernatants was
quantified using enzyme linked immunosorbent assay (ELISA). (d) Tumor cell lines transduced with
luciferase (luc) were cultured with T-cells at the indicated effector to target ratios. Residual luciferase
signal was calculated after 24 hours. Data is normalized to lysis of the CD19-CD28Z control CAR-bearing
T-cells against the cell lines indicated, which are all CD19(-). 3#68 and 3#54 B7-H4 CARs lyse B7-H4(+)
OVCAR3-luc, but do not lyse B7-H4(-) cell lines 624 and MDA231. MOV19-CD28Z CAR T-cells,
specific for human FRα protein, lyse FRα(+) MDA231 and OVCAR3, but do not lyse FRα(-) 624. Lytic
capability of the 3#68 B7-H4 CAR is significantly higher at the 1:1 E:T in comparison to the 3#54 B7-H4
CAR (p<0.0001 utilizing an unpaired t-test with Welch’s correction). (b-d) Error bars represent mean +/standard deviation (SD) of triplicate wells. Representative donors shown.

92

Figure 3.4

Figure 3.4. 3#68-CD-28Z CAR T-cells show rapid anti-tumor efficacy in vivo, followed by
late-onset toxicity and death. Mice bearing established (>200mm3) OVCAR3 tumors were treated
intraperitoneally with one dose of 4e6 CAR(+) T-cells. CD19-CD28Z served as a negative control. The
MOV19 CAR targeting FRα served as a positive control for anti-tumor efficacy since OVCAR3-luc cells
express endogenous levels of human FRα and human B7-H4. The number of CAR+ T cells per cohort was
determined and normalized via flow cytometric staining with an anti-heavy chain light chain IgG antibody.
(a) 3#68 B7-H4 CAR T-cell-treated mice show a significant reduction in tumor growth in a late treatment
model. Luminescence signal is shown 3 days before, as well as 11 and 25 days after T-cell administration.
(b) Quantified luminescence signal shows reduced OVCAR3-luc tumor burden compared to the negative
control CD19 CAR. (c) Caliper measurement over time shows a reduction in OVCAR3-luc tumor volume
(y-axis) in the 3#68 CAR T-cell-treated cohort. (d) Survival curve for the tumor bearing mice (shown in ac) shows death of the 3#68 B7-H4 CAR-treated mice with a median survival of 47 days. (e) Survival curve
of non-tumor bearing mice shows death of the 3#68 B7-H4 CAR-treated mice with a median survival of 48
days. (d,e) Log-rank (Mantel-Cox) test was used to determine the statistical significance of the survival
curves. (f-g) TruCount analysis shows the concentration (cell/uL blood , y-axis) of CD45(+)CD3(+) (left),
CD45(+)CD3(+)CD8(+) (middle), and CD45(+)CD3(+)CD8(-) (right) T-cells of the indicated cohorts 28
days (f) and 42 days (g) post T-cell administration. (b-c, f-g) Error bars represent mean +/- standard error of
the mean (SEM) of five mice per group. (b,c; f-g) Unpaired, two-tailed Student t tests, without assuming a
consistent standard deviation, were performed between cohorts for each time point. *, p<0.05; **,p<0.01
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Figure 3.5

Figure 3.5. Anti-tumor efficacy and safety of the 3#68-CD-28Z CAR T-cells in an early
treatment model. OVCAR3-luc tumor-bearing mice were treated in the intraperitoneal cavity with one
dose of 4e6 CAR(+) T-cells 16-22 days post tumor injection. Tumor growth was assessed by
bioluminescent imaging (BLI). Untreated, CD19-CD28Z, or T-cells transduced with GFP (no CAR) served
as negative controls. The FRα-specific MOV19 CAR was a positive control for anti-tumor efficacy since
OVCAR3-luc cells expresses endogenous levels of human FRα and human B7-H4. The number of CAR+ T
cells per cohort was determined and normalized via flow cytometric staining with an anti-heavy chain light
chain IgG antibody. (a) Quantified luminescence of the early treatment model shows reduction of
OVCAR3-luc cells following 3#68 B7-H4 CAR T-cell injection in comparison to the CD19 CAR control.
Data is normalized to tumor luminescence prior to treatment (Day 0) for two independent experiments. (b)
Survival curve shows death of the 3#68 B7-H4 CAR-treated mice with a median survival of 60 days post
T-cell treatment. (c) Enumeration of CD45(+)CD3(+) (left), CD45(+)CD3(+)CD8(+) (middle), and
CD45(+)CD3(+)CD8(-) (left) T-cells in the peripheral blood T-cells of indicated cohorts 28 days (c) and 49
days (d) post T-cell injection. (a; c-d) Unpaired, two-tailed Student t tests, without assuming a consistent
standard deviation, were performed between cohorts for each time point. (b) Log-rank (Mantel-Cox) test
was used to determine the statistical significance of the survival curves. Number of mice per group is
indicated below graphs.*, p<0.05; **,p<0.01;***, p<0.001.
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Figure 3.6

Figure 3.6. In vitro growth kinetics and evaluation of CAR T-cells bearing different B7-H4
or control CARs. (a) Schematic of control 3#68 B7-H4 CAR lentiviral constructs. Vectors contain a
GFP reporter linked to the CAR transgene by a viral P2A ribosomal skipping peptide. In comparison to the
3#68-CD28Z CAR, 3#68-Z lacks the CD28 endodomain, the 3#68-CD28 chimera lacks the CD3ζ
endodomain, and the 3#68-null lacks both the CD28 and CD3ζ endodomains. T-cell populations were
cultured as described in the materials and methods. Recombinant, human IL-2 was maintained in the
culture media throughout the study. (b) Mean size (left) and population doubling (right) of the indicated
CAR-bearing T-cell populations over time. Error bars represent mean +/- standard error of the mean (SEM)
of two independent experiments. Statistical differences between the indicated CAR T-cell populations was
not significant. (c) Frequency of GFP reporter expression (CAR) for the indicated CAR-bearing T-cell
populations 14 (top) and 30 (bottom) days post activation with anti-hCD3/hCD28 beads. Cells are gated on
size and viability. (d). Frequency of CAR transgene (GFP, y-axis) versus B7-H4 expression (x-axis) of the
indicated CAR+ T-cell populations 14 days after T-cell activation. Cells are gated on size and viability.
UNT, untransduced; GFP, green fluorescent protein transduced (no CAR). CD19 and MOV19 CAR
constructs are GFP-. m923 CAR construct is GFP+. (c,d) Representative donor shown. VH, variable heavy;
L, linker; VL, variable light; CD28, CD28 intracellular domain; CD3ζ, CD3ζ intracellular domain.
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Figure 3.7

Figure 3.7: Validation of anti-B7-H4 antibodies for immunohistochemistry. The mouse
mesothelioma cell line AE17 was transduced with lentiviral vectors encoding murine or human B7-H4
linked to a GFP reporter by a viral P2A ribosomal skipping peptide to create cell lines stably expressing
murine (AE17.mB7-H4) or human (AE17.hB7-H4) B7-H4 protein. (a) We confirmed species-specific B7H4 surface expression using various anti-B7-H4 antibodies (x-axis). Left to right columns: rat anti-mouse
B7-H4 Clone 9, mouse anti-human B7-H4 MIH43, mouse anti-human/mouse B7-H4 AMP6H3, and
AMP841- the humanized version of AMP6H3. The top row shows the parental AE17 cell line. AE17.mB7H4 is in the middle and AE17.hB7-H4 is on the bottom. GFP reporter expression is shown on the y-axis.
Clone 9 was directly conjugated to PE. All other antibodies were biotinylated as described in the materials
and methods. Streptavidin-APC was used as a secondary reagent. (b) Cell pellets from parental AE17 (left),
AE17.mB7-H4 (middle), and AE17.hB7-H4 (middle), and OVCAR3 (right) after immunohistochemical
staining with mouse anti-human/mouse B7-H4 AMP6H3. 20x photomicrograph magnification.
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Figure 3.8

Figure 3.8. Assessment of murine B7-H4 expression. OVCAR3luc-beaing NSG mice that received
4e6 GFP(+) T-cells in the full autopsy study were sacrificed 77 days post tumor injection. Tissues were
formalin-fixed, paraffin-embedded, and assessed for expression of murine B7-H4 protein via
immunohistochemistry (IHC). (a) B7-H4 staining using the 6H3 antibody, which recognizes both human
and murine B7-H4 protein. (b). Staining of tumor sections with B7-H4 (6H3, left) or the isotype control
(mouse IgG1, right). Representative photomicrographs are shown. Magnification is shown in the bottom
left corner. All data represents three mice per tissue.
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Figure 3.9

Figure 3.9. B7-H4 is expressed endogenously in murine tissue. Immunohistochemistry was used
to evaluate the expression of B7-H4 in murine tissue. NSG mice from the full autopsy study bearing
OVCAR3-luc tumors in the flank were treated with 4e6 GFP(+) T-cells and sacrificed 77 days post tumor
injection. Tissues were harvested, formalin-fixed, paraffin-embedded, and stained with the anti-B7-H4
antibody 6H3, which recognizes both human and murine B7-H4 protein. (a) Representative
photomicrographs are shown. Magnification is shown in the bottom left corner. Black boxes and arrows
indicate zoomed in cutout. (b) Bar graph represents the expression score obtained from evaluation of the
photomicrographs. Scoring: 0, undetectable; 1, rare positive; 2, mildly positive; 3, moderately positive; 4,
strongly positive; 5, very strongly positive. All data represents three mice per tissue.
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Figure 3.10

Figure 3.10. 3#68-CD28Z CAR-T-cell treated mice exhibit histologic lesions consisting
primarily of multiorgan lymphocytic infiltration as compared with control CAR-T-cell
treated mice at 37 and 53 days post treatment. OVCAR3-tumor bearing mice were treated with one
dose of 4e6 CAR(+) T-cells. Mice were sacrificed before the 3#68 B7-H4 CAR-treated animals showed
signs of overt toxicity (37 days post T-cell treatment) or when showing evident signs of toxicity (55 days
post T-cell treatment). Tissue pathology was evaluated by hemotoxylin and eosin (H&E) staining. (a) At
day 37, 3#68 B7-H4 CAR-treated mice (top) exhibited lymphocytic infiltration of the pulmonary
interstitium, portal area of the liver, renal interstitium, and periductally within the pancreas as compared to
control CD19 CAR-treated mice (bottom), which had no significant lesions. No lesions were observed in
the heart, thyroid gland or adrenal gland in any cohort at either time point. (b) At day 53, 3#68 B7-H4
CAR-treated mice (top) exhibited similar, but more severe, lesions as compared to the early time point. No
lesions were observed in the CD19 CAR control CAR-treated mouse (bottom). Symbols indicate the
absence (-) or presence (+) of pathology. ++ indicates a more severe phenotype. Representative tissues and
photomicrographs shown. Magnification is shown in the bottom left corner.
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Figure 3.11

Figure 3.11. Presence of hCD3 lymphocytes and B7-H4 expression in murine tissue.
Confirmation of hCD3 expression in various murine tissues after transfer of 4e6 CAR+ T-cells in
OVCAR3-luc tumor-bearing mice in the full autopsy study. Mice were treated with 3#68 B7-H4 CAR or
control CD19 CAR-bearing T-cells. Animals were sacrificed 37 days post treatment and tissues were
harvested, formalin-fixed, paraffin-embedded, and stained with the indicated antibody via IHC. (a) hCD3
staining of tumor xenografts from CD19 or 3#68 B7-H4 CAR treated mice. (b-c) Expression of hCD3 (top)
or murine B7-H4 (bottom) in the pancreas (b) and liver (c) of 3#68-B7-H4 CAR treated mice. (d-e)
Immunohistochemical staining for hCD3 in the pancreas (d) or liver (e) of control CD19-CD28Z CAR Tcell-treated mice. Representative photomicrographs shown. Magnification is shown in the bottom left
corner. Data represents three mice per group.
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Figure 3.12

Figure 3.12. Expression on B7-H4 protein in normal human tissue. Immunohistochemical
staining of a microarray of normal human tissues using the anti-B7-H4 antibody 6H3. Magnification is 20x
unless otherwise noted in the bottom left corner. Representative photomicrographs are shown. Data
represents three sections per tissue.
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CHAPTER 4. Establishing a large animal model for immune
therapy: Treating Canine Malignancies with CAR-bearing Canine T
cells

Summary
Preclinical murine models of chimeric antigen receptor (CAR) T cell therapy are widely applied,
but are greatly limited by their inability to model the complex human tumor microenvironment
and adequately predict safety and efficacy in patients. We therefore established a preclinical
model of CAR T cell therapy in canines with spontaneous cancers. We developed an expansion
methodology that yields high numbers of canine T cells from normal or lymphoma-diseased dogs.
mRNA electroporation was utilized to express a first-generation canine CD20-specific CAR in
expanded T cells. cCD20 CAR expression was efficient and transient, and electroporated T cells
exhibited antigen-specific IFN-γ secretion and lysed cCD20+ targets. In a first-in-canine study,
autologous cCD20- CAR T cells were administered to a dog with relapsed B cell lymphoma.
Treatment was well tolerated and led to a modest, but transient, anti-tumor activity, suggesting
that stable CAR expression may be necessary to attain durable remissions in vivo. Our study
establishes the methodologies necessary for CAR T cell therapy in canines with spontaneous
cancers and lays the foundation for the use of a large, outbred, animal model of spontaneous
malignancies to evaluate the safety and efficacy of CAR therapy and its optimization prior to
translation into humans.
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Introduction
Chimeric antigen receptors (CARs) combine MHC-independent recognition of a target antigen
with potent T cell activation signals, and can be used to re-direct T cell specificity (Gross et al.,
1989). Adoptive immunotherapy using CAR-bearing T cells has led to major advances in the
treatment of hematological cancers, including leukemia (Grupp et al., 2013; Maude et al., 2014;
Porter et al., 2015; Porter et al., 2011). However, the success of CAR T cell therapy in other
tumor types, including solid cancers, has been limited. Lack of efficacy, in part, may be due to
lack of bona fide, tumor-specific targets and the limited ability of CAR T cells to penetrate
tumors and function in an immunosuppressive environment (Beatty et al., 2014; Caruana et al.,
2015; Chen et al., 2013; Lo et al., 2015; Moon et al., 2014; Textor et al., 2014). The field is
currently evaluating the distribution of novel tumor-specific targets, and further genetic
manipulation of primary T cells to introduce cytokines, chemokines, switch receptors, and suicide
genes to enhance T cell safety, expansion, tumor trafficking, and functionality in a suppressive
environment (Ankri et al., 2013; Di Stasi et al., 2009; Fedorov et al., 2013; Hoyos et al., 2010;
Lanitis et al., 2013b; Straathof et al., 2005; Urbanska et al., 2012). Additionally, the production of
TCR-ablated CAR T cells is being explored for allogeneic transfer to increase manufacturing
efficiency and broaden treatment availability (Torikai et al., 2012).

To date, the preclinical testing of safety and function of these next generation modified T cells
has largely been explored in murine models. While preclinical human xenograft mouse models in
immune compromised mice have played an important role in establishing proof-of-principle of
the CAR T cell approach, they are limited in their clinical relevance and predictive value.
Specifically, injected tumors in immune compromised mice may not fully recapitulate the
immunosuppressive tumor microenvironment. Additionally, human antigen-specific CAR T cells
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may not cross react with murine antigen, failing to accurately assess for risk of on-target, offtumor adverse events in normal tissue that could be, and have been, catastrophic in human
patients (Kalos et al., 2011; Lamers et al., 2013; Linette et al., 2013; Morgan et al., 2013; Morgan
et al., 2010). Given the rapid and on-going advances in CAR T cell technology in the laboratory,
it now becomes necessary to identify and develop an outbred, large animal spontaneous cancer
model, in which the safety of novel targets and therapeutic effectiveness of re-directed T cells can
be evaluated and optimized. This would accelerate the translation of the safest and most
promising CAR therapies into the human clinic.

Pet dogs share a close phylogenetic relationship and living environment with humans and develop
spontaneous cancers with similar genetics, biology, treatment regimens/responses and outcomes
(Breen and Modiano, 2008; Modiano et al., 2007; Steplewski et al., 1987). Additionally, companion
dogs with spontaneous cancers are being increasingly recognized as a relevant and potentially
predictive pre-clinical model of human disease and as such, could serve as a model system to test the
safety and efficacy of next generation CAR T cell therapies (Ito et al., 2014; Jubala et al., 2005;
Kalos and June, 2013; Marconato et al., 2013; Mata et al., 2014; O'Connor et al., 2012; Schiffman
and Breen, 2015). In particular, canine cancer patients lend themselves far better than murine models
to evaluation of immunotherapies, as pre-conditioning regimes, engraftment, cellular trafficking into
malignant lesions, transferred cell persistence, immune memory development, and effectiveness in
preventing relapse can be evaluated in this more representative model (Baron et al., 2006; Chen et
al., 2011b; Jochum et al., 2007; Maekawa et al., 2014; Sato et al., 2013).

The development of reagents and methods to effectively expand and genetically modify canine T
cells for adoptive transfer is necessary for the preclinical evaluation of next generation CAR T cell
therapies in dogs with spontaneous cancer. Therefore, we expanded on the work of Kazim Panjwani,
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a PhD candidate in Dr. Nicola Masons’s lab, to develop a robust method to activate and expand
primary T cells from the peripheral blood of healthy dogs and dogs with spontaneous malignancies.
Furthermore, we have developed a protocol to electroporate these expanded primary T cells with
CAR-encoding mRNA to achieve high level, transient CAR expression and antigen-specific effector
T cell function. Finally, we provide proof-of-principle that this CAR T cell approach can be
employed therapeutically in a clinical setting.
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Materials and Methods

Generation of cell-based artificial APCs: The human erythroleukemic cell line K562 was stably
transduced with a self-inactivating lentiviral vector, pCLPS, containing the human FcRII (CD32)
and cloned by single cell sorting to produce KT32 as previously described (Maus et al., 2002;
Suhoski et al., 2007). KT32 cells expressing cCD86 were generated by amplifying canine CD86
from cDNA derived from PHA and rhIL-2 stimulated canine PBMCs using RT-PCR with primers
flanked with BamHI and XhoI restriction sites. The resulting cDNA was cloned into the pCLPS
vector. Lentivirus was generated as previously described and used to transduce KT32 cells.(Parry
et al., 2003; Reiser, 2000) KT32 cells expressing high levels of cell surface canine CD86 were
bulk sorted to produce KT32.cCD86, referred herein as artificial Antigen Presenting Cells
(aAPCs). aAPCs were cultured in K562 media containing RPMI 1640 with 2mM L-glutamine
(Mediatech, Manassas, VA), 10% heat-inactivated fetal bovine serum (Atlanta Biologicals,
Lawrenceville, GA), 10mM HEPES (Gibco, Grand Island, NY), 1mM sodium pyruvate
(Mediatech), 100U/mL penicillin and 100μg/mL streptomycin (Gibco), and 30μg/mL gentamicin
(Gibco), and filtered through a 0.22μM filter Stericup (Millipore, Billerica, MA).

Generation of anti-canine CD3/CD28 magnetic beads: Agonistic mouse anti-canine CD3
(clone CA17.2A12, ABD Serotec, Raleigh, NC) and mouse anti-canine CD28 (clone 5B8, a
generous gift of Dr. Rainer Storb) were conjugated to magnetic tosylactivated Dynabeads (Life
Technologies, Grand Island, NY) according to the manufacturer’s protocol. In brief, 25μg of both
antibodies were incubated with 108 activated beads for 24 hours at room temperature in the
presence of sterile filtered 0.01% BSA (Sigma-Aldrich, St. Louis, MO) to prevent non-specific
binding. Beads were then incubated at 37°C for 4 hours to deactivate unused tosyl-groups.
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Conjugated beads were stored at 4x108/mL in 0.1% BSA w/v in DPBS (Mediatech) with 2mM
EDTA (Gibco) and 0.01% sodium azide (Amresco, Solon, OH) at 4°C.

Peripheral Blood Mononuclear Cell (PBMC) isolation & T cell culture: This methodology
was tested and performed by Kazim Panjwani in the laboratory of Nicola J. Mason. Canine
PBMCs were isolated by discontinuous density centrifugation over Ficoll-Paque PLUS (s.g.
1.077, GE Healthcare, Uppsala, Sweden). PBMCs were washed twice in T cell media (TCM)
containing RPMI 1640 with 2mM L-Glutamine (Mediatech), 10% heat-inactivated fetal bovine
serum (Atlanta Biologicals), 10mM HEPES (Gibco), 100U/ml penicillin and 100µg/ml
streptomycin (Gibco) and filtered through a 0.22μM filter Stericup (Millipore). Live PBMCs
were enumerated by hemocytometer using trypan blue exclusion, and then plated on 10cm
diameter tissue culture dishes (Falcon, Corning, NY) at 1x106 cells/mL at 37°C for overnight
culture. Supernatants enriched for viable peripheral blood lymphocytes (enriched PBLs) were
collected the following day and pelleted following centrifugation at 218g for 5 minutes. For
experiments using aAPCs for T cell activation and expansion, aAPCs cells were irradiated with
10,000 rads, washed in TCM, and re-suspended at 5x105 cells/mL. Cells were co-cultured with at
a 1:2 ratio of aAPCs:enriched PBLs to a final concentration of 5x105 enriched PBLs and 2.5x105
aAPCs per mL with 0.5μg/ml mouse anti-canine CD3. For experiments using antibodyconjugated beads, beads were washed three times with DPBS and once with TCM before addition
to enriched PBLs at a 3:1 ratio of beads:enriched PBLs. For lectin-induced proliferation, PBMCs
were cultured with 2.5ng/ml of concanavalin A (Sigma-Aldrich) with 100U/mL recombinant
human IL-2 (Gibco) added after 48 hours. In all cases, cells were cultured at 37°C and 5% CO2
with TCM. Where indicated, 30U/mL recombinant human IL-2 (rhIL-2, Gibco) and 10ng/mL
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recombinant human IL-21 (rhIL-2, eBioscience) were added at the time of stimulation and every
second day thereafter. Kazim Panjwani in the laboratory of Nicola J. Mason performed this work.

Flow cytometric analysis of canine T cells: PBMCs were washed twice with DPBS,
resuspended to 1x107 cells/mL in DPBS, and labeled with Carboxy-Fluoroscein Succinimidyl
Esterase (CFSE, 5µM, Sigma Aldrich) for 5 min at 37°C. Labeling was quenched with 5x
volumes TCM. Cells were washed twice and re-suspended in TCM prior to stimulation. At the
time points indicated, cells were harvested and washed in FACS buffer (1% heat-inactivated FBS
in DPBS with calcium and magnesium) prior to surface staining with a combination of the
following antibodies: APC- or PacificBlue-labeled rat anti-dog CD4 (clone YKIX302.9, ABD
Serotec), PE-labeled rat anti-dog CD5 (clone YKIX322.3, eBioscience), PE- or AF647-labeled
rat anti-dog CD8 (clone YCATE55.9, ABD Serotec), mouse anti-dog CD20 (clone 6C12,
Invivogen, San Diego, CA) with BrilliantViolet421- or AlexaFluor488-labeled goat anti-mouse
IgG secondary (clone Poly4053, Biolegend or Life Technologies), PECy7-labeled mouse antihuman CD45 (clone HI30, Biolegend, San Diego, CA), and the cell viability dye 7-AAD
(Biolegend). Following surface staining, cells were washed twice in FACS buffer and fixed in
1% paraformaldehyde (Ted Pella, Redding, CA). Where indicated, cells were permeabilized with
0.1% saponin (Sigma Aldrich) post-fixation and stained with a cross-reactive APC-labeled mouse
anti-human CD79a antibody (clone HM57, BD Biosciences, San Jose, CA). Surface detection of
the CAR was performed by labeling with a biotinylated rabbit anti-mouse IgG H+L antibody
(Jackson ImmunoResearch Laboratories, West Grove, PA) followed by fluor-conjugated
streptavidin secondary (BD Biosciences) prior to all other surface staining.
T cells were defined by expression of CD5, B cells were defined by expression of CD79a, and
aAPCs were gated out based on human CD45 positivity. For flow cytometric enumeration,
labeled samples were spiked with a known number of CountBright Beads (Life Technologies)
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prior to acquisition, and cell numbers were calculated based on bead recovery. Acquisition was
performed on a FACSCalibur, FACSCanto II, or LSR Fortessa flow cytometer (BD Biosciences)
and data was analyzed using FlowJo software version X (Treestar, Ashland, OR).

Cell lines: K562 cells, K562 cells expressing human CD19 (K562.hCD19), and the human
primary pancreatic adenocarcinoma cell line BxPC3.hCD19 were kindly provided by Dr. Carl
June. The murine fibroblast line 3T3 was kindly provided by Dr. Jonathan Maltzman. To
generate canine CD20 (cCD20) expressing target cell lines, cCD20 was amplified from PBMC
cDNA and cloned into pCLPS. The cCD20 transgene and the IRES-GFP reporter cassette 3’ of
the transgene were under the control of a CMV promoter. Lentivirus was generated as previously
described (Parry et al., 2003; Reiser, 2000), and concentrated supernatant was used to infect K562
and 3T3 cells to generate cCD20-expressing K562 cells (K562.cCD20) and 3T3 cells
(3T3.cCD20). Creation of the cCD20 engineered cell lines was performed by Josephine
Gnanandarajah and Kazim Panjwani in the laboratory of Nicola J. Mason.
3T3 and 3T3.cCD20 cells were grown in DMEM (Mediatech) with 10% heat-inactivated
fetal bovine serum (Atlanta Biologicals), L-glutamine (2mM), 100U/ml penicillin and 100µg/ml
streptomycin (Gibco), and filtered through a 0.22μM filter Stericup (Millipore). All K562 cell
lines were grown in K562 media, while BxPC3.hCD19, canine malignant B cell lines 17-71 and
GL-1, and canine B cell lymphoma cell line CLBL-1 were grown in TCM. All cell lines were
cultured at 37oC and 5% CO2.

Quantitative RT-PCR: Total RNA was extracted from 2x106 cultured cells 14 days after in vitro
stimulation using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA). Reverse transcription was
performed using random hexamers and Superscript II reverse transcriptase according to the
manufacturer’s instructions (Life Technologies). Primers to amplify canine granzyme B were
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designed using Primer3 software (http://frodo.wi.mit.edu/primer3/) with the maximum selfcomplementarity score set at 5 and the maximum 3 self-complementarity score set to 0 to
minimize primer-dimer formation. Primers for canine granzyme B were: Forward: 5'ATCAAGTGTGGTGGGTTCCT-3', Reverse: 5'-TGCTGGGTCTTCTCCTGTTC-3' and for the
housekeeping gene GAPDH were: Forward: 5’-GGCAAATTCCACGGCACAGTCAAGGC-3’,
Reverse: 5’-CAGAGGGGCCGTCCACGGTCTTCTGGGTGG-3’. Primers were synthesized by
Sigma-Aldrich. qRT-PCR assays were performed in triplicate using cDNA generated from 2.5ng
of RNA, SYBR Green (ThermoFisher), and 100nM primers. Standard conditions were used on an
Applied BioSystems 7500 Fast Real-Time PCR System device. Dissociation curves were
performed after each experiment to confirm the specificity of product amplification. Data was
analyzed using 7500 Fast System Software version 1.4.0. This work was performed by Kazim
Panjwani in the laboratory of Nicola J. Mason.

Generation of anti-ccCD20 and anti-hCD19 RNA CARs: A DNA plasmid containing the
murine anti-cCD20 scFv was obtained from Collen O’Connor in the laboratory of Laurence
Cooper at MD Anderson Cancer Center (Houston, Texas). cCD20 scFv sequence was polymerase
chain reaction (PCR)-amplified using the following primers: cCD20 scFv-Sense 5’ACGCGGATCCGACATCGTGCTGTCCCAGAGCCCCGCCATC-3’ (BamHI underlined) and
cCD20 scFv-Anti-sense 5’-ACGCGCTAGCGCTGGACACGGTCAGTGTGGTGCCCTGGCC3’ (NheI underlined). A DNA plasmid containing the murine anti-hCD19 (FMC63)-based CD28Z
CAR was used as a template to amplify the hCD19 scFv using the following primers: CD19
scFv- Sense 5’- ACGCGGATCCGACATCCAGATGACACAGACTACATCCTCC-3’ (BamHI)
and

CD19

scFv-Anti-sense

5’-

ACGCGCTAGCTGAGGAGACGGTGACTGAGGTTCCTTGGCC-3’ (NheI).(Milone et al.,
2009) Amplified sequences were gel purified, double digested with the indicated restriction
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enzymes, and ligated into a BamHI and NheI-digested pD-A.lenti cloning site.2bg.150A (PDA)
vector backbone that contained the following human components: CD8α leader, CD8α hinge,
CD8α transmembrane domain, and a CD3ζ intracellular signaling domain.(Zhao et al., 2010)
Insertion of the scFv was confirmed by sequencing.
RNA was synthesized as previously described by Keith Schutsky in our laboratory
(Schutsky et al., 2015b) Briefly, the cCD20-ζ CAR PDA plasmid was linearized by digestion
with SpeI. RNA in vitro transcription (IVT) was then performed using the T7 mScript Standard
mRNA production system (CellScipt Inc., Madison, WI) as per the manufacturer's instructions to
obtain capped and tailed RNA. RNA vector was aliquoted into single use vials and stored at 150°C until use.

RNA Electroporation: Canine T cells were electroporated with mRNA vectors after
approximately 14-16 days post-activation with the aAPC platform once T cells were rested down
(<300 fL size, Coulter Count, Beckman Coulter).

Previously described methods for

electroporation of human T cells were used to guide testing of optimal conditions for canine T
cells.(Schutsky et al., 2015b) T cells were washed twice with cold Optimem media (Gibco) and
resuspended at 108 cells/mL. We assessed increasing voltages (range: 200-600V) with constant
time (700 μs) and RNA (1μg/106 cells), increasing time (700 μs, 1 ms) with constant voltage
(500V) and RNA (1μg/106 cells), and increasing RNA (0.1, 1, 2μg/106 cells) with constant
voltage (500V) and time (700 μs). Optimal conditions were similar to those previously described
for human T cells (Schutsky et al., 2015b). Briefly, canine T cells were washed twice with cold
Optimem media (Gibco) and resuspended at 108 cells/mL. 20μg mRNA CAR vector and 2x107
cells (1μg/106 cells) were electroporated in cuvettes (0.2cm, Bio Rad, Hercules, CA) at 500 volts
for 700 μs (Electro Square Porator, BTX Harvard Apparatus, Holliston, MA). Cells were then
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cultured in TCM with rhIL-2 at 1-2x107 cells/mL in multiple wells of 12-well plates (BioExpress,
Kaysville, UT).

CAR T Cell Functional Assays: All functional assays were performed 24 hours postelectroporation of mRNA CAR vectors. Number of live cells was enumerated using a
hemocytometer. Transfection efficiency was generally >90%. Cytokine release: 106 T cells were
co-cultured with 106 cell targets in 200μL TCM in triplicate wells. 24 hours after co-culture,
canine IFN-γ production in cell-free supernatants was assessed via enzyme-linked
immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN). Cytotoxicity: 104 chromiumlabeled targets were plated in sextuplicate in 96-well plates. T cells were added at the indicated
E:T ratios. Co-cultures were incubated for 4hr at 37oC in phenol-free TCM. Specific lysis was
measured using a liquid scintillation counter (1450 Microbeta Plus, Long Island Scientific).
Percent lysis = 100–[(experimental cpm- spontaneous cpm )/(maximum cpm-spontaneous cpm
wells)] x 100, where spontaneous is cpm of target cells with T cells electroporated without
mRNA and maximum lysis is cpm of target cells with addition of 5% dimethyl sulfoxide
(DMSO).

Ethics Statement and Regulatory Approvals: This study was approved by the University of
Pennsylvania’s Institutional Animal Care and Use Committee (Protocol number 805496) and
signed owner consent was required prior to enrollment. The use of recombinant DNA was
approved by the University of Pennsylvania’s Institutional Biosafety Committee (IBC #14-103).

Eligibility Criteria and Study Design: The purpose of the study was to determine the safety and
effectiveness of mRNA-transfected, autologous T cells expressing a canine CD20-specific first
generation

CAR

against

B

cell

lymphoma.
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Dogs

with

a

histopathological

and

immunohistochemical diagnosis of B cell lymphoma that had relapsed following induction
chemotherapy were eligible for screening. Patients were required to have at least one measureable
target lesion that could be repeatedly measured and evaluated by aspiration or biopsy. A thorough
physical exam, Complete Blood Count, Chemistry Screen, and Urinalysis were performed to
determine general health status. Thoracic radiographs and abdominal ultrasound were also
performed to determine extent of disease burden. Dogs were pre-treated with diphenhydramine
(2mg/kg i.m) prior to administration of CAR T cells. CAR T cells were infused in 0.9%
Plasmalyte over 15 minutes. Blood samples were taken pre-infusion and 6, 24, 48, 72 hours after
each infusion, and lymph node aspirates were performed pre-infusion and 72 hours post-infusion,
to determine presence of CAR T cells, B cells, and anti-mouse immunoglobulin antibodies
(CAMA). Affected lymph nodes were measured ultrasonographically pre-infusion and 72 hours
post-infusion, with 2 perpendicular dimensions taken for each enlarged lymph node. Lymph node
volume was calculated as previous described (Gaurnier-Hausser et al., 2011).

Cytokine Bead Array: Peripheral blood was collected in glass vacutainers (BD) and allowed to
clot for 30 minutes before centrifugation at 1983g for 5 minutes. Serum was separated and stored
at -80°C prior to analysis. Samples were run in duplicate using the Canine Cytokine Magnetic
Bead Panel (Cat. No. PN CCYTOMAG-90K-PX13, EMD Millipore Corporation). Data
collection was performed on the Luminex 200 using xPONENT software, and calibrated and
verified according to the manufacturer’s instructions. The data report was generated using
Millipore Analyst Software. This work was performed by Kazim Panjwani in the laboratory of
Nicola J. Mason.

Detection of serum anti-mouse immunoglobulin antibodies: Serum samples, collected and
stored as above, were analyzed by ELISA in triplicate using a human-anti-mouse Ig Kit
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(Biolegend). Anti-mouse immunoglobulin antibody concentrations were calculated from standard
dilutions fit to a 5-parameter curve and validated by QC samples included in the kit. The lower
limit of detection for the assay was 7.8ng/mL. This work was performed by Kazim Panjwani in
the laboratory of Nicola J. Mason.
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Results
Artificial antigen presenting cells (aAPCs) induce robust proliferation of canine T cells
The broadly mitogenic lectins phytohemaglutinin and concanavalin A (ConA) or plate-bound
agonistic anti-canine CD3 antibody are commonly used methods for short-term stimulation of
canine lymphocytes in vitro (Graves et al., 2011; Kato et al., 2007). Human T cell expansion for
adoptive immunotherapy has been achieved using a combination of CD3 and CD28 stimulation,
either in the form of agonistic antibodies conjugated to magnetic beads or loaded onto a
CD32/CD64-expressing artificial antigen presenting cell line such as K562 cells (Levine et al.,
1997; Maus et al., 2002; Suhoski et al., 2007).

Kazim Panjwani in the laboratory of Nicola J. Mason evaluated various expansion methods to
determine if stimulation via both CD3 and CD28 could provide robust activation and proliferation
of canine T cells. Freshly isolated, CFSE-labeled canine PBMCs were stimulated with either
Concanavalin A (ConA) alone, anti-CD3 and anti-CD28 loaded magnetic beads (Beads
stimulation), or anti-CD3 antibody-loaded K562 cells that were transduced to express the canine
CD28 ligand CD86 (aAPC stimulation). While all three stimuli induced lymphocyte division by
day six of culture, aAPC-based stimulation induced the greatest T cell division and numerical
expansion across multiple donors (Figure 4.1a-b). aAPC-based stimulation consistently led to the
greatest cell expansion (5.8±1.0-fold) compared to Beads (1.7±0.8-fold) and ConA (0.4±0.2-fold)
(Figure 4.1b-c). Notably, cells from some donors were able to expand using aAPCs despite an
inability to proliferate in response to Beads (Figure 4.1a, bottom, and 4.1c). These data
demonstrate that while all three forms of stimulation can induce cell division, aAPCs
reproducibly expand the largest number of primary T cells ex vivo.
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Supplementation of aAPCs with rhIL-2 and rhIL-21 enhances canine T cell expansion
The addition of recombinant human IL-2 (rhIL-2) and IL-21 (rhIL-21) enhances human T cell
proliferation and preferentially expands the CD8+ subset, respectively (Bucher et al., 2009). In
order to determine the effects of rhIL-2 and rhIL-21 on ex vivo canine T cell expansion, Kazim
stimulated enriched PBLs from healthy dogs with aAPCs in the presence of 30U/mL rhIL-2,
10ng/mL rhIL-21, both cytokines, or no cytokine. Cytokines were added to the cultures every
other day for 14 days, at which point the cells were harvested, counted, and evaluated by flow
cytometry and qRT-PCR for phenotypic analyses and expression of granzyme B, a serine
protease most commonly found in the granules of cytotoxic T cells. Addition of rhIL-2, alone or
in combination with rhIL-21, resulted in a dramatic increase in T cell expansion two weeks after
stimulation (Figure 4.1d). qRT-PCR showed that expression of granzyme B was increased in
cultures receiving rhIL-21, alone or in combination with rhIL-2, 14 days after activation (Figure
4.1e). Additionally, flow cytometric analysis at day 14 showed that while all conditions resulted
in an increase in CD8:CD4 ratio compared to baseline, this increase was greatest in cultures that
contained rhIL-21 (Figure 4.1f).

Next, we determined the expansion kinetics of peripheral blood T cells from normal dogs using
aAPCs with rhIL-2 and rhIL-21. Characterization of peripheral T subsets in enriched peripheral
blood lymphocytes (PBL) from healthy canines at baseline revealed that 40.8±2.5% of live
lymphocytes were CD4+, and 22.9±1.7% were CD8+ (Figure 4.2a). Fourteen days post
activation with the aAPC/rhIL-2/rhIL-21 method resulted in an average of 25% CD4+ and 53%
CD8+ canine T cells among five healthy donors (Figure 4.2b). All conditions contained a
population of CD4+CD8+ double-positive cells (Figure 4.2c-d), a subset that has been reported
to appear in highly activated CD4 and CD8 single positive populations (Bismarck et al., 2012) .
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Prior to activation, CD79a+ B cells represented 10.6±5.9% of live lymphocytes (Figure 4.2c). After
fourteen days of expansion, minimal CD79a+ B cells or human CD45+ aAPCs were detected under
the culture conditions (Figure 4.2d). Additionally, canine T cells from enriched PBLs could be
expanded approximately 100-fold (Figure 4.2e, left), with an average of 6.6 population doublings at
14 days post-activation (Figure 4.2e, right). Taken together, these data suggest that the use of
aAPCs plus rhIL-2 and rhIL-21 provides robust expansion of canine peripheral blood T cells,
especially the CD8+ subset, to sufficient numbers required for autologous T cell therapy.

Canine T cells transiently express cCD20-specific CAR following mRNA electroporation
The B cell antigen CD20 is uniquely expressed on B lymphocytes in both humans and dogs.
Importantly, the majority of human and canine B cell lymphomas express CD20, representing an
ideal target for redirected T cell therapy (Ito et al., 2015; Nadler et al., 1981). Therefore, we sought
to create a CAR target canine CD20 (cCD20) as a proof of concept to test the hypothesis that
functional tumor-specific CAR T-cells can be generated and applied in patient dogs with
spontaneous cancer in order to establish a large animal model for immune therapy (Figure 4.3a).

We generated canine CD20-specific and human CD19-specific RNA CARs, referred to as cCD20-ζ
and hCD19-ζ, respectively (Figure 4.3a), as described in Materials & Methods. The hCD19-specific
RNA CAR was used as a specificity control since the scFv does not cross-react with canine CD19
(data not shown). To optimize mRNA electroporation of primary canine T cells, ex vivo expanded T
cells were electroporated with various voltages, pulse lengths, and amounts of mRNA (Figure 4.4).
We found that the greatest transfection efficiency and viability was achieved using 500 volts (Figure
4.4a). Longer pulse duration led to reduced viability without a significant increase in CAR surface
expression (Figure 4.4b). The highest transfection efficiency was achieved using 2μg CAR
mRNA/106 T cells (Figure 4.4c), however, the modest increase in CAR surface expression
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compared to 1μg CAR mRNA/106 T cells did not justify doubling the amount of mRNA vector for
large scale CAR T cell production.

The cCD20-ζ CAR was highly expressed (>95% frequency) on the surface of both canine CD4+ and
CD8+ T cells (Figure 4.5a), as assessed by staining cells with an anti-murine heavy chain/light
chain antibody. Similar analyses showed >90% expression of cCD19-ζ or cCD20-ζ CAR in bulk T
cells 24 hours post-electroporation. Importantly, we observed a gradual reduction in CAR frequency
(Figure 4.5b) and median fluorescent intensity (Figure 4.5c) over time, confirming transient surface
expression of CAR by T cells after electroporation. The cCD20-ζ CAR was detectable up to 14 days
post-electroporation. Notably, high frequencies of cCD20-ζ CAR expression were consistently
observed in expanded T cells from multiple canine donors (Figure 4.5d).

Canine CAR T cells demonstrate potent effector functions in vitro
We next sought to determine if canine T cells transiently redirected with CAR mRNA possess
antigen-specific, CAR-mediated effector functions against cCD20+ targets. First, we utilized flow
cytometry to assess surface cCD20 expression on the target cell lines. Murine 3T3 and human K562
cells engineered with cCD20 complementary DNA (3T3.cCD20 and K562.cCD20, respectively), but
not their parental cell lines, specifically expressed cCD20 (Figure 4.6a). The canine malignant B cell
lines GL-1 and 17-71 did not express cCD20 (Figure 4.6b). However, CLBL-1, a canine B cell
lymphoma line, showed high level surface expression of cCD20 antigen (Figure 4.6b).

Next, we co-cultured target cells with cCD20-ζ or hCD19-ζ CAR T cells 24 hours after their
electroporation with the mRNA CAR vectors (Figure 4.6c). cCD20-ζ CAR T cells specifically
secreted IFN-γ in response to exposure to cCD20+, but not cCD20-, cell targets. Control hCD19-ζ
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CAR T cells did not produce IFN- in response to the cCD20+ cell lines, but specifically recognized
the hCD19+ target cell line, K562.hCD19.

Given that effective T cell-mediated anti-tumor activity is dependent upon cytotoxic T cell function,
canine T cells redirected with the cCD20-ζ CAR were evaluated for antigen-specific cytolytic
activity. Canine T cells transfected with either the cCD20-ζ or hCD19-ζ CAR were co-cultured with
antigen positive and negative cell lines at a 10:1 E:T ratio. hCD19-ζ CAR T cells specifically lysed
the BxPC-3.hCD19 human cell line that was engineered to express hCD19 (Figure 4.6d). cCD20-ζ
CAR T cells demonstrated antigen-specific lysis of cCD20+ 3T3.cCD20 and CLBL-1 cell lines, but
not against cCD20- 3T3 or GL-1 cell lines (Figure 4.6d). Together, these results demonstrate that
canine T cells transfected with CAR exhibit CAR-mediated, antigen-stimulated IFN- production
and cytolytic activity.

Feasibility of CAR T cell production from a canine patient for in vivo therapeutic use
Having demonstrated high-efficiency transfection and CAR-mediated effector function in vitro of the
cCD20-ζ CAR in primary T cells from healthy dogs, we investigated the feasibility of CAR T cell
production for therapeutic use in a privately owned dog with relapsed lymphoma. A clinical trial
using mRNA-transfected, autologous, cCD20-ζ CAR T cells in pet dogs with relapsed, spontaneous
B cell lymphoma was initiated.

Patient 434-001 presented with relapsed B cell lymphoma one month after finishing a 26-week
course of induction chemotherapy with a standard CHOP based protocol (L-asparaginase,
vincristine, cyclophosphamide, doxorubicin, and prednisone) for the treatment of stage 3,
multicentric lymphoma. At relapse, the dog was treated with a single dose of L-asparaginase and
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referred for CAR T cell therapy. At initial presentation, the dog was asymptomatic and clinical
disease was limited to mild, bilateral submandibular lymphadenopathy. Complete blood count (CBC)
and chemistry screen (CS) analysis showed no significant abnormalities. Flow cytometry analyses
performed by Kazim Panjwani in the laboratory of Nicola J. Mason indicated that only 6 % of
leukocytes within the therapy target node (right prescapular lymph node) were CD79a+ cCD20+ B
cells (Figure 4.7a, left). Two weeks later, one day prior to the first T cell infusion, the
submandibular lymph nodes had enlarged and flow cytometry of leukocytes from the right
prescapular lymph node showed that over 86% of the cells were now CD79a+ cCD20+ B cells
(Figure 4.7a, right). Greater than 99% of CD79a+ B cells stained positive for cCD20 one day before
treatment (Figure 4.7a), and cytology confirmed the return of an aggressive B cell lymphoma (data
not shown).

Starting at day -16, three weekly peripheral blood collections were drawn to generate three separate
infusion products. PBLs consisted of a normal 2:1 ratio of CD4:CD8 T cells (Figure 4.7b, left).
Enriched PBLs were stimulated with aAPCs in the presence of rhIL-2 and rhIL-21 and expanded for
14 days. Expanded cell products contained both CD8+ and CD4+ cells (Figure 4.6b, right), and
underwent between 5 and 7 population doublings providing approximately 109 cells per infusion
product (Figure 4.7c). Overall, PBL preparations underwent 34-, 162-, and 120-fold expansions for
infusion products #1, #2, and #3, respectively (Figure 4.7d). Time course of therapy for is illustrated
in Figure 4.8.

Following expansion for 14 days, canine patient T cells were electroporated with cCD20-ζ CAR
mRNA to obtain the preclinical CAR T cell product. Greater than 90% of CD4+ and CD8+ T cells
showed surface expression of the CAR 24 hours post mRNA electroporation (Figure 4.9a). Parallel
electroporations with hCD19-ζ and cCD20-ζ CAR vectors were also performed to evaluate the
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duration of CAR expression and antigen-specific effector function of T cells expanded from this
lymphoma patient in vitro.

Both hCD19-ζ and cCD20-ζ CARs were highly expressed (>90%) in canine patient T cells 24 hours
post-electroporation, and CAR surface expression gradually decreased over 14 days (Figure 4.9b-c).
We next performed CAR-mediated cytokine production and cytolytic assays to determine the
functional capacity of the re-directed T cells. Twenty-four hours post electroporation, cCD20-ζ or
hCD19-ζ CAR 434-001 T cells were co-cultured with target cells (Figure 4.9d). Patient cCD20-ζ
CAR T cells secreted IFN- in response to all cCD20+ target cells, as assessed by ELISA. No IFN-
was secreted in response to cell lines that did not express cCD20. hCD19-ζ CAR T cells specifically
produced IFN- in response to hCD19+ targets, and did not recognize hCD19- cell lines. Similarly,
patient cCD20-ζ CAR T cells demonstrated antigen-specific lysis of cCD20+ target cells, but not of
cCD20- target cells in a standard chromium-release assay (Figure 4.9e). Thus, large numbers of
functional, cytolytic CAR T cells can be derived from the peripheral blood of a dog with
spontaneous lymphoma that are suitable for adoptive cell transfer therapy.

Efficacy and Safety after mRNA CAR treatment in a canine patient
Patient 434-001 received a total of three infusions of cCD20-ζ CAR T cells at weekly intervals. The
doses of total T cells were 240x106 cells for the first infusion, 54x106 cells for the second infusion,
and 226x106 cells for the third infusion. Infusions #1 and #2 were intravenously (IV) administered,
and infusion #3 was split between IV and intra-nodal (IN) injection. No overt, serious adverse effects
of treatment were observed in the canine patient. Following the third infusion, the dog developed a
mild, transient fever that resolved following fluid therapy. The size of the target, diseased lymph
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node (right prescapular lymph node) was measured by ultrasound before and 72 hours after each
infusion in order to calculate the estimated volumes.

Within 72 hours of each infusion, the diseased lymph node volume increased and then remained
stable until the next infusion (Figure 4.10a). Additionally, aspirates were collected from the target
lymph node prior to each infusion and 72 hours later for assessment of cellular composition via flow
cytometry by Kazim Panjwani in the Mason laboratory. At each 72 hour time point, there was a
modest reduction in the percentage of live CD79a+cCD20+ B cells within the affected lymph node,
which returned to pre-infusion levels by the next infusion (Figure 4.10b, left). Concomitant with the
decrease in B cell frequency, an increase in CD5+ T cell frequency within the target lymph node at
72 hours was observed following each treatment dose (Figure 4.10b, right).

Using cytokine bead array, we observed a two-fold increase in serum levels of IFN- compared to
baseline 24 hours post- infusion #1, which was the largest single IV dose administered (Figure
4.10c, left). The increase in serum IFN-γ following infusion #1 was confirmed by ELISA (data not
shown). Since human clinical investigation with CAR T cell therapy has shown significant toxicities
associated with increased serum IL-6 (Kalos et al., 2011; Porter et al., 2011), we also examined
serum IL-6 by cytokine bead array. Serum IL-6 levels increased 1.8 and 1.6 fold 24 hours following
dose #1 and dose #2, respectively (Figure 4.10c, right).

In human clinical trials, patients have developed human anti-mouse immunoglobulin antibodies
(HAMA) and anaphylaxis upon repeat administration of CAR T cells expressing a xenogenic murine
scFv (Beatty et al., 2014; Kershaw et al., 2006; Maus et al., 2013). Therefore, we hypothesized that
canine anti-mouse immunoglobulin antibodies (CAMA) against the murine scFv may be induced
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following multiple injections of cCD20-ζ CAR T cells. Sera collected at baseline and 6, 24, 48 and
72 hours after each infusion was tested for CAMA by ELISA. This assay was performed by Kazim
Panjwani in the laboratory of Nicola J. Mason. CAMA levels were below the limit of detection until
the time of the infusion #3, and rose sharply over the 72 hours after the third infusion (Figure 4.9d),
indicating that dogs can develop anti-mouse antibodies, similar to human patients, in response to
repeated exposure to a xenogenic murine scFv expressed on the surface of CAR T cells.
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Discussion
Companion dogs have an important role to play in informing human clinical oncology trials, as
underscored at the recent workshop held by the Institute of Medicine’s National Cancer Policy
Forum.(National Cancer Policy et al., 2015) This is particularly relevant in cancer immunology
and immunotherapy. Given the recent success of CAR T therapies in hematological malignancies,
there has been a surge of interest in evaluating new targets and next generation CAR T cell
approaches. However, in the absence of appropriate preclinical models, the clinical translation of
these new, non-vetted approaches comes with added safety concerns.

We have generated a robust, physiological method to activate, expand, and genetically modify
primary canine T cells for adoptive immunotherapy. Our expansion protocol relies on a
combination of an anti-canine CD3 antibody loaded onto K562 cells engineered to express canine
CD86, and addition of exogenous rhIL-2 and rhIL-21 cytokines. Using these classical 3 activation
signals, we achieved an average of 105-fold expansion (56-167 fold range) of canine T cells from
peripheral blood over 14 days – the largest reported expansion for a single stimulation protocol
(Mata et al., 2014; O'Connor et al., 2012) – which provides a baseline that can be tested and
varied in our newly developed large animal model. Additionally, we were able to generate an
average 105-fold expansion of canine T cells from enriched PBLs of a heavily pretreated patient
with refractory B cell lymphoma patient for three CAR T cell infusion products.

The stark bimodal response of canine enriched-PBL to anti-CD3/CD28 beads compared to the
consistent proliferation in response to the aAPCs suggests that a phenotype of canine T cells
exists that is resistant to activation with CD3 and CD28 stimulation alone. This phenotype may be
due to variability in the expression of CD28 on the surface of canine T cells. Early preliminary
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studies suggest that T cells from certain canine donors express CD28 at low levels and are unable
to be expanded utilizing the bead method, despite successful activation/expansion using the aAPC
protocol (data not shown). The failure to expand substantially is reminiscent of human clinical
trials, where potential subjects were excluded because their T cells do not expand ex vivo with
anti-human CD3/CD28 beads (Porter et al., 2015). The beads are a reductionist system, providing
only CD3 and CD28 signals, while the aAPCs may provide broader effects through additional
uncharacterized secreted factors and cell surface ligand-receptor interactions. If these additional
“rescuing” factors are identified, they could supplement the anti-CD3/CD28 beads to generate a
system just as broadly effective as aAPC stimulation for both canines and humans, but without
the unknown variables that come with a xenogenic co-culture.

Electroporation of ex vivo expanded primary T cells with CAR-encoding mRNA is an attractive
approach for evaluating novel targets. CAR expression post-electroporation is both very efficient
and transient, providing a critical built-in safety switch. Transient expression may allow for
evaluation of safety and efficacy for CAR T cell therapies against target tumor-associated
antigens that are also expressed on normal tissues in the host. Additionally, mRNA synthesis
through in vitro transcription and electroporation are also easily scalable for large numbers of
cells and patients.

This is the first report of mRNA electroporation of primary canine T cells. Surface CAR
expression diminished over the course of three weeks, with reduction to 90% CAR- T cells within
two weeks, similar to reports of CAR mRNA-electroporated human T cells (Schutsky et al.,
2015b). Even with transient expression, these CAR T cells exerted dramatic effects on antigenexpressing cells, including robust IFN-γ production and killing of target cells in vitro. While
sustained anti-tumor effects may be necessary for significant tumor regression, the transience of
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mRNA CARs makes the platform a critical exploratory tool (Beatty et al., 2014; Zhao et al.,
2010). With the built-in mechanism of short-lived CAR expression, we can now preliminarily
screen therapies for safety in “first-in-dog” trials targeting novel antigens. Candidate antigens
deemed safe through our mRNA CAR platform could then be examined in stably expressed CAR
systems to assess long-term efficacy. Similarly, mRNA CARs could be used as a short-term, but
potent pre-conditioning, method to modulate the tumor microenvironment and potentiate stably
expressed CAR efficacy (Lo et al., 2015).

The growth of T cells from the peripheral blood of both humans and dogs with advanced
hematological neoplasia can be challenging and the inability to generate a CAR T cell product
from these patients has led to trial exclusion (Porter et al., 2015). Still, we were able to generate
an average of 105-fold expansion from patient 434-001’s enriched PBLs ex vivo for three infusion
products. Interestingly, quality of PBMC isolation and expansion was significantly decreased in
our product derived from the first blood draw, which was taken closest to the patient’s most
recent dose of chemotherapy. We have observed this with another potential patient, where the
second blood draw successfully expanded several weeks after the first blood draw that only grew
two-fold (data not shown). Still, T cells that were collected from a host with an aggressive
malignancy, that evaded the immune system and recurred after both first line and rescue
chemotherapy, were efficiently expanded, genetically modified and highly functional.

The

potential broad immunodepleting effects of ongoing or prior chemotherapy on T cells are a major
hurdle for human therapy that is rarely accounted for in mouse immunotherapy models, but can
be addressed in this canine model.
Despite robust effector activity against canine cCD20+ B cell lymphoma cells ex vivo, we
observed modest, transient anti-tumor effects after adoptive cell transfer of three doses of mRNA
cCD20-z CAR T cell therapy in patient 434-001. We observed growth of the diseased lymph
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node immediately following intravenous CAR T cell infusion, with a concomitant decrease in
cCD20+ B cell frequency and increase in CD5+ T cell frequency. These data support the
hypothesis that infiltrating CAR+ T cells partially account for the initial growth of the lymph
node, potentially reducing the cCD20+ B cells in the 72 hours post-infusion. Still, the transient
nature of mRNA-based CAR expression may be responsible for the rebound effect seen prior to
infusion of dose #2 and #3.

The presence of the murine scFv within most CAR constructs has led to concerns about the
development of human anti-mouse immunoglobulin antibodies, or HAMA. This could lead to
decreased long-term efficacy due to CAR T cell clearance by the host immune system, and has
led to anaphylaxis (Maus et al., 2013). Indeed, we observed the induction of canine anti-mouse
immunoglobulin antibody (CAMA) in our patient, which developed between the second and third
infusion. Anti-mouse immunoglobulin antibodies would not be generated in an immune deficient
xenograft mouse model, highlighting the shortfalls of using a non-autologous model for
predicting unknown dangers when translating to human patients. Together, this emphasizes the
need to make CARs less immunogenic in their host, through the humanization or caninization of
the murine scFv.

Having demonstrated robust growth of primary canine T cells, effective redirection of these T
cells against tumor associated antigens, and the feasibility of treating a canine patient with
spontaneous malignancy, our next step will be to improve the long-term efficacy and durability of
CAR therapy in this model. While long-term proliferation and persistence are not necessary for
RNA CAR T cells due to their transient nature and function, these characteristics are critical for
effective, durable responses by T cells with stably-expressed CARs. The addition of CD28
signaling is known to increase CAR T cell proliferation and cytokine production, and 4-1BB has
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improved long-term engraftment of CAR T cells in the host, when combined with CD3ζ
(Carpenito et al., 2009; Finney et al., 2004; Geiger et al., 2001; Long et al., 2015; Milone et al.,
2009; Song et al., 2011). To this end, we have initiated a clinical trial using stably-transduced
canine CAR T cells using CAR constructs that include co-stimulatory signals that is currently
ongoing.

These findings lay the foundation and elucidate the path forward for adoptive immunotherapy in
dogs, a model that more faithfully recapitulates the challenges faced and progress made in human
therapy. Many potential modifications and novel constructs for CAR therapy are being
developed, such as switch-receptors that bypass tumor-mediated inhibition, universal receptors
that work in tandem with tumor-specific monoclonal antibodies, trans-CAR receptors that
function only in the presence of two antigens to reduce off-target effects, TCR-ablated cells to
prevent Graft Versus Host Disease, and many others (Ankri et al., 2013; Di Stasi et al., 2009;
Fedorov et al., 2013; Hoyos et al., 2010; Lanitis et al., 2013b; Straathof et al., 2005; Torikai et al.,
2012; Urbanska et al., 2012). Our work establishes a canine model that allows for further
evaluation of these novel immune therapies for spontaneous cancers, or other disease, in a host
that mimics human disease, treatment, and side effects, without direct risk to humans, largely
filling a wide gap in preclinical to clinical translation.
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Tables and Figures

Figure 4.1

Figure 4.1. Expansion of canine T cells varies in response to different activation stimuli and
cytokines. (a-c) Enriched peripheral blood lymphocytes (PBL) isolated from healthy canine donors were
stimulated with three different methods including (1) anti-CD3 antibody loaded-artificial antigen presenting
cells engineered to express canine CD86 (aAPCs), (2) anti-CD3/CD28 antibody-coated beads (Beads), (3)
concanavalin A (ConA), or (4) left unstimulated. (a) Canine PBL were labeled with CFSE and activated
utilizing the indicated condition. Proliferation kinetics was assessed by CFSE dilution over time. Two
representative healthy donors are shown. (b) Enumeration of live cells post-activation under the indicated
conditions as determined by trypan blue exclusion. Data represent mean ± SEM of four independent canine
donors. (c) Fold change of live cells 6 days post-activation in comparison to pre-activation (Day 0) as
enumerated by trypan blue exclusion. Each symbol represents one of four canine donors from independent
experiments. Horizontal bars represent the mean. * represents p<0.05 as measured by Dunn’s multiple
comparison test following 1-way ANOVA. (d-f) Enriched PBL were stimulated utilizing the aAPC method
with addition of no cytokine (No Cyt.), recombinant human IL-2 (rhIL-2), recombinant human IL-21 (rhIL21), or both cytokines. (d) Live T cells (7AAD-, CD5+) were enumerated using CountBright beads for flow
cytometric analyses. Fold change indicates number of live T cells 14 days after culture versus preactivation (Day 0). (e) Canine granzyme B (GZMB) expression measured by qRT-PCR at Day 14 postactivation in the indicated cytokine-treated cultures normalized to the no cytokine condition. * represents
p<0.05 as measured by Dunn’s multiple comparison test following 1-way ANOVA. (f) Flow cytometric
evaluation of CD4 and CD8 subsets among live T cells (size, 7-AAD-, CD5+) pre-activation and 14 days
after activation under the indicated condition. This work was performed by Kazim Panjwani in the
laboratory of Nicola J. Mason.
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Figure 4.2

Figure 4.2. Characterization of cellular phenotype and expansion following activation with
the optimized aAPC method. (a-d) Flow cytometric analyses of cellular subsets pre- and postactivation with the rhIL-2/rhIL-21/aAPC methodology. (a-b) CD4 and CD8 expression among live
lymphocytes in a representative donor and quantified in heathy canine donors pre-activation (Day 0)(a) and
14-15 days post-activation (b). Bar graphs represent mean ± SEM of five healthy canine donors from two
independent experiments. (c) Expression of the B cell marker CD79a in CD4- CD8- cells (35% of live,
lymphocytes) from enriched peripheral blood lymphocytes (PBL). Histogram from a representative donor
and quantified values of CD79a+ B cells frequency among live lymphocytes from four healthy donors preactivation (Day 0). (d) Representative histogram shows a loss of B cells (CD79a+)(left) 14 days postactivation. Populations are gated on live, CD4- and CD8- lymphocytes. Human CD45 staining (right)
shows a loss of aAPCs. Gray histogram indicates day 0. Black line indicates Day 14. Populations are gated
on live cells. (e) Enumeration of live, canine T cells by trypan blue exclusion. Fold change (left) and
population doublings (right) 14 days post-activation versus pre-activation (Day 0). Data and number
indicated represent mean ± SEM of five healthy canine donors.
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Figure 4.3

Figure 4.3. Development and evaluation of the activity of an anti-canine CD20 (cCD20)
CAR in canine T cells. (a)100% of canine B cell lymphoma samples demonstrate expression of CD20
on the cell surface. Therefore, we sought to test the hypothesis that Dogs with B cell lymphoma can be
treated by re-directing canine T cells against cCD20. Canine T cells were re-directed against cCD20
through RNA electroporation with a cCD20-CD3ζ CAR. We obtained the anti-cCD20 scFv from Collen
O’Conner in Laurence Cooper’s laboratory at MD Anderson Cancer Center. (b) Schematic of canine CD20
(cCD20) and human CD19 (hCD19) CAR mRNA constructs. Vectors contain a CD8α leader followed by a
murine anti-cCD20 scFv (top) or the murine anti-hCD19 (FMC63) scFv, allowing the CAR to bind cCD20
and hCD19, respectively. CAR constructs also contain a CD8α hinge and transmembrane (TM) domain,
and a CD3ζ intracellular signaling domain.
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Figure 4.4

Figure 4.4. Determination of optimal electroporation conditions for canine T cells. Cultured
canine T cells were electroporated with varying (a) voltages, (b) pulse lengths, and (c) amounts of cCD20-ζ
CAR mRNA used per 106 canine T cells. Surface CAR expression was assessed by flow cytometry 1, 3, 5,
and 7 days post-electroporation. Viability (7AAD-) was examined by flow cytometry 24 hours postelectroporation. Data show a representative canine donor per condition set.
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Figure 4.5

Figure 4.5. The cCD20-ζ CAR is efficiently and transiently expressed in canine T cells after
mRNA electroporation. Canine T cell populations were expanded with the aAPC/ rhIL-2/rhIL-21
method for 14 days before electroporation with mRNA CAR vectors. (a) Binding of an anti-murine heavy
chain, light chain IgG antibody was used to visualize CAR protein on the surface of cCD20 CARtransfected CD4+ (left) or CD8+ (right) T cells 24 hours post-electroporation. (b-c) Histograms (b) and bar
graph of frequencies (c) of flow cytometric staining for surface CAR expression in hCD19 or cCD20 CARtransfected T cells over time. (a-c) Representative healthy donor shown. Gray histogram indicates cells
electroporated with no mRNA, black line indicates cells electroporated with CAR mRNA. Populations are
gated on live lymphocytes. (d) Frequency of cCD20 CAR+ cells 24 hour post-electroporation in nine
healthy canine donors. Frequencies displayed under graph represent the mean ± SEM.

133

Figure 4.6

Figure 4.6. cCD20-ζ CAR T cells secrete IFN-γ and lyse target cells in an antigen-specific
manner. (a-b) Expression of cCD20 on the surface of murine and human (a) or canine (b) target cell lines.
Anti-cCD20 mAb staining (open histograms) overlaid with isotype control (gray, filled histograms) as
assessed by flow cytometry. Numbers in the right, upper corner represent signal-to-noise ratios, which were
calculated using the mean fluorescence intensity of anti-cCD20 antibody binding versus an isotype control.
(c) Cultured canine T cells electroporated with hCD19-ζ CAR, cCD20-ζ CAR, or no mRNA were cocultured with the indicated cell lines at a 1:1 effector to target (E:T) ratio. IFN-γ in 24 hour supernatants
was quantified by ELISA in triplicate wells. Data represent mean ± SEM of two normal canine donors from
independent experiments. (d) Cultured canine T cells electroporated with hCD19-ζ CAR or cCD20-ζ CAR
RNA were cultured with chromium-labeled tumor cell lines at a 10:1 E:T ratio. Specific lysis was
calculated after 4 hours. Data is normalized to lysis of target cells when cultured with T cells electroporated
with no RNA. Error bars represent mean ± SEM of sextuplicate wells from three healthy canine donors.
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Figure 4.7

Figure 4.7. Generation of CAR T cell product for a canine B cell lymphoma patient. (a) Flow
cytometric evaluation of B cell frequency (CD79a) and cCD20 expression among live lymphocytes in
aspirates taken from the target lymph node (right prescapular lymph node) 16 days prior and 1 day prior to
treatment of patient 434-001. (b) Flow cytometric evaluation of CD4 and CD8 populations among hCD45-,
live lymphocytes in enriched peripheral blood lymphocytes (PBL) prior to stimulation (Day -15) and one
day prior to infusion (Day -1) into the patient for infusion product #1. (c-d) Growth kinetics of all three
infusion products. Enumeration of live, canine T cells by trypan blue exclusion. Fold change (c) and
population doublings (d) over time post-activation. Number on graph indicates mean ± SEM of three
infusions products for patient 434-001.
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Figure 4.8

Figure 4.8. Timeline of patient treatment. Diagram depicting the staggered peripheral blood
mononuclear cell (PBMC) isolation (Iso.), enriched peripheral blood lymphocyte stimulation (Stim.),
electroporation (Electro.), infusion, and post-infusion sample collections (hr, hour) of each dose used to
treat patient 434-001.
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Figure 4.9

Figure 4.9. The cCD20-ζ CAR is expressed and functional in canine patient T cells after
mRNA electroporation. (a-c) Flow cytometric evaluation of surface CAR expression in a canine
patient’s T cells from infusion product #1 following electroporation with hCD19-ζ CAR mRNA, cCD20-ζ
CAR mRNA, or no mRNA. Populations are gated on live lymphocytes. (a) cCD20-ζ CAR expression
among CD4+ and CD8+ T cells 24 hours after electroporation with cCD20-ζ CAR mRNA (empty
histograms) or no mRNA (filled gray histograms). (b-c) Surface CAR expression measured over time
following electroporation with hCD19-ζ CAR mRNA, cCD20-ζ CAR mRNA, or no mRNA showed by
histograms (b) and median fluorescence intensity (MFI) of CAR+ cells (c). (d) 24 hours after
electroporation with hCD19-ζ CAR mRNA, cCD20-ζ CAR mRNA, or no mRNA, patient T cells were cocultured with the indicated cell lines at a 1:1 effector to target (E:T) ratio. IFN-γ in 24 hour supernatants
was quantified by ELISA in triplicate wells. Bar graphs represent mean ± SEM. (e) 24 hours after
electroporation with cCD20-ζ CAR mRNA or no mRNA, patient T cells were cultured with chromiumlabeled target cell lines at a 10:1 E:T ratio. Specific lysis was calculated after 4 hours. Data is normalized to
lysis of target cells when cultured with T cells electroporated with no mRNA. Data represents mean ± SEM
of sextuplicate wells.
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Figure 4.10

Figure 4.10. Effects of RNA CAR treatment in a canine B cell lymphoma patient. (a) Volume
of the target lymph node (LN)(right prescapular LN), as calculated from ultrasound measurements. Arrows
indicate the time of CAR T cell infusions. (b) Flow cytometric evaluation of aspirates collected from the
right prescapular LN, enumerating the frequency of CD79a+cCD20+ cells (left) and CD5+ cells (right)
among live lymphocytes prior to (pre-infusion) and 72 hours after the indicated CAR infusion. (c) Serum
levels of IFN-γ (left) and IL-6 (right) at the indicated time points for each infusion as measured by cytokine
bead array (CBA). Data represents mean of duplicate tests. (d) The serum levels of canine anti-mouse
antibody (CAMA) at the indicated time points as measured by enzyme-linked immunosorbent assay
(ELISA). Data represent mean ± SEM of triplicate wells. Dotted line represents the lower limit of detection
(LLOD) for each assay. This work was performed by Kazim Panjwani in the laboratory of Nicola J. Mason.
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CHAPTER 5. All Together Now
Towards Clinical Application of the ErbB2369-377 TCR
Improvement of the ErbB2369-377 TCR platform
Although the ErbB2369-377 TCR(+) T cells significantly delayed progression of ErbB2+ HLA-A2+
human tumor in an in vivo xenograft model, we expect that modifications and improvements to
the platform may result in a more robust anti-tumor effect. As discussed previously, decreased
expression in primary human T cells in comparison to supT1 cells that lack an endogenous TCR
(Figure 2.5) suggests that endogenous mispairing may play a role in the decreased frequency of
tetramer(+) cells in human CD8+ T cells.

Since the beginning of this dissertation work, we have optimized the ErbB2 TCR7 platform
utilizing codon optimization and introduction of two cysteine residues to promote preferential
pairing of the exogenous TCR through disulfide bridges (Cohen et al., 2007; Voss et al., 2008).
We generated lentiviral vectors as discussed previously for the ErbB2 TCR7 and the “new
bridge” (NB) ErbB2 TCR7. The ErbB2 NB TCR7-transduced primary human T cells
demonstrated an increased ability to bind ErbB2369-377 tetramer in comparison to the original
ErbB2 TCR7 as evidenced by frequency (Figure 5.1a) and MFI (Figure 5.1b).

Notably, the ErbB2 NB TCR7 was able to secrete increased levels of IFN-γ 24-hours post coculture with 10ug/mL-0.1ug/mL ErbB2369-377 peptide-pulsed targets (Figure 5.1c). As expected,
we did not observe cross reactivity with ErbB2373-382 peptide in ErbB2369-377 TCR7 or ErbB2369-377
NB TCR7-specific T cells (Figure 5.1c). We did not directly assess for increased pairing of the
exogenous TCR, but rather focused on the functional comparisons of the TCRs. The possibility
remains that increases in ability to bind tetramer and secrete cytokine were afforded by increases
139

in transduction of the ErbB2 NB TCR7 in comparison to the parental ErbB2 TCR7. Future assays
will transduce primary human T cells at a limiting dilution of lentiviral vector such that only one
viral vector transduced each T cell. Additionally, we can transduce supT1 or gamma delta T cells
to ensure that reporter and tetramer binding ability are equal between the parent and NB TCR7
vectors.

Lastly, preliminary co-culture experiments testing IFN-γ against HLA-A2(+) ErbB2(+) MDA231
did not show increased reactivity of the tumor cell line (Figure 5.1d). These data suggest that
further optimization of the TCR may be necessary to improve anti-tumor efficacy. Future aims of
the project could lessen chimeric dimer formation by replacing the constant region of the human
TCR chains by their murine counterparts (Cohen et al., 2006) and/or eliminating expression of
the endogenous TCR. In previous studies, knock down has been performed using inclusion of
zinc finger nucleases (ZFN) (Provasi et al., 2012) or small interfering RNA (siRNA) to
specifically down-regulate the endogenous TCR (Okamoto et al., 2009). However, new
CRISPR/Caspase 9 technology that utilizes the nuclease Cas9 directed at a specific RNA
sequence of interest may allow for more efficient elimination of the endogenous TCR. Following
optimization, the anti-tumor efficacy of the parental versus new ErbB2369-377 TCR7 can be
evaluated in NSG xenograft models, leading to advancement of the most promising therapy.

Safety of the ErbB2369-377 TCR platform
The safety profile of anti-ErbB2 T cell modalities must be carefully considered due expression of
ErbB2 protein in normal tissue, including pulmonary epithelium (Morgan et al., 2010). Active
clinical trials at Baylor College of Medicine will assess the safety of second generation ErbB2
CAR T cell therapy beginning at low doses (1e7) (clinicaltrials.gov NCT02442297) since toxicity
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was observed utilizing a large dose (1e10) of high affinity ErbB2 CAR T cells bearing CD28, 41BB, and CD3ζ ICDs (Morgan et al., 2010). Recent work by Yangbing Zhao’s group
characterized “affinity-tuned” ErbB2 CAR T cells that utilize scFvs that can discriminate between
high levels of surface ErbB2 protein in the tumor versus low levels of ErbB2 protein on normal
cells (Liu et al., 2015). These novel strategies have revived the potential of safe and efficacious
targeting of ErbB2.

Still, the safety of ErbB2369-377 –directed T cell therapy cannot be assessed in current NSG
xenograft models due to the TCR’s lack of cross reactivity with murine MHC Class I/peptide
ErbB2369-377. New preclinical models must be developed in order to address these limitations.
Future experiments could test the reactivity of the ErbB2 TCR7 in transgenic NSG mice that are
engineered to express human HLA-A2 (Taconic) and human ErbB2. Alternatively, inducible
suicide gene systems could be employed to eliminate CAR-bearing T cells (Gargett and Brown,
2014). Still, these methods will need sustainable preclinical testing in models that recapitulate ontarget off-tumor toxicity. Once shown to be safe in preclinical models, the ErbB2369-377 TCR7
platform could be tested in clinical studies.

Here, There, and Everywhere: Future Applications of the B7-H4 CAR
Platform
“Regulate-able” CARs
Our data suggests that clinical application of anti-B7-H4 CAR therapy should be carefully
considered due to our findings of widespread B7-H4 expression in normal tissues. Notably, death
following B7-H4 CAR T cell therapy occurred at a delayed time point, while still controlling
tumor burden. This finding suggests that regulation of our B7-H4 CAR therapy could potentially
be applied safely. Transient expression of CAR using inducible suicide genes (Dotti et al., 2014)
141

or RNA electroporation (Zhao et al., 2010) could be utilized to avoid long term on-target, offtumor toxicity to normal tissue.

Additionally, the 3#68B7-H4-CD28Z CAR could be modified to remove the CD3ζ endodomain,
thereby preventing activation in the absence of signal 1 for T cell activation (Lanitis et al.,
2013a). To this end, we constructed a 3#68-CD28 chimera that was efficiently expressed in
primary human T cells (Figure 3.6 and Figure 5.2a-b). When expressed in tumor-specific T
cells, this switch receptor/chimera could act as a decoy for the putative B7-H4R on T cells and
provide co-stimulation in the presence of TAA and B7-H4 expressed on tumor cells (Figure
5.2c). Future studies could test the ability of the B7-H4 chimera to overcome B7-H4-mediated
hypofunction of ErbB2 TCR-transduced T cells in order to test the hypothesis that indirect
elimination of the inhibitory role of B7-H4(+) targets utilizing an anti-B7-H4 switch receptor in
TCR engineered T cells will enhance anti-tumor T cell function.

Lastly, it is possible that differences in epitope, affinity, or avidity conferred by the untested 26,
56, and 3#54 B7-H4 CAR may allow for safe application of B7-H4 CAR therapy in vivo. As
mentioned previously for the ErbB2 CAR (Liu et al., 2015), detuning the scFv may lead to
discrimination between TAA and normal expression of B7-H4. Future studies could examine
these different anti-B7-H4 CARs in NSG xenograft models to examine treatment efficacy against
tumor and safety.

Regulatory T cell (Treg) B7-H4 CAR
Evidence for B7-H4’s function in the periphery has been limited since studies from 2003-2011
were unable to detect protein expression on human tissue or did not report staining in murine
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tissue. After detecting B7-H4 protein in pancreatic islet cells, Wei et al. showed that transfer of
pancreatic-specific T cells lead to increased severity of diabetes in a B7-H4-deficient mouse and,
conversely, that overexpression of murine B7-H4 in pancreatic islets abrogated disease induction
(Lee et al., 2012; Wei et al., 2011). This report highlights the potential for B7-H4 to act in
peripheral T cell tolerance.

While we have used our B7-H4 platform as a classic CAR approach to target antigen on tumor
cells, it could also be applied in an autoimmunity setting. Transfer of regulatory T cells (Tregs)
expressing a carcinoembryonic antigen (CEA)-specific CAR lessens the severity of colitis in
preclinical animal models (Blat et al., 2014). Since pancreatic islet cells express B7-H4,
investigation of B7-H4 CAR-bearing Tregs could have therapeutic potential in Type-1 diabetes.
Future experiments could test the immune suppressive nature of B7-H4 CAR transduced Tregs.

Targeting B7-H4(+) TAMs in the TME
Existence of TAMs and other pro-tumor accessory cells can promote tumor growth, metastasis,
angiogenesis, and immune evasion (Martinez and Gordon, 2014; Mills et al., 2000). Since an
increased number of TAMs correlates with a worse overall prognosis in ovarian cancer (Zhang et
al., 2012), creating therapies that target TAMs alone or in combination with tumor cells could
augment anti-tumor effects.

The cell surface expression of B7-H4 protein on tumor-associated macrophages (TAMs) n
ovarian cancer (Dangaj et al., 2013a; Kryczek et al., 2006b) has been described. Greater than 70%
of CD14+ tumor macrophages freshly isolated from tumor ascites expressed B7-H4 by flow
cytometry, and a similar percentage was seen by immunofluorescence for Ham56 + tumor
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macrophages (Kryczek et al., 2006b). Notably, B7-H4 expression levels on TAMs inversely
correlate with patient survival in ovarian cancer (Kryczek et al., 2007), suggesting that
therapeutic targeting may be advantageous.

Mechanistically, surface expression of B7-H4 is likely dynamic and influenced by its
microenvironment. Exposure to tumor-associated macrophages (TAMs) induces membrane
bound B7-H4 expression on lung cancer cell lines (Chen et al., 2012), and is likely to occur in
other in vitro models once formally examined. In the tumor microenvironment, high levels of
secreted IL-6 and IL-10 cause up-regulation of B7-H4 expression on the surface of TAMs
(Kryczek et al., 2007; Kryczek et al., 2006a; Kryczek et al., 2006b). Although its mechanism is
not fully understood, in vitro studies have shown that B7-H4 expression on macrophages is
stimulated by T-regulatory cells (Tregs), and not by conventional T cells (Kryczek et al., 2006a).
Tregs induce IL-6 and IL-10 production by macrophages that leads to autocrine signaling that
augments B7-H4 expression on macrophages (Kryczek et al., 2006b). Of note, high serum levels
of IL-6 are seen in serous endometrial cancers, a more aggressive form of endometrial cancer
compared to endometrioid cancers (Bellone et al., 2005).

Ectopic B7-H4 expression also causes normal macrophages to become suppressive. In support of
their in vitro work, in 2007 Kryczek et al. demonstrated that B7-H4 expression in macrophages
was significantly correlated with Treg cell numbers in patients with ovarian cancer. Additionally,
Treg count and macrophage B7-H4, but not tumor B7-H4, were negatively associated with
patient outcome (Kryczek et al., 2007). Although up-regulation of B7-H4 expression on tumor
cells was not seen in the 2006 report by Kryczek, a study by Chen et al. in 2011 demonstrated
that IL-10 secreted by TAMs induces B7-H4 expression of tumor cells in a lung carcinoma
mouse model in vivo (Chen et al., 2011a). Therefore, a stronger evaluation of the impact of
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cytokines or other factors in the induction of B7-H4 protein expression is necessary to fully
understand the mechanism of B7-H4 up-regulation in the tumor microenvironment.

Aim 2 of our study focused on eliminating B7-H4(+) tumor cells from the TME, but a future goal
of the original study was to target B7-H4(+) TAMs in combination with B7-H4(+) tumor cells in
the TME as a multifaceted approach against ovarian cancer. However, induction of toxicity in the
preclinical xenograft model refocused our study toward identification of B7-H4 protein in normal
murine tissue. Preliminary testing in our subcutaneous OVCAR3 xenograft model did not detect a
large population of murine monocytes/macrophages (CD45+, CD11b+, F4/80+) in the tumor
(data not shown). Preliminary work utilizing a different model in which we injected OVCAR3in
the intraperitoneal cavity (IP) of NSG mice revealed the presence of murine CD45+, CD11b+,
F4/80+ macrophages in the xenograft tumor following digestion of the tumor. B7-H4 expression
was not assessed in this model due to the lack of available anti-murine B7-H4 reagents at the time
of testing. Future work could evaluate the expression of murine B7-H4 in the IP OVCAR3 model
and test regulatable B7-H4 CAR T cell therapy in in order to assess the anti-tumor efficacy and
safety of targeting B7-H4(+) TAMs alone or in combination with B7-H4(+) tumor cells.

Lastly, future studies could examine key differences between B7-H4 expressed on normal tissue,
tumor, or macrophages that would allow for cell-type specific targeting. Safe targeting of the B7H4(+) macrophages alone through use an RNA or other regulatable CAR may allow for
remodeling of the TME, potentially leading to an increase in the efficacy of anti-TAA CARs such
as anti-mesothelin or anti-FOLR1 CAR T cell therapy.
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Future of B7-H4 Therapy

Our data cautions against use of non-regulatable CAR T cell-based strategies targeting
B7-H4. However, compounds such as anti-B7-H4 scFvs (Dangaj et al., 2013b), ADCCmediating antibodies (Jeon et al., 2014) and antibody drug conjugates (Leong et al., 2015) that
cross react with murine B7-H4 have demonstrated anti-tumor effects without concomitant
toxicity in mouse models. This may inherently be due to the differences in treatment modalities,
as scFvs and antibodies are rapidly cleared, may not efficiently penetrate tissue, and lack the
same potent effector functions as T cells (Chames et al., 2009). This has been evident clinically in
targeting ErbB-2, a protein expressed at low levels on pulmonary parenchyma. Monoclonal
antibody therapy (Herceptin) has not shown adverse events, but treatment with a relatively high
dose of a third generation, Herceptin scFv-based CAR with IL-2 and previous lympho-depletion
resulted in death of a patient and discontinuation of the trial (Morgan et al., 2010). Future work

by our laboratory could create blocking antibodies, ADC, or bi-specific antibodies from
our anti-B7-H4 scFvs. Lastly, discovery and characterization of the B7-H4R expressed
on activated T cells may lead to creation of anti-B7-H4R blocking antibodies more akin
to anti-PD-1 therapy.

We Can Work It Out: Improvement of Our Canine Model
Advanced Modification of Canine T cells
Aim 3 established the methodologies necessary for CAR T cell therapy in canines with
spontaneous cancers, demonstrating feasibility of treatment of a companion canine with B cell
lymphoma. However, anti-tumor effects of RNA-based CAR therapy were transient suggesting
that further product optimization is needed to attain remission.
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Future goals of Aim 3 will utilize methods to stably integrate the CAR into the canine T cell
genome in order to improve the durability of CAR therapy in this model. Stable integration
vectors that will be tested include lentiviral and retroviral vectors with various envelope proteins
and promoters to identify the optimal system for transduction. All methods to genetically modify
canine T cells with CAR should confer a moderate-high level of transduction efficiency and more
importantly, a sufficient shift in median fluorescent intensity (MFI) of CAR expression via
binding of anti-surface CAR antibody by flow cytometry. Indications from use of RNA CARelectroporated human T cells demonstrates little to no evidence of

effector function after

reduction in CAR surface expression below 1 log shift via flow cytometric analysis (Schutsky et
al., 2015a). Additionally, evidence utilizing our biotin binding immune receptor (BBIR) platform
against multiple antigens suggests that a >1 log shift of biotinylated antibody binding is necessary
for avidin-CAR firing (Urbanska et al., 2012) and Smith and Urbanska unpublished data).
Although increases >1 in MFI can be a goal, empirical testing of all CAR systems will be
performed. Lastly, the timing of addition of vectors post stimulation will also be assessed.

In addition to use of integrating vectors, we will also utilize second-generation CAR constructs
to provide co-stimulation through canine CD28, 4-1BB, or other intracellular signaling domains.
Future experiments will test if use of second generation CAR T cell platforms in canine T cells
will increase proliferation and persistence of the CAR(+) T cells in vivo as seen in human CAR T
cell systems (Carpenito et al., 2009; Finney et al., 2004; Geiger et al., 2001; Long et al., 2015;
Milone et al., 2009; Song et al., 2011). Lastly, future treatment of canine patients will include
lymphodepleting preconditioning prior to administration of CAR therapy, a regime that has
improved response rates following transfer of T cells (Robbins et al., 2004) and is widely used in
CAR T cell trials. To this end, Dr. Nicola Mason has initiated a clinical trial using stably
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transduced canine CAR T cells using CAR constructs that include co-stimulatory signals that is
currently ongoing.

Lastly, future studies will explore T cell phenotypic markers across various stimulation/expansion
methods to determine key factors in creating an “optimal” T cell product including the T cell
memory/effector frequencies, and levels of “exhaustion” markers such as PD-1. A lack of
availability of reagents have limited this work to date, but major interest in the platform generated
by our work will result in generation and acquisition of novel reagents to test these questions.

Beyond CD20(+) B cell lymphoma: Future of Canine CARs
The first CAR we tested in our model targeted canine CD20 since the antigen is expressed on the
surface of 100% of tested canine B cell lymphoma samples (Ito et al., 2014)(Mason lab
unpublished data) and is not expressed in essential normal tissues. Additionally, over 80,000 dogs
are diagnosed with B cell lymphoma annually in the United States (Modiano et al., 2007) and the
disease accounts for the highest frequency of deaths from cancer in dogs (Schiffman and Breen,
2015). The CD20 CAR established a proof of concept for feasibility, but we sought to examine
other promising targets.

We assessed antigen expression on various canine tumor cells via flow cytometry. We observed
binding of anti-human ErbB2 antibody Trastuzumab (4D5 clone) and anti-human FRα antibody
(MOV18 clone) to a canine mammary carcinoma (CAMAC-2), pulmonary carcinoma (CaCaL#3
and CaCaL#5), mesothelioma, and multiple osteosarcoma cell lines (BW-KOSA, MC-KOSA,
and SK-KOSA) with varying ability (Figure 5.3a). Of note, CAR therapies derived from the
Trastuzumab and MOV18 antibody are available, allowing us to target the canine tumor cells
directly with clinical relevant anti-human CAR therapy platforms. To this end, we co-cultured
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ErbB2(+) and ErbB2(-) canine cell lines with human T cells transduced to express the 4D541BBZ CAR. We observed specific secretion of IFN-γ against predicted ErbB2(+) canine cell
lines BW-KOSA, SK-KOSA, MC-KOSA, and CaCaL3# and did not observe recognition of
predicted ErbB2(-) cell lines GL-1 and 17-71 (Figure 5.3b).

These results suggest that we could co-opt established anti-human CAR T cell therapies for use in
our canine immune therapy model. Canine T cells could be engineered with anti-ErbB2 CAR
such as the 4D5 or affinity-detuned CARs (4D5.3 or 4D5.5) (Liu et al., 2015). Additionally, our
laboratory has obtained the MOV18 scFv (Miotti et al., 1987), which has previously been tested
as a CAR modality against human cancer (Kershaw et al., 2006; Parker et al., 2000). Notably, we
found that ErbB2 and FRα are highly expressed in the canine osteosarcoma, a disease that affects
approximately 10,000 dogs a year and increasingly being recognized as a good clinical model for
the human malignancy (Dobson, 2013). Additionally, various anti-B7-H4 platforms could be used
to test the safe application prior to translation into human clinical trials. Future work will
establish the use of these CAR therapies in osteosarcoma and other malignancies in our canine
immune therapy platform.

The Long and Winding Road: Improving Preclinical Animal Models
Improving limitations in available murine and other animal models is fundamental to the current
state of the field. Countless published models demonstrate potent anti-tumor effects and cures in
murine cancer models which cannot be reproduced in humans. Additionally, modifications made
to improve T cell trafficking or persistence cannot be interrogated in models were T cell therapies
are not limited by these issues. Creating models that recapitulate the difficulties in treating solid
tumors and others will assist in exploring the “optimal” T cell therapy.
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Syngeneic murine models may be useful in assessing toxicity and efficacy shortly after T cell
injection, but long term assessment is difficult due to the short-lived nature of murine T cells even
with use of lymphodepleting preconditioning and addition of exogenous cytokine. Future work
can improve these models, but should the field put efforts into creating an anti-murine counterpart
for every anti-human therapy?

Additionally, regulatory and ethical standards expect robust analysis of safety prior to usage in
clinical trials, but what studies should be performed? What is the threshold for toxicity if the
target protein is expressed in normal tissue? This question can be addressed in murine models
utilizing murine/human cross reactive therapies, but predictions may fall short if the target is not
regulated or expressed differentially between species. In addition, these murine models may not
predict possible side effects due to cross reactivity with a human homolog of the target protein or
a structurally similar epitope. Prior studies have utilized co-culture with normal human cells or
peptide/MHC binding algorithms, but even these have failed in foreseeing lethal side effects in
patients.

In our work we established a canine model of immune therapy in order to build upon observations
seen in human clinical trials and quickly transition promising anti-human/canine therapies from
the veterinary clinic in to human patients. Still, fundamental differences between available
methodology and reagents may limit the extrapolation of results in the canine model to humans.
Future work should attempt to optimize the canine platform in a way most analogous to the
human setting in order to minimize these differences and maximize the predictive value of the
dog.
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The field as a whole must work to perform and continue to develop the best possible interrogation
of safety and efficacy while balancing what is feasible to asses in a time and cost effective
manner. All models have an inherent level of uncertainty and the field will need to draw the line
on what is acceptable.

The End
In conclusion, our work has established and characterized three novel cancer immunotherapy
platforms in preclinical model systems. Re-direction of primary human T cells with our novel
ErbB2369-377 TCR conferred recognition of ErbB2+ HLA-A2+ tumor cell lines in vitro and in vivo,
providing a potential therapeutic for adoptive immunotherapy of ErbB2-expressing malignancies.
Secondly, the generation of B7-H4-specific CARs that recognized both human and murine
antigen revealed an important finding of treatment-related toxicity that is not typically assessed in
xenograft model systems. Additionally, the platform led to discovery and comprehensive
assessment of B7-H4 protein in normal murine tissue, advancing our understanding of B7-H4 and
fostering intelligent design of novel B7-H4-specific therapeutics for the clinic. Finally, we
demonstrated that tumor-specific CAR T-cells can be generated and applied in companion dogs
with spontaneous cancer, establishing a large outbred model of immune therapy that more
faithfully recapitulates the challenges faced and progress made in human therapy. All together
these findings lay the foundation and elucidate the path forward for safe application of promising
novel adoptive immunotherapy strategies in patients with cancer.
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Tables and Figures

Figure 5.1

Figure 5.1. In vitro characterization of the optimized ErbB2369-377 “New Bridge” TCR7.
Addition of two cysteine residues and codon optimization were performed to create the new ErbB2 NB
TCR7. Primary human T cells were transduced with retroviral vectors encoding the ErbB2 NB TCR7 or
parental ErbB2 TCR7. Untransduced (UNT) T cells were utilized as a control. (a) Ability to bind ErbB2369377 tetramer (red) or control MART1 27-35 tetramer (black) was assessed six days following transduction. (b)
Median fluorescence intensity (MFI) of tetramer binding six days following transduction. (c) Co-culture of
the indicated T cell populations with peptide-pulsed T2 target cells at a 1:1 effector to target ratio (E:T).
IFN-γ was assessed after 24 hours. (d) Co-culture of the indicated T cell populations with breast cancer cell
lines at an E:T ratio of 1:1. IFN-γ was assessed after 24 hours. MDA468 (HLA-A2-, ErbB2-), MDA468.A2
(HLA-A2+, ErbB2-), and MDA231 (HLA-A2+, ErbB2+). Error bars represent mean +/- SD. *, p <0.5.
N.S., not significant.
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Figure 5.2

Figure 5.2. Generation of a B7-H4-CD28 Chimera. (a) We generated a B7-H4-CD28 lentiviral
vector construct (middle) by eliminating the CD3ζ intracellular domain (ICD) from the 3#68 B7H4-CD28Z CAR construct (top). We also created a non-signaling (null) control vector that lacks
both CD28 and CD3ζ ICDs (bottom). (b) Expression of the green fluorescence protein (GFP)
reporter (y-axis) versus surface CAR expression (x-axis) via staining with an anti-human heavy
chain light chain (HC/LC) IgG antibody in B7-H4 CAR, B7-H4 chimera, and B7-H4-null T cell
populations six days post transduction. (c) Schematic demonstrating use of the B7-H4 chimera
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Figure 5.3

Figure 5.3. Feasibility of targeting other tumor-associated antigens in canine tumor cells. (a)
Binding of anti-human HER2 mAb (Trastuzumab) to the indicated cell lines (row 1, 3). Binding
of anti-human FRα (MOV18) to the indicated cell lines (row 2,4). Blue histograms represent
binding of biotinylated antibody. Shaded, red histograms represent binding on non-biotinylated
antibody. All staining was performed utilizing streptavidin APC as a secondary reagent.
Populations are gated on live cells. (b) Primary human T cells were transduced with anti-HER2
(4D5)-41BBZ CAR or GFP were co-cultured with the indicated cell lines for 24 hours at an
effector to target ratio of 1:1. IFN-γ was quantified using ELISA. Error bars represent mean +/standard deviation.
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